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ABSTRACT OF DISSERTATION 
 
 
SYNTHESIS AND CHARACTERIZATION OF POLY(SIMVASTATIN) - 
INCORPORATED COPOLYMERS AND BLENDS FOR BONE REGENERATION 
 
Common biodegradable polyesters such as poly(lactic acid) (PLA), poly(lactic-
co-glycolic acid) (PLGA) and poly(ε-caprolactone) (PCL) are used as drug delivery 
vehicles for tissue regenerative applications.  However, they are typically bioinert, with 
drug loading limitations.  Polymerizing the active agent or precursor into its respective 
biodegradable polymer would control drug loading via molar ratios of drug to initiator 
used for synthesis.  Simvastatin was chosen due to its favorable anti-inflammatory, 
angiogenic, and osteogenic properties.  In addition, its lactone ring lends itself to ring-
opening polymerization and, consequently, the synthesis of poly(simvastatin) with 
controlled simvastatin release.  
Simvastatin was first polymerized with a 5kDa methyl-terminated poly(ethylene 
glycol) (mPEG) initiator and catalyzed via stannous octoate to form poly(simvastatin)-
block-poly(ethylene glycol).  Molecular weights ranged from 9.5kDa, with a 
polydispersity index (PDI) of 1.1 at 150 °C, to 75kDa with a PDI of 6.9 at 250 °C.  First-
order propagation rates were seen.  Infrared spectroscopy showed carboxylic and methyl 
ether stretches unique to simvastatin and mPEG in the copolymer, respectively.  Slow 
degradation was seen in neutral and alkaline conditions, with simvastatin, simvastatin-
incorporated macromolecules, and mPEG identified as degradation products.    
  
Alternatively, triazabicyclodecene (TBD) was used to mediate simvastatin 
polymerization.  A lower temperature of 150°C led to successful polymerization using 
5kDa mPEG, compared to at least 200 °C via stannous octoate.  TBD was also successful 
for reactions using 2 or 0.55kDa mPEG.  The biodegradability of poly(simvastatin)-
block-poly(ethylene glycol) via TBD improved, losing twice more mass in phosphate-
buffered saline, pH 7.4, than the copolymer synthesized via stannous octoate.  Release 
rates of three different copolymers synthesized demonstrated tunable simvastatin 
release.         
To further modulate degradation, poly(simvastatin)-block-poly(ethylene glycol) 
was blended with 5, 2, or 0.55kDa mPEG-initiated PLA copolymers.  The blends showed 
a compressive elastic modulus ranging from 26 to 44MPa, within the magnitude of 
trabecular bone (approximately 50MPa).  Tunability in mass loss and release was also 
seen due to varied ratios of incorporated PLA copolymers.   
Lastly, copolymer degradation byproducts inhibited HMG-CoA reductase and 
showed possible enhancement of osteoblastic activity in vitro.  A pilot study using a 
rodent calvarial onlay model showed tolerability of the polymers and potential for long-
term evaluations of bioactivity. Poly(simvastatin) may be useful in regenerative 
applications. 
Keywords: poly(simvastatin), ring-opening polymerization, drug delivery, simvastatin, 
regenerative applications 
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Ch. 1 Introduction 
The development of biodegradable polydrugs is an emerging and rapidly growing 
area in drug delivery as they serve to significantly increase the weight percent of the 
bioactive agent in the biomaterial, allowing the biomaterial to be comprised almost 
entirely of the drug, while providing controlled release upon degradation.  Polyactives, 
termed by Uhrich’s group,1 encompass a broad range of therapeutic agents that are used 
as monomers which are ultimately polymerized into their homopolymers or into a 
polymer backbone.  These systems have been investigated in response to drawbacks seen 
in more common poly(lactic acid) (PLA)- and poly(lactic-co-glycolic acid) (PLGA)-
based drug eluting systems where the percentage of drug encapsulated or bound to the 
polymer backbone can be limited. Different polyactives have been developed 
incorporating well known therapeutic drugs into polymerized forms.  However, little 
investigation has been done that has taken advantage of lactonized structures found in 
prodrugs or active agents to utilize ROP in effectively polymerizing their respective 
resorbable polymers, specifically for tissue regenerative therapeutics.  Ahead, the 
synthesis of a copolymerized form of simvastatin, a commercially available and 
lactonized prodrug, and characterization of the degradable biomaterial is discussed for 
bone regenerative applications. 
Chapter 2 gives an overview of current treatments for bone repair and the 
chemical and physical properties of common biodegradable polyesters utilized for bone 
and soft tissue therapeutic applications.  The chapter further delves into different 
polymerization mechanisms which occur during polyester synthesis, most often 
2 
 
determined by the catalyst used, and secondary monomeric or polymeric components 
incorporated into the polyester by copolymerization or blending to help in tuning 
degradation rates.  The evolution of different methods used to incorporate bioactive 
agents or drugs into the polymer matrix or backbone are also discussed, with a stronger 
emphasis on osteogenic active agents. The discussion then leads into intended treatment 
applications which include maxillofacial bone defects or fractures and periodontitis.  The 
chapter concludes with the specific aims of the project. 
Chapter 3 addresses the different reaction conditions attempted to synthesize a 
novel poly(simvastatin)-block–poly(ethylene glycol) copolymer using tin (II) ethyl-
hexanoate (stannous octoate) as the catalyst. Quantitative analysis of copolymer growth 
throughout the reactions, followed by copolymer degradation in different pH conditions, 
was primarily discussed. Further qualitative characterization of the resulting copolymer 
and degradation products via chromatography and spectroscopy methods was another 
focus to demonstrate success in forming a polymeric biomaterial. 
Chapter 4 alternatively elaborates on the synthesis of poly(simvastatin)-mPEG 
diblock copolymer using triazabicyclodecene (TBD) as a catalyst, and touches on the 
differing ring-opening polymerization mechanism it governs from stannous octoate.  A 
comparison between the two catalysts focuses on the reaction conditions, capability of 
using different block components for copolymerization, and quality of the resulting 
copolymer expressed by the biodegradability of the resulting copolymer.  The 
comparison demonstrates the advantages of using TBD over stannous octoate in 
3 
 
synthesizing poly(simvastatin) and in synthesizing poly(simvastatin) copolymers with 
different drug release rates. 
Chapter 5 focuses on blending the most hydrophilic poly(simvastatin) copolymer 
synthesized with different poly(lactide)-block-poly(ethylene glycol) copolymers at two 
different weight ratios. Mass loss and resulting simvastatin amounts released in neutral 
and enzymatic conditions were quantified to demonstrate the effect of blending on the 
degradation rate of poly(simvastatin). Mechanical and crystalline properties were also 
quantified to show the effect of blending on the physical properties of the resulting 
blends. 
Chapter 6 primarily looks at the bioactivity of the poly(simvastatin) copolymer 
degradation products via  alkaline phosphatase expression and degree of myotube 
formation in a muscle cell line.  Biocompatibility of the copolymer was also observed in 
a pilot in vivo study.  Comparisons between the activities of degraded poly(simvastatin) 
and poly(D,L-lactide) copolymers against the monomer and general controls demonstrates 
the potential of tunable poly(simvastatin)-incorporated polymer biomaterials for bone 
regeneration. 
Overall, this dissertation focuses on the repurposing of simvastatin, well-known 
for cholesterol-regulation, for regenerative applications by polymerizing the drug into a 
biodegradable biomaterial for controlled simvastatin release.  ROP was investigated as a 
mechanism, novel in polymerizing simvastatin.  The continued investigation of 
polyactives, including poly(simvastatin), can extend to other lactonized active agents 
4 
 
which advantageously use ROP as another method to create more effectively controlled 
drug delivery systems for therapeutic applications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Theodora Atta Asafo-Adjei 2017 
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Ch. 2 Background and Significance 
2.1 Bone Grafts and Substitutes 
The high incidence of bone defects results from a range of causes including 
injury, infection, tumor resection, and abnormalities to bone and vascular diseases from 
osteoporosis to various forms of necrosis.
2-4
 In many instances, these complications are 
so extensive that natural bone repair becomes impaired and is no longer capable of 
completely healing the wound. This hindered process leaves remaining fractures, voids, 
and non-unions in need of external clinical intervention. Approximately 500,000 to 
600,000 bone grafting procedures are performed annually in the US.
5
  Autografts, as well 
as allografts, are used in approximately 2.2 million orthopaedic surgeries each year, 
worldwide.
6
 Investigations that are being done to improve upon the disadvantages of 
current treatment focus on multiple forms of biological and synthetic bone substitutes 
which incorporate the desirable characteristics of synthetic polymers.  Some of these 
devices may administer drugs to enhance efficacy of the biomaterial. The development of 
these materials aims towards developing the ideal material that eliminates the risk of 
disease transmission and rejection, improves biocompatibility, and provides an easily 
available, inexpensive, and abundance necessary for bone defect-related procedures.  
2.1.1 Autologous and Allogenic Bone Grafts 
Autografts are used as the primary bone graft of choice, or the “golden standard,” 
because their use diminishes the possibility of rejection and infectious disease 
transmission due to its harvest from the iliac or pelvic crest of the same patient in need of 
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the implant.
7
 They also possess four main properties needed for successful bone grafting: 
osteoconduction, osteoinduction, osteogenesis and osteointegration.
6
 Osteoconduction is 
the stimulation of bone tissue growth within the graft. Osteoinduction involves the 
differentiation of mesenchymal stem cells into osteoblasts, leading to bone growth. 
Osteogenesis stems from osteoprogenitor cells remaining in grafts that further proliferate 
and differentiate into characteristic bone cells which adhere within the graft. 
Osteointegration is the integrative bonding of the graft to surrounding bone tissue. Even 
though the autograft seems ideal by possessing these primary characteristics, it requires 
additional surgery to harvest the bone needed for the graft which increases the risk of 
complication.
3
  In fact, 8 to 20% of complications arise from harvesting host bone.
6
  
Allografts, harvested from cadavers or another host of the same species, are also used but 
have an increased chance of rejection due to being foreign to the host along with 
increased chances of transmitting infection or disease.
3, 7, 8
 
2.1.2 Calcium-Based Substitutes  
Ceramics used as synthetic bone substitutes are developed from calcium sulfate 
(CaS), calcium phosphate (CaP), or bioactive glass derivatives.
9, 10
  Due to chemical 
structure of CaP, which include hydroxyapatite (HA), ceramics being found in the 
inorganic components of bone, these scaffolds are found to be favorably biocompatible, 
and have been a focus alongside bone grafts to minimize the risk of infection otherwise 
seen with bone grafts.
11
 Their biocompatibility is defined by bioactive ceramic surfaces 
being able to form hydroxyl carbonate apatite (HCA) which bonds with surrounding 
tissues at the implant interface.
12
  This characteristic enhances osteointegration, and its 
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porosity gives it osteoconductive properties as well, for bone tissue growth.  However, 
they are brittle leading to inadequate structural support.
9
  Also, while they are capable of 
being resorbed, the resorption rate of some HA-incorporated implants can be extensively 
slow.
13
  Shindo et al.  showed that approximately half the amount of their porous 
hydroxyapatite cement implants were resorbed in bone within 9 and 18 months.
14
  
Biodegradable polymers have instead been combined with these ceramics to improve 
their mechanical and resorptive properties, and have also emerged on the forefront of 
biomaterials being investigated for tissue repair and regeneration. 
2.2 Common Biodegradable Polymers 
Biodegradable polymers are increasingly being used for biomedical therapeutic 
applications.  This is due to their desirable characteristics which include tunable 
degradation, mechanical properties, and relative biocompatibility in the body.  Their 
ability to degrade allows for the avoidance of revision surgery to remove the implant, as 
opposed to some fixation devices, after therapeutic treatment is done. This capability is 
due to the hydrolytically labile bonds present within the polymer backbone of these 
resorbable materials.  Specific characteristics of each of the more common biodegradable 
polymers make each very unique and the most favorable for their specific use.  
2.2.1 Poly(lactic acid) (PLA) 
Lactic acid, the monomer of PLA was first isolated in 1780 and commercialized 
in 1880.
15
  PLA was then first developed into synthetic biodegradable sutures in 1969 
before being considered for many other biomedical and drug delivery applications.
16
  
Good mechanical properties, thermoplasticity, and a thermal degradation temperature of 
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200 ˚C makes PLA a very suitable candidate for widescale processing (while within a 
narrow temperature range of 185 to 190 ˚C).15  At desirably processable molecular 
weights over 100 kDa, a high tensile strength and modulus around 61 MPa and 2.2 GPa, 
respectively, are reached, which can be modified based on the ratio of lactide isomers 
used in synthesis, making it adaptable for its intended application.
17
  The ratio of D to L-
lactide isomers also determines how amorphous or crystalline the polymer will be 
allowing its degradation rate and glass transition temperature, normally around 55 ˚C, to 
be slightly altered as well.
15
 Poly(D,L-lactic acid) is known to be the amorphous polymer 
because of the randomized configuration of methyl groups in the polymer backbone, 
creating more incoherent polymer matrix regions. Poly(L-lactic acid) has a uniform 
backbone resulting in a rigid uniform matrix that water is less likely to penetrate.  Upon 
degradation, when PLA degrades into lactic acid, the simplest of its degradation products 
via hydrolysis, it is recognized as a product developed in the body, and is later 
metabolized into carbon dioxide and water via the Krebs cycle.
18
  PLA has been 
copolymerized with poly(ethylene glycol) (PEG) and combined with hydroxyapatite to 
develop different types of fabrications for bone regeneration.
19, 20
 It has also been 
formulated into micro- and nanoparticles to release various classes of drugs for bone and 
soft tissue healing, along with cancer therapies. 
2.2.2 Poly(lactic-co-glycolic acid) (PLGA) 
Like PLA, PLGA possesses many similar mechanical and degradation 
characteristics making it amendable to processing for biomedical applications.    The 
incorporation of glycolic acid and its properties into the polymer backbone does 
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introduce a broader range of adaptable changes in mechanical and degradation tunability. 
With its lack of a methyl group, glycolic acid is more hydrophilic than lactic acid, 
allowing PLGA to become a more hydrophilic and generally faster degrading polymer or 
vice versa depending on the lactic acid to glycolic acid molar ratio in the polymer 
backbone.  However, the structural state of the polymer matrix plays the most influence 
in its degradation at a 50:50 molar ratio which has been found to have the fastest 
degradation rate compared to a greater incorporation of either monomer in the 
backbone.
21
 This characteristic is most likely due to an increasing amorphous nature as 
the incorporation of either lactide or glycolide monomer increases up to 50% as the 
amorphous regions allows easier access of water into the polymer matrix allowing for 
faster degradation.  Each of the homopolymers of the L-lactide stereo-isomer and 
glycolide are known to be semi-crystalline, at 37 and 45-55%, respectively.
22, 23
  The Tg 
range for PLGA can range from 44 to 55 ˚C, increasing in Tg as the lactide content and/or 
MW increases.
24, 25
.    Like lactide, glycolide is also metabolized in the body or excreted 
by the kidneys. Different localized formulations for bone, such as microparticle-sintered 
scaffolds for growth plate regeneration and other micro- and nanoparticle systems have 
been developed for drug delivery.
26, 27
 
2.2.3 Poly(ε-caprolactone) (PCL) 
PCL has previously been used in microelectronics, as an adhesive, and as an 
ecological biodegradable plastic.
28, 29
 Originally viewed as a biodegradable ecological 
plastic that degraded into non-toxic products via various microorganisms within the 
natural environment, PCL soon began being used for medical applications due to its 
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mechanical properties being similar to that of non-biodegradable polymers and for its 
ability to degrade in the body.
28
  Due to its lack of functional groups attached to the 5-
carbon portion of the aliphatic chain, PCL is very hydrophobic and degrades very slow 
compared to PLA and PLGA.  Additionally, the lack of bulky side groups permits PCL to 
form a semi-crystalline structure, with a -60 ˚C Tg, which becomes increasingly 
crystalline as it degrades in its amorphous regions, allowing degradation to take up to 
years via hydrolysis.  Its degradation properties, in combination with faster degrading 
polymers, has led to the synthesis of PCL block copolymers for sutures, such as 
Monocryl®, and bioglass composites formulated into fixation screws, among other 
devices for biomedical applications.
23, 30
 Compost microorganisms including Aspergillus 
spp. and Penicillium funiculosum are able to enzymatically degrade PCL into succinic 
acid, butyric acid, valeric acid, and hexanoic acid.
28
  However, within the physiological 
environment of the body, studies have shown it incapable of degrading enzymatically.
31, 
32
 Thus, solely hydrolysis at its ester linkages allows the polymer to degrade into its 
degradation products of 6-hydroxyhexanoic acid, its ε-caprolactone monomer, and the 
cyclic dimer and trimer of the monomer.
28
  PCL has now been repeatedly utilized in bone 
regeneration and other biomedical applications due to its degradation and mechanical 
properties.  PCL/hydroxyapatite composites and scaffolds have been developed as a 
result.
33, 34
 
2.2.4 Poly(anhydrides) 
The unique chemistry of poly(anhydrides) sets them apart from other 
biodegradable polymers, allowing multiple subclasses of the polymer to be synthesized 
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which can ultimately degrade by surface erosion, instead of the bulk erosion experienced 
by polyesters like PLA, PLGA, and PCL.  Aliphatic poly(anhydrides) were originally 
synthesized and extruded into fibers in 1932 by Carothers and Hill
35
 and was eventually 
used in textiles, but was later discarded from the industry because of its hydrolytic 
instability.  Langer and his group later took advantage of the polymer’s degrading 
properties for therapeutic controlled drug delivery in 1980.
36
  Since then, the polymer’s 
desirable bioerodible qualities have been used in more localized drug release therapies for 
malignant tumors, thrombosis and restenosis, infection, but moreso for glaucoma, retinal, 
and neurological disorders.
37, 38
  For example, poly(anhydrides) have been fashioned into 
disks and injectable microparticles releasing 5-fluorouridine to extend the reduction of 
intraocular pressure after glaucoma filtration surgery.
39, 40
  An FDA approved 
poly(anhydride), known as Gliadel
®
, has been formulated into wafers releasing 
carmustin, a chemotherapeutic, for treating brain tumors.
37
 Cylinders of the polymer have 
also been made to locally deliver anesthetic to the sciatic nerve for pain.
41
 Bioerodible 
poly(anhydrides) in medicine are generally synthesized with diacids resulting in the labile 
anhydride group embedded within the polymer chain capable of degrading within weeks.  
In non-degradable poly(anhydrides), the anhydride is instead a side group.  They are 
crystalline, opaque polymers with melting points between 50 ˚C and 120 ˚C dependent on 
the manipulation of their polymer chemistry.   Altering their chemistry has led to the 
development of poly(ester-anhydrides)
42
, aromatic, aliphatic-aromatic, unsaturated, 
branched, and crosslinked poly(anhydrides) among many others, for different 
applications.
37
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2.3 Polymer Synthesis 
Different types of polyester synthesis are utilized to achieve a desired polymeric 
architecture. The mechanisms by which these architectures are constructed may be 
dictated by the catalyst and is confined to the chemistry of the monomers and initiators 
being used. A combination of these different forms of polymerization can be used 
sequentially in order to develop the desired biomaterial.  
2.3.1 Radical Polymerization 
In radical polymerization, a free radical, or possible cation or anion, acts as the 
initiator by cleaving a pi-bond within the monomer and forming a new reactive species 
that continues chain propagation, repeating the process.  One form of radical 
polymerization is photopolymerization.
43
 It is generally used to achieve a desired gelation 
or crosslinking of polymer chains to form hydrogels in various drug delivery applications 
and to cure non-amalgam restorative dental applications.
44-46
  The degree of crosslinking 
directly relates to the amount of swelling the hydrogel is capable of undergoing in order 
to release entrapped drug. The method and reaction of photopolymerization is usually 
very simple and quick, requiring an accessible ultraviolet (UV) light source and 
photoinitiator within the macromer acrylate mixture. Afterwards, the gel is washed in an 
aqueous medium to remove any residual macromer and initiator. UV light bombards light 
susceptible photoinitiators, cleaving C-C, C-Cl, C-O, or C-S bonds in double bonds to 
form radicals and initiate propagation.  The UV light may also promote hydrogen atom 
transfer from a H donor to the photoinitiator forming hydrogen and ketal radicals for 
polymerization, also known as hydrogen abstraction.  Sawhney et al. developed acrylate-
13 
 
terminated PEG-block-oligo(lactide) and PEG-block-oligo(glycolide) macromers which 
were made into crosslinkable gels via photopolymerization.
47
 
2.3.2 Direct Condensation of Biodegradable Polymers  
Poly(α-hydroxy acids) like PLA and PLGA can be synthesized by direct 
condensation when the simplest reactant units of the polymer, lactic acid and glycolic 
acid, are chosen for synthesis.  In this form of step polymerization, the hydroxyl and 
carboxylic terminal end-groups of these monomers allows them to undergo an 
intermolecular reaction with like monomers. This results in the formation of dimers, 
trimers, and oligomers of varying lengths, along with the loss of a water molecule driven 
by the high temperature conditions of the reaction. At times a coupling agent, such as 
zinc compounds, carbodiimide or a phosgene compound,
48
 is used to enhance the 
efficiency of polymerization, but otherwise the aid of a catalyst is not needed.
49
  While 
the methodology for direct condensation is fairly simple, the process generally forms 
oligomeric low molecular weight (MW) polymer chains. The mechanically unstable and 
quickly degrading formulations these polymers would make are not ideal for biomedical 
therapeutics.  The increasing difficulty of distilled water removal with increased melt 
viscosity, followed by the equilibrium between water and acid reactants limit the 
progression of polymer chain growth.
17
 
In other instances, the monomers can be bifunctional, such as diols or diacids.  
This characteristic only allows one type of monomer to react with a different monomer 
type within the mixture.
50
  However, some exceptions to this to this concept have been 
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reported by Uhrich et al. which includes the melt condensation of dicarboxylic acid 
monomers to develop salicylic acid-based poly(ester-anhydrides).
42, 51
 
2.2.3 Ring-Opening Polymerization of Poly(α-hydroxyacids) or Poly(lactones) 
Ring-opening polymerization (ROP) requires the use of cyclic monomers, such as 
the lactone or cyclic dimer structures of lactic and glycolic acid, otherwise known as 
lactide and glycolide. An initiator and catalyst are usually necessary for the reaction to 
begin and to further mediate the type of ROP mechanism that occurs.  The main 
mechanisms of ROP that exist are coordination-insertion or pseudo-anionic, anionic, 
cationic and monomer activated ROP.
29
 Coordination-insertion involves an alkoxide 
nucleophilic initiator which coordinates with the lactone ring moiety of the monomer, 
then inserts the monomer into its metal-oxygen bond while cleaving the ring open at the 
acyl-oxygen bond to propagate the polymer chain.  The metal remains at the end of the 
chain to continue propagation, otherwise known as a living polymerization.
29, 52
  It is the 
most common form with an array of metal and metal alkoxide catalysts that mediate this 
mechanism, which include tin (II) octoate, tin triflate, and lanthanum, aluminum, and 
yittrium isopropoxide.
29
  Anionic ROP also has a nucleophilic initiator which acts on the 
carbon atom of the carbonyl group of the lactone, which in turn drives open the ring at 
the acyl-oxygen bond.  Catalysts that mediate anionic ROP mechanisms include small 
oxides like potassium methoxide,
53
 to organocatalysts such as 1,3-dimesitylimidazol-2-
ylidene (IMes), diazabicycloundecene (DBU), and triazabicyclodecene (TBD).
54, 55
  In 
cationic ROP, the oxygen in the carbonyl group of the lactone acts on the cationic 
catalyst to initiate ring opening of the lactone. Various acid cosystems can be used as the 
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catalyst for this mechanism, such as hydrochloric acid in diethyl ether.
56
 Lastly, the 
monomer can act as an activated catalyst that continuously adds to the end of the polymer 
chain.  In all instances, ROP reactions lead to the synthesis of high MW polymers with 
relatively low polydispersity and is considered one of the more preferred methods of 
polyester synthesis.   
2.4 Tuning Polymer Degradation 
The mechanisms and properties influencing polymer are invaluable to understand 
in their development for specific drug delivery applications.  Depending on whether the 
therapy is intended for bone tissue healing, which may require longer times of treatment, 
to fibrotic tissue prevention, requiring relatively shorter treatment periods, the rate of 
degradation will have to accommodate the recovery time of the specific type of injured 
tissue in question. 
2.4.1 Polymer Architecture 
The architecture of the polymer chain may influence how the resulting polymeric 
biomaterial degrades. Polyesters, such as PLA, PLGA, and PCL undergo bulk erosion 
which creates an increasingly acidic environment within the bulk as more ester bonds 
cleave within polymer chains, exposing carboxylic end groups.  An accelerated form of 
degradation results from this occurrence, known as autocatalysis, which is represented by 
a first-order rate with respect to the copolymer, water, and autocatalytic acid products.
57, 
58
  Polymers like poly(anhydrides) generally undergo surface erosion due to a 
combination of high hydrophobicity and highly water-labile bonds, impeding water 
penetration into the polymer matrix while easily cleaving linkages on the surface of the 
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bulk sample.  This process is represented by zero-order degradation kinetics and near 
zero-order drug release from the matrix.
1, 59
  However, when the linear chains of some of 
these polymers have been chemically manipulated to incorporate branched members of 
the polymer chain or branched linkers, the rate of polymer degradation may be affected. 
An increased degradation rate was seen in star-branched PLGA and PLA copolymers 
with multi-arm poly(ethylene glycol) (PEG) initiators compared to their linear block 
copolymer counterparts due to the extended retention of multifunctional PEG in the 
microparticle polymer matrix.
60
  Biphasic forms of degradation, presented in terms of 
decreasing molecular weight, was discovered of hyperbranched poly(silyl-esters)  
compared to its linear polymer counterpart, showing a more linear decrease in MW with 
time.
61
  Many other graft, comb, and dendritic types of branched polymers have been 
explored as potential biomaterials for drug delivery due to some of their unique 
degradation properties. 
62, 63
 
2.4.2 Poly(ethylene glycol) (PEG) Conjugation and Blending 
PEG is a hydrophilic polymer synthesized from ethylene oxide via ring opening 
polymerization.
64
  It has repeatedly been coated on, copolymerized and covalently 
bonded with aliphatic polyesters that have been formulated into micro- and nanoparticle 
systems for targeted drug delivery.
65
  PEG’s common use stems from its protective 
qualities that prolong circulation throughout the body, extending the drug release and 
therapeutic treatment of these particles, and ultimately increasing their biocompatibility.  
The terminal-end hydroxyl groups and ether linkages throughout the backbone solubilize 
PEG in water. Its hydrophilic nature combined with an absence of functional groups 
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allows for PEG incorporated surfaces to become more nonionic, minimizing protein 
adsorption, and further masking the immunogenicity of the system and its bioactive 
agents, systemically and locally.
65-67
  More specifically, the polymer and agents are 
shielded from premature and proteolytic degradation from phagocytic cells before 
reaching targeted tumors or the blood-brain barrier for treatment.
68
 
While PEGs are useful for creating relatively bioinert biomaterials, they also 
serve as avenues to tune the degradation rate and crystallinity of aliphatic polyester-based 
materials as a plasticizer, blend, or via copolymerization. Hydrophobic polymers like 
PLA, PLGA, and PCL which can be slow to degrade, can be made more hydrophilic via 
copolymerization, enhancing water uptake of the polymer. As the MW of PEG increases, 
the more hydrophilic the copolymer becomes. While the Tg of PEG remains at -60 ˚C as 
MW increases,
69
 crystallinity increases up to a point which may contribute to better 
toughness of the resulting polymeric biomaterial. Li et al. found that at 10 wt% of PEG in 
PLA/PEG blends, crystallinity and impact strength decreased as PEG MW increased up 
to 6000 Da. Crystallinity and impact strength increased as PEG MW increased from 6000 
Da to 20 kDa.
70
  However, as seen with Li et al.’s study, the weight percent and MW of 
PEG chosen can also impede specific mechanical properties.  Sungsanit et al. found that 
blending PLA with 1000 Da PEG increased impact strength, crystallinity, and elongation-
at-break and decreased the modulus and tensile strength with increasing PEG wt%.
71
 
2.5 Drug Encapsulation in Polymeric Systems 
Encapsulating drugs or bioactive molecules was first explored in the early 1930s 
as a method of protection before the technique was adapted to drug delivery concepts 
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utilizing biodegradable polyesters (i.e. PLA and PLGA) in the 1970s, and has since 
become the most common and well-known method for drug incorporation.
72
  The most 
common and simplistic forms of drug encapsulation in micro- and nanoparticle systems 
include oil-water (o/w) and water-oil-water (w/o/w) emulsions which entrap the drug to 
be released.  Bioactive agents significantly soluble in organic solvents undergo the o/w 
technique where the polymer and drug are dissolved in an organic solvent, such as 
dichloromethane or acetone, before adding to an aqueous solution with an incorporated 
surfactant, such as poly(vinyl alcohol) or Pluronic F-68, to obtain polymeric spherical 
particles with entrapped drug after the solvent is evaporated.  For agents more soluble in 
water, an additional water phase is added (i.e, w/o/w).  Parameters that affect the rate of 
release include polymer composition, polymer molecular weight, polymer-to-drug 
interactions and ratios.  Proteins are known to adsorb onto PLGA matrices which can 
cause slow dissolution rates or lead to incomplete cumulative release in drug delivery 
systems.
73
  
Lax or vague consideration of the volume ratios of dispersed to continuous 
phases, the organic solvents and aqueous solutions chosen in relation to drug solubility, 
or the partitioning characteristics of the drug between organic and aqueous phases, may 
result in low encapsulation efficiencies.  For example, using an o/w method for 
encapsulating a hydrophobic drug like hydrocortisone, also partially soluble in aqueous 
phases, would lead to expected low drug loading.  As a result, emulsion techniques such 
as oil-in-oil (o/o) and solid–in oil-in water (s/o/w) exist, along with other method 
variations.
72
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In fluorescein isothiocyanate (FITC)-dextran and FITC-immunoglobulin G (IgG) loaded 
PLGA/PEG blended microparticles, developed by Cleek et al., the percent encapsulation 
efficiencies increased from 67 to 77% as the PEG content decreased with dextran 
incorporation, and increased from 85 to 92% as the PEG content also increased with 
IgG.
74
  These percentages lead to total drug loading weight percents ranging from 0.67 to 
0.92 which are close to the theoretical loading of 1 wt%. Weight percents reported in the 
study represent a normal range for some polymeric microparticle systems, and while 
others have attained higher loading percentages, the formulation exposes a limitation or 
predictable cap to the drug payload, despite their effectiveness. Polymeric microparticle 
systems in the market include Decapeptyl® Depot, Vivitrol®, and Lupron Depot® 
formulated using coacervation (water-in-oil), o/w, and w/o/w methods, respectively, to 
entrap peptides and proteins for cancer, disease, and substance dependency therapies.
72
 
2.6 Polymer-Drug Conjugations 
Most of the previously described polymeric systems have bioactive agents 
dispersed throughout the polymer matrix, which may have limitations in drug loading 
capacity or premature burst drug release due to the structure of the polymer matrix.  To 
better control release, various forms of polymer-drug conjugations have been 
formulated.
1
 Ringsdorf first introduced the concept of polymeric drugs in 1975 by 
proposing a model which included a polymer backbone, targeting moiety, and linker 
molecule from the polymer backbone which covalently linked to the bioactive agent.
75, 76
 
Since then, many different types of non-degradable polymeric drug formulations have 
been synthesized, utilizing PEG, poly(lysine), poly(glutamic acid), poly(phosphazene), 
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and crosslinked hydroxypropyl methacrylate (HPMA) polymers, bound to antioxidant, 
anticancer, and anti-inflammatory drugs such as peroxidase, doxorubicin, and 
methotrexate, respectively.
66, 76
 A couple of PEG-drug conjugated systems in the market 
are Oncaspar
®
, and Macugen
®
 for leukemia and macular degeneration, respectively.   
The field has continued to grow with the development of biodegradable polymeric 
active systems. Systems where the drug still remains as a side group, but bound to a 
hydrolytically labile polymer backbone, include the synthesis of linear PEG, sebacic acid, 
and glycerol comprised polyesters with ketoprofen side groups, developed by Wang et. 
al.
1
 Novel polyesters with ibuprofen and naproxen side groups have also been 
synthesized by Uhrich’s group.1  Antioxidant and anti-microbial phenols such as 
curcumin and quercetin have also served as active pendant groups conjugated into 
poly(β-amino ester) backbones.77, 78  Biodegradable polydrugs or polyactives have also 
been developed where the bioactive structure is either chemically incorporated into the 
polymer backbone or serves as the monomer to its respective homopolymer.  Different 
examples of this class of polyactives include the novel synthesis of salicylic-based 
poly(ester-anhydride)s, poly(trolox-ester) and poly(peroxalate-ester) polymers, along 
with polymers comprised of antibiotic, analgesic and antiseptic monomers for bone, anti-
inflammatory, and antioxidant therapeutics.
1
  Before polymerization, the bioactive 
molecules are most likely activated or further synthesized into a diol or diacid monomer 
precursor, either by reacting with a cyclic anhydride, acyl chloride, or other linker 
component, before typically undergoing a solution polymerization via a step mechanism 
using a coupling agent.  The advantage of polyactives over more common encapsulation 
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methods is that the drug weight percent within the polymer system is significantly 
increased while controlled release rates are still maintained. 
2.7 Osteogenic Bioactive Agents 
Different bioactive factors are commonly incorporated into biodegradable 
polymeric systems to enhance bioactivity, more specifically, osteogenic and 
osteoinductive agents for bone. Osteogenic agents include families of growth factors such 
as insulin-like growth factor (IGF-1) and transforming growth factor (TGF) β, which 
includes bone morphogenetic proteins (BMPs) [4-7].  Statins are also recognized for their 
osteogenic properties which have been taken advantage of in drug delivery systems for 
bone regenerative applications.
79-84
 
2.7.1 Bone Morphogenetic Proteins (BMP)  
BMPs are a class of osteoinductive proteins that belong to the TGF-β superfamily. 
More specifically, they are known as differentiation factors since they induce 
vascularization, proliferation, and maturing of mesenchymal cells into bone and cartilage 
cells.
85
  They differentiate cells by binding to surface cell receptors which initiate the 
Smad transduction pathway, and causes the expression of an osteoblastic phenotype.  
BMPs initiate osteoblastic phenotypic expression in cells not related to bone, such as fat 
and muscle cells.
86
  In the1970s, Urist found that these BMP amino acid sequences 
responsible for osteoinductive activity could be isolated and extracted from the mineral 
component of bone.  Since then, more than 20 different types of proteins related to BMPs 
have been discovered.
87
  BMP-2 and BMP-7 have been FDA approved and extensively 
investigated in literature for bone regeneration, since both have similar sequences and 
mechanistic pathways, activity in vivo, and induce osteoinduction at lower concentrations 
compared to other BMPs.
85, 87
  Among other BMP-2-incorporated polymer systems,
88, 89 
Laurencin et al. also constructed a system using PLGA/hydroxyapatite composites with 
seeded BMP-2 expressed cells.
90
  Alveolar and mandibular bone formation was also seen 
in surgically made defects using collagenous and demineralized bone matrices with BMP 
-2.
87
  Currently, BMPs are produced by either transfecting BMP DNA coding into
mammalian cells which express and amplify the sequence and is later removed from the 
cells (recombinant BMP) or by purifying the protein from the bone extract using 
chromatography.
85
  However, reproducing the protein has very high costs due to low 
recovered yields from its expression in mammalian systems.
91, 92
  Ectopic bone formation 
leading to a delayed onset of nerve compression has also been seen with its use in lumbar 
spinal fusion treatments, which adds to its disadvantages in bone repairing applications.
93
2.7.2 Statins in Bone Repair 
Statins are most well known as lipid-regulating agents by inhibiting 3-hydroxy-3-
methyl-glutaryl coenzyme A (HMG CoA) reductase in the mevalonate pathway.
94
  The 
inhibition of the committed step, occurring early in the pathway, subsequently inhibits 
geranyl and farnesyl pyrophosphate isoprenoid precursors, which lead to the prenylation 
of Ras and Rho proteins involved in multiple cell signaling pathways influencing cell 
proliferation and differentiation.
94, 95
  As a result, statins are also attributed pleiotropic 
properties which can be utilized for tissue repair.  Agents within the statin family include 
lovastatin, simvastatin, mevastatin and pravastatin, directly and indirectly derived from 
the fungus Aspergillus terreus, along with synthetic statins: atorvastatin, cerivastatin, 
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fluvastatin, pitavastatin and rosuvastatin.
96
  Their slight differences in structural 
chemistry allow for some, mainly pravastatin and rosuvastatin, to be hydrophilic 
molecules, while the others remain lipophilic, more capable of crossing cellular 
membranes by passive diffusion and being metabolized hepatically by P450 cytochrome 
enzymes, excluding pitavastatin.
96
  Expressed activity levels also differ between statins. 
Mundy et al. tested lovastatin, among many other natural products, with an assay 
measuring the BMP-2 expression, a strong promoter of osteoblastic proliferation and 
differentiation.
97
 The group found the statin to be the only product from their collection 
to upregulate BMP-2, and subsequently tested other statins for comparable osteogenic 
activity.  Simvastatin, at an oral 5 to 50 mg/kg/day dose, caused a 25 to 94% increase in 
trabecular bone volume in ovariectomized rats after 35 d. Since this investigation, 
simvastatin has been extensively studied for bone formation and has been utilized in 
many polymeric drug delivery devices for bone repair in maxillofacial and periodontal 
therapeutics. For example, alveolar bone growth was seen in mandibular tooth sockets 
after the implantation of a simvastatin-loaded PLA-PGA copolymer system.
95
  Yazawa et 
al. also found that simvastatin enhanced cell proliferation and alkaline phosphatase 
activity in periodontal ligament cells.
98
 However, statins have been seen to induce 
myositis, rhabdomyolysis, and hepatotoxicity at high doses,
99
 which is why local instead 
of systemic delivery may be a better avenue for treating bone. 
2.8 Significance  
A reported 66-87% of bone fractures seen in trauma centers in the US and Puerto 
Rico are head injury related.
100
  Other cranio-maxillofacial bone defects include cleft
23 
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palate, and alveolar to calvarial deformations left from trauma, disease, and genetic 
events requiring complex treatment. The World Health Organization reported 1/2000 
births with cleft palate in the world’s western populations and 1/1600 newborns affected 
with other craniofacial anomalies.
2
 In adults, periodontitis is a common disease causing 
bone loss in the alveolar region from severe stages of chronic gingival infection. The 
disease is prevalent in 42.7% of adults in the US and 70.1% of adults 65 yr and older.
101
  
Bone defects caused by these factors often lead to repeated surgeries involving graft 
implantation.  Autologous bone grafting has continued to be the standard for treatment 
for osseous defects but has also contributed to post-operative complications.  
Bioresorbable polymeric biomaterials have been included in a host of bone 
substitutes investigated to improve upon the drawbacks of current treatment. They serve 
to degrade and release bioactive agents to promote bone growth, while also preventing 
the need for revision surgery.  However, some of these polymeric biomaterials come with 
their own disadvantages, such as a limited loading capacity of active agents which may 
not be sufficient for sustained delivery or localized tissue repair. Synthesizing a 
degradable osteogenic polymerized prodrug would serve to combat these issues for bone 
tissue regeneration. Simvastatin was chosen for investigation due to ample amounts of 
existing literature investigating its osteogenic properties, its chemical structure being 
amendable to polymerization, multiple properties benefiting the healing and growth of 
supporting vascular tissue, relatively inexpensive cost, and ease in accessibility. 
Synthesizing poly(simvastatin)-block-poly(ethylene glycol) would prolong simvastatin 
release while increasing the simvastatin loading capacity to weight percentages not 
characteristically seen in current polymeric systems, making the biomaterial more 
efficient for localized treatment.  
2.9 Specific Aims 
Aim 1: Synthesize and characterize a degradable mPEG-poly(simvastatin) diblock 
copolymer.  The molecular structure of simvastatin possesses a lactone moiety 
amendable to ring opening polymerization (ROP).  Reaction conditions were determined 
for polymerizing simvastatin.  The synthesized product was analyzed using various 
separation and spectroscopy techniques to determine bond formation, composition and 
quality.  The copolymer was then degraded to characterize its degradation products. 
Aim 2: Assess the tunability of the mechanical and degradation properties of 
poly(simvastatin)-block-poly(ethylene glycol) and poly(simvastatin)-based 
biomaterials. Poly(ethylene glycol)s of different MWs can alter the rate of water uptake, 
and thus degradation, of the resulting copolymer when copolymerized with a more 
hydrophobic polymeric block.  Blending poly(simvastatin)-block-poly(ethylene glycol) 
with another aliphatic polyester with different degrading and physical properties will 
influence the degradation and simvastatin release rate of the poly(simvastatin) component 
of the blend, along with altering mechanical properties.  PLA copolymers initiated with 
three different MW PEGs were blended with poly(simvastatin)-block-poly(ethylene 
glycol) (5 kDa mPEG) at 2 different weight percentages to examine effects on 
mechanical strength and degradation. 
Aim 3. Test the bioactivity of its degradation products biochemically and in vitro 
and in vivo. Degradation products of the implant will remain active and furthermore 
25 
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promote osteogenic effects on surrounding tissue to restore natural bone.  Cytotoxicity of 
poly(simvastatin)-block-poly(ethylene glycol) and its degradation products were 
investigated. The copolymer and degradation products were then tested biochemically 
and in vitro for osteogenic activity. Biocompatibility was also observed in vivo. 
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Ch. 3 Synthesis and Characterization of a Poly(ethylene 
glycol)- Poly(simvastatin) Diblock Copolymer 
 
This chapter was reproduced from a published manuscript, “Asafo-Adjei T.A., T.D. 
Dziubla, D.A. Puleo, Synthesis and characterization of a poly (ethylene glycol)–poly 
(simvastatin) diblock copolymer. RSC Advances. 2014;4(102):58287-98.” 
 
3.1 Introduction 
 
The use of biodegradable polymers in therapeutic applications has grown due to 
their favorable characteristics, which include biocompatibility, tailorable degradation, 
and the ability for some polymer degradation products to be metabolized.
23, 102
  
Poly(glycolic acid) (PGA), poly(lactic acid) (PLA), and poly(lactic-co-glycolic acid) 
(PLGA) are among the earliest biodegradable polyesters to be investigated.  Unlike the 
degradation products of some polyesters, such as poly(ε-caprolactone), glycolic and lactic 
acid are fully metabolized in the body.
103
  Commercial products based on these polymers 
include PGA/PLA sutures, approved by the FDA in 1971, to PLGA-collagen and PLA 
meshes and devices on the market for clinical regenerative treatments.
104
  These 
degradable biomaterials can also encapsulate active agents within their matrices or in 
reservoirs, but polymers have also carried covalently conjugated drugs.
105
  Polymer-drug 
conjugates have been a prevalent method of drug delivery since their conceptual 
development in 1975 to many different conjugates currently used.
106, 107
  These systems 
have used synthetic polymers, such as poly(lysine), poly(glutamic acid), and 
poly(phosphazene), to bind anti-cancer and anti-inflammatory drugs along their backbone 
via cleavable hydrazine bond linkers.
108, 109
   
While several characteristics of polyesters are advantageous, promoting their 
recurrent use in drug delivery, these biomaterials can have a limited capacity to entrap 
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drug.
110, 111
  Also, if structural or mechanical loading-induced defects exist in coated or 
drug repository devices, dose-dumping could lead to concentrations high enough for toxic 
effects to occur.
112-114
  Drug conjugation to the polymer backbone can prevent this issue, 
and it can preserve activity by shielding drugs from degradation as well as prolong drug 
circulation.
107
  However, this system also has the disadvantage of limited linkages 
available for drug loading.
109
   
Incorporation of drug into the polymeric backbone, such as the degradable 
aspirin-derivatized poly(anhydride ester)
115
 and poly(trolox ester) polymers
116
 developed 
for anti-inflammatory and antioxidant therapeutic applications, respectively, circumvents 
limited drug loading.  In these polymers, the weight percentage of drug is increased to 
nearly 100% as a result of these active molecules essentially being linked to each other to 
form a macromolecule.  The step growth and esterification polymerization mechanisms 
used to synthesize polydrugs such as the ones mentioned can require multiple reaction 
steps, however.  Little literature exists on utilizing the molecular chemistry of a 
therapeutic agent to create the backbone of its homopolymer or copolymer via ring-
opening polymerization (ROP), such as the polymerization of lactonized ricinoleic 
acid.
117
   
ROP has been utilized to polymerize lactones, among many types of cyclic 
monomers, into their respective polymers.  Lactide and glycolide are examples of lactone 
monomers used to synthesize PLA, PGA, and PLGA via ROP, which can be initiated by 
metal or organic catalysts to obtain high molecular weight macromolecules.
118
  Potential 
drawbacks that exist in the mechanism include competing depolymerization reactions and 
other side reactions that can influence the yield and quality of the resulting polymer.
119
  
29 
 
However, ROP is versatile in using a range of hydroxyl-containing macromolecules and 
alcohols to initiate polymerization and alter polymer properties, and minimal steps are 
usually necessary to develop the polymer.  ROP also has the ability to develop high 
molecular weight chains depending on the type of catalyst and molar ratios chosen for 
synthesis, which control the number of monomeric units attached.  These advantages 
reveal the usefulness of ROP to create a unique polyprodrug as a biomaterial for drug 
delivery. 
The therapeutic prodrug simvastatin contains a 6-membered lactone ring that is 
theoretically capable of being opened and reacted to form a polymer via ROP, much like 
monomers of PLA and PGA.  Simvastatin is well known as the active ingredient in 
Zocor, an oral medication for treating hypercholesterolemia.  However, the drug also 
exhibits anti-atherosclerotic, anti-inflammatory, angiogenic, and osteogenic properties in 
its active hydroxyacid form.
120-123
  Different polymeric devices have already explored 
encapsulation and release of simvastatin for bone regenerative applications.
79, 124, 125
  
Simvastatin is readily metabolized, ensuring removal from the body.
126
  Oral 
administration of statins can cause adverse muscular and hepatic effects
127
 that likely are 
related to the high frequency of large doses needed to overcome first-pass metabolism.  
Polymerizing simvastatin addresses the issue of dose dumping, removes the need for a 
bioinert polymeric carrier, and provides the option of increasing the loaded amount of 
simvastatin while prolonging release at therapeutic concentrations.     
 The objective of the present studies was to investigate the polymerization of 
simvastatin using ROP.  Reactions were conducted at different temperatures to evaluate 
30 
 
the effects of temperature via kinetic analysis.  The copolymer was also subjected to 
alkaline conditions to test degradation via hydrolysis.   
3.2 Experimental 
3.2.1 Materials 
Simvastatin was purchased from Haouri Pharma-Chem (Edison, NJ).  Tin (II) 
ethylhexanoate (stannous octoate), monomethyl ether poly(ethylene glycol) (mPEG), 
anhydrous toluene, anhydrous diethyl ether, dichloromethane (DCM), and deuterated 
chloroform (CDCl3) were purchased from Sigma-Aldrich (St. Louis, MO).  
Tetrahydrofuran (THF) stabilized with 3,5-di-tert-butyl 4-hydroxytoluene (BHT) was 
purchased from Fisher Scientific (Pittsburgh, PA).  
3.2.2 Methods 
3.2.2.1 Poly(ethylene glycol)-block-Poly(simvastatin) Synthesis.  Approximately 400 
mg microscale reactions of simvastatin (400 mg, 0.956 mmol) and mPEG (47.8 mg, 9.56 
μmol) were performed to assess reaction kinetics using a procedure adapted from the 
literature.
128
  All reactions were performed at 150 to 250 °C in a silica sand bath for 
improved temperature control.  Internal solution temperatures were found to be 10 to 20 
ºC lower than the sand bath temperatures.  The reactant components were dried at 130 °C 
in a nitrogen atmosphere for 1 hr followed by the reaction temperature for an additional 
hour.  Samples for the initial time point were taken after the reactants melted into a 
homogenous bulk mixture and before catalyst addition.  After the drying period, 1 wt% of 
stannous octoate dissolved in toluene was added to the melt by syringe.  Each reaction 
ran for 24 hr, with three samples taken at each of 0, 1, 4, 8, 12, 18, and 24 hr.  The 
theorized reaction scheme is shown in Figure 3.1a. 
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A macroscale synthesis of the diblock copolymer (2.5 g) was performed at 230 °C 
for 24 hr with the same reaction conditions described in the preceding paragraph.  The 
crude product was purified by vacuum filtration after obtaining the precipitate using 
DCM as the solvent and cold diethyl ether in excess as the anti-solvent to further remove 
any residual monomer.  Simvastatin (0.4 g) with and without catalyst addition was heated 
at 240 °C for 24 hr to assess the effect of temperature on its molecular weight.  
  
32 
 
 
 
Figure 3.1 a) Tin alkoxide complex formation and proposed mechanism of ROP reaction 
to form poly(ethylene glycol)-block-poly(simvastatin). b) Proposed mechanism of 
hydrolytic degradation of the copolymer. 
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3.2.2.2 Gel Permeation Chromatography (GPC).  Molecular weight was measured 
using a Shimadzu Prominence LC-20 AB HPLC system with a Waters 2410 refractive 
index detector.  Two 300 x 7.5 mm, 3 µm particle size ResiPore columns (Agilent 
Technologies) in series were used for sample separation.  Samples were injected using 
THF as the eluent at a 1.0 ml/min flow rate.  Standard curves were prepared using 
polystyrene standards ranging from 160 Da to 370 kDa.  Shimadzu Lab Solutions 
software was used to calculate weight- (Mw) and number-average molecular weight (Mn) 
and the polydispersity index (PDI, Mw/Mn).  Simvastatin monomer conversion (i.e., 
molecular weight growth of the poly(simvastatin) block) was determined as a function of 
time.  
3.2.2.3 Nuclear Magnetic Resonance (NMR) Spectroscopy.  H-NMR spectra were 
developed from Varian Gemini NMR 400 MHz spectrometers connected to a VnmrJ 
software interface.  Samples of the copolymer and a melted mixture of simvastatin and 
mPEG (100:1 molar ratio) weighing 5 to 7 mgs each were dissolved in 1ml of CDCl3, 
transferred into NMR sample vials and analyzed for additional structure characterization.  
3.2.2.4 Fourier Transform Infrared (FTIR) Spectroscopy.  Spectra were obtained 
using a Varian FTS-7000e FTIR spectrophotometer with a 0.25 cm
-1
 resolution.  Samples 
weighing 3 to 5 mg were placed directly onto a germanium attenuated total reflectance 
crystal and compressed for analysis. The functional groups of the copolymer (synthesized 
at 230 °C) were compared to those found in a melted mixture control of simvastatin and 
mPEG, as well as the components individually.  Peak locations and heights of stretches 
characteristic of simvastatin and mPEG were identified in the copolymer and its control.  
Comparisons of peak location and height were assessed.   
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3.2.2.5 In Vitro Degradation.  Small 16 to 18 mg disks were made by dissolving in 
dichloromethane (60 wt%) and pipetting the polymer solution onto a Teflon plate to 
evaporate the solvent overnight.  Disks were placed in 3 ml of 1 M NaOH (aq) or 
phosphate-buffered saline, pH 7.4 (PBS).  Disks were weighed and medium was 
completely replaced at each time interval.  Total dry weight of the disks was measured at 
2 and 6 weeks.  Aliquots were retrieved at intervals and analyzed for absorbance at 240 
nm using a PowerWave HT Microplate Spectrophotometer with a Gen5 analysis software 
interface.  The theorized mechanism of degradation is shown in Figure 3.1b.   
3.2.2.6 Matrix-Assisted Laser Desorption/Ionization – Time of Flight Mass 
Spectrometry (MALDI–TOF MS).  Degradation supernatants were analyzed for 
product identification, relative abundance of different products, and molecular weight 
distribution using a Bruker Ultraflextreme MALDI-TOFMS in positive ion mode.  This 
instrument provides a smartbeam-II solid state laserbeam (355 nm) focus as low as 10 
µm for quality spatial resolution, speed of up to 2 kHz, and a detector with a resolving 
power and mass accuracy of 40, 000 and 1 ppm, respectively.  Samples of simvastatin, 
mPEG, and degraded products in PBS were lyophilized and then solubilized in THF.  The 
sample solutions were then centrifuged at 2500 rpm for 3 min to remove the undissolved 
salts.  The remaining supernatants containing the dissolved compounds were syringe 
filtered (0.45 µm) before analysis.    Approximately 1 µL of each sample solution was 
analyzed on a stainless steel target.  Alpha-cyano-4-hydroxycinnamic acid (CHCA) was 
used as the matrix. 
3.2.2.7 Statistical Analysis.  Two-way ANOVA with a Bonferroni post-test was 
performed on the kinetic data to test the effects of reaction time and temperature on the 
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molecular weight growth of the copolymer and the effects of degradation time and pH on 
simvastatin release from the copolymer.  An unpaired student t-test was conducted to test 
for differences between means of mass lost.  Values of p<0.05 were deemed statistically 
significant.  Data were plotted as mean and standard deviation. 
 
3.3 Results 
Synthesizing poly(ethylene glycol)-block-poly(simvastatin) at 150 ºC and above 
generated crude copolymers that increased in Mw with time (Figure 3.2).  At 150 ºC, a 
minimal Mw of 9.5 kDa was observed, which correlated to approximately two simvastatin 
monomers in each chain.  However, as the temperature of reaction increased above 200 
ºC, polymer growth increased significantly, reaching poly(simvastatin) chain lengths of 
19 to approximately 260 monomeric units attached to an mPEG block.  The latter 
corresponded to a Mw of 74 kDa formed at 250 °C.  The kinetics of the temperature-
dependent reactions fitted best to a first-order rate model, 
 𝑀𝑊𝑡 = 𝑀𝑊𝑜𝑒
−𝑘𝑡                                                                                                                           (1) 
where MWt is molecular weight at time t, MWo is initial molecular weight, and k is the 
rate constant (Table 1).  Reactions run at 150 and 200 °C showed significantly lower 
rates of Mw growth, with constants of 0.0033 and 0.0169 hr
-1
 (Figure 3.2).  First-order 
kinetics became more evident as the temperatures of 215, 230, 240, and 250 °C led to 
higher rate constants of 0.0052, 0.0042, 0.0782, and 0.0806 hr
-1
, respectively.  Regardless 
of the molecular weight values obtained at each temperature, the Mn values for the crude 
products did not exceed 13 kDa (Table 1).   
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Figure 3.2. Mw of copolymer during ROP at increasing temperatures.  Simvastatin and 
mPEG (5 kDa) were mixed at a 100 to 1 molar ratio for each reaction.  The 0 hr time 
point represents the Mw of mPEG before poly(simvastatin) chain growth.  The GPC 
molecular weight of mPEG registered higher than its theoretical value due to differences 
in chemistry between mPEG and the polystyrene standards used.  Data are mean ± 
standard deviation (n=3). 
  
37 
 
Table 3.1 Summary of the highest MW obtained, derived rate equation, and percentage in 
the crude product at each temperature at 24 hr. 
 
Figure 3.3 shows a chromatogram depicting the conversion of monomers (i.e., 
simvastatin, represented by the peak at 22 min) to a larger Mw product at 250 °C.  A 
marked decrease in the monomer peak area represented rapid consumption to form 
intermediate simvastatin-conjugates (17.5 to 21 min).  The formation of product with a 
Mw higher than that of mPEG followed.  The extended Mw growth of the copolymer was 
represented by a slight leftward shift from the peak of mPEG (17 min) and a broadened 
shoulder, beginning at 10 min, to the maximum peak height at 16.5 min. 
The PDIs corresponding to the Mw kinetics are shown in Figure 3.4.  At 150 °C, 
where minimal molecular weight growth was seen, the PDI remained at 1.05 after 24 hr. 
However, at 200 and 230 °C, the values increased up to 1.3 and 1.9, respectively.  PDIs 
reached 4.8 and 6.9 at the highest temperatures of 240 and 250 °C, respectively.  
Temperature        
(°C) 
Rate equation 
 
Rate 
constant     
(hr
-1
) 
Mw at 24 
hr (kDa) 
Mn at 24 
hr (kDa) 
% in 
crude 
product 
150 𝑦 = 8.74𝑒0.0033𝑡 0.0033 9.5 9.1 8.5 
200 𝑦 = 9.20𝑒0.017𝑡 0.017 13.6 10.7 38 
215 𝑦 = 8.88𝑒0.052𝑡 0.052 31.6 13.1 64 
230 𝑦 = 8.57𝑒0.042𝑡 0.042 23.5 12.2 60 
240 𝑦 = 9.40𝑒0.078𝑡 0.078 53.2 11.1 69 
250 𝑦 = 9.81𝑒0.081𝑡 0.081 74.6 10.9 75 
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Figure 3.3 GPC chromatogram showing monomer (simvastatin) attachment to the mPEG 
block to form copolymer at 250 °C.  Chromatograms were normalized to the copolymer 
peak. The 1 hr mPEG and simvastatin peaks are excluded from normalization due to the 
monomer peak registering at a high intensity (6.4).   
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Figure 3.4 Changes in PDI at different temperatures of 24 hr ROP reactions.  The PDI at 
0 hr represents solely the mPEG block, and the subsequent points reflect addition of 
simvastatin monomers.  Data are mean ± standard deviation (n=3). 
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Further characterization of copolymer purification is shown by a GPC analysis of 
the crude product and the resulting retentate (desired copolymer) and filtrate (lower 
molecular weight products) (Figure 3.5).  The copolymer peak after separation was seen 
at an elution time of 16.5 min.  Intermediate products and unreacted simvastatin, 
represented by the elution time range of 18 to 22 min in Figure 3.3, were removed from 
the crude copolymer by subsequent vacuum filtration.  The vacuum filtration step 
isolated the purified copolymer product in the retentate.    
Analyzing the rate of propagation and the process by which the simvastatin 
monomer converted to copolymer at high temperatures led to heating the monomer, with 
and without the catalyst, at 240 °C to assess effects in the absence of mPEG as the 
initiator.  Interestingly, heating simvastatin alone and simvastatin with catalyst produced 
molecular weights of 10±4.7 kDa and 14±11kDa with PDIs of 2.3±1.5 and 4.7±2.5, 
respectively.  Both products still had lower Mw values than the product obtained in the 
high temperature copolymer reaction at 240 °C, which was 53 kDa with a PDI of 4.8.  
The majority of the conjugation produced was represented by the intermediate 
simvastatin product peaks, shown in Figure 3.3, most of which did not appear after 
purification (Figure 3.5, Table 3.2).  
NMR spectra of the monomer and copolymer synthesized at 230 ˚C are shown in 
Figure 3.6.  Integration measurements showed approximately 38 simvastatin monomers 
attached within the poly(simvastatin) block in the sample.  Simvastatin has a molecular 
weight value of 418.57 Da, which led to a calculated Mw of 21 kDa, similar to the Mw 
seen in the kinetics analysis at 230 ˚C.    
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Figure 3.5 GPC chromatogram of separated products after purification of the crude 
copolymer. 
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Table 3.2. Summary of product Mw distributions from purification, measured via GPC. 
Sample Component Mw (kDa) Composition 
(%) 
Yield (%) 
Crude 
copolymer 
highest Mw 
intermediates 
monomer 
11.5 
2.1 
0.3 
28 
48 
24 
- 
Purified 
copolymer 
highest Mw 
intermediates 
monomer 
10.2 
0.4 
0.2
a)
 
87 
6.2 
6.8 
 
18 
Separated low 
Mw weight 
product 
intermediates 
monomer 
3.2 
0.3 
66 
34 
- 
a)
 The GPC calibration curve has greater error for molecules with theoretical molecular 
weight values below 0.5 kDa, which may explain why the value for simvastatin monomer 
is not consistent in the table and why the value registers lower than the molecular weight 
value of 418.57 Da. 
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Figure 3.6  H-NMR spectra in CDCl3 (7.25 ppm) of: a) simvastatin and mPEG mixed at 
a 100:1 molar ratio and b) poly(ethylene glycol)-block-poly(simvastatin).   
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FTIR analysis of the functional groups of the synthesized copolymer is shown in 
Figure 3.7.  Comparing the copolymer spectrum to the spectra of simvastatin and a 
mixture of simvastatin and mPEG revealed a carbonyl (–C=O) band shift from 1704 cm-1 
to 1722 cm
-1
.  An increase in the band intensity ratio of the –CH-CH– peak (2900-3000 
cm
-1
) to –C=O band was seen in the copolymer spectrum compared to the control 
mixture.  The copolymer spectrum also exhibited stretches characteristic of both 
simvastatin and mPEG, with the carbonyl band at 1722 cm
-1
 and the methyl ether band of 
mPEG at 1096 cm
-1
.
129, 130
     
Mass loss and drug release of the disks in PBS and 1 M NaOH are shown in 
Figure 3.8.  Over the first two weeks, water uptake by the samples led to an average 
maximum mass four and three times the initial mass for incubation in PBS and NaOH, 
respectively.  The dry weights decreased 11 and 14% in the PBS and NaOH, respectively, 
during this time.  At 6 weeks, the wet masses were 102 and 68% of the initial mass for 
PBS and NaOH, respectively, and the dry masses were 13 and 21% lower.  The dry mass 
loss for the NaOH group had a larger mean decrease compared to samples in PBS, but the 
difference was not significant.  The cumulative drug amounts released were 108 and 266 
µg in PBS and NaOH, respectively.  After an initial burst of 59 µg in 24 hr, a zero-order 
release rate was observed in NaOH with a constant of 7.4 µg∙hr-1 between 1 and 10 days.  
A first-order release rate followed with a constant of 21 d
-1
 for the remainder of the 
degradation period.  In PBS, after an initial burst of 37 µg in 24 hr, only 2.5 µg was 
released during the following 8 days. A zero-order release constant of 2.1 µg∙d-1 was 
determined for the remainder of the degradation period.  The amounts of simvastatin 
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released in PBS and NaOH were significantly different at day 2 (p<0.05), day 3 (p<0.01), 
day 4 (p<0.001), and days 5 to 44 (p<0.0001). 
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Figure 3.7 FTIR spectra of: a) mPEG, b) simvastatin, c) simvastatin and mPEG blended 
at the same molar ratio used for the reaction (100:1), and d) poly(ethylene glycol)-block-
poly(simvastatin). 
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Figure 3.8 Degradation and drug release during incubation of samples in PBS or 1 M 
NaOH.  a) Wet mass loss, b) dry mass loss, and c) drug release.  Data are mean ± 
standard deviation.  
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Figure 3.9 Mass spectra of a) simvastatin, b) mPEG (5 kDa), c) low molecular weight 
degradation products, and d) high molecular weight degradation products. 
 
Mass spectral data identifying different species of degradation products are shown 
in Figure 3.9.  The mass spectrum of simvastatin (Figure 3.9a) shows a peak of the 
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highest abundance at 441 mass–to–charge ratio (m/z), simvastatin’s ion or the parent ion, 
and another distinct peak at 702 m/z.  The mPEG mass spectrum (Figure 3.9b) displayed 
a pattern of a bell-shaped distribution of peaks with the highest relative abundance at 
5207 m/z, which corresponds well with the theoretical molecular weight of the mPEG 
used for synthesis.  Within the low molecular weight spectrum of the degradation 
products released (Figure 3.9c), the 441 m/z peak is present along with a peak at 460 m/z 
among a multitude of distinct peaks ranging from 490 to 1062 m/z to the right of the 
parent ion and 385 to 430 m/z to the left.  In the high molecular weight spectrum of 
degradation products released, the highest relative ion abundance at 5312 m/z (Figure 
3.9d) and a similar but rightward shift in the distribution of peaks compared to mPEG.  
Although present, the abundance of the 441 and 460 m/z peaks were approximately 50, 
35, 60, 50, and 35% of the ions represented at a m/z of 402, 430, 551, 920, and 5312, 
respectively, the peaks of the highest relative abundance representing the degradation 
products. 
3.4 Discussion 
3.4.1 Copolymer Characteristics  
The molecular and therapeutic properties of simvastatin are desirable for 
investigating the synthesis of a novel degradable poly(ethylene glycol)-block-
poly(simvastatin) copolymer for its potential use in drug delivery.  Different derivatives 
of poly(ethylene glycol), which include mPEG, have been used as initiators for the 
synthesis of block copolymers due to their reactive hydroxyl end groups, 
biocompatibility, and ability to increase the solubility of hydrophobic counterparts.
131
  
Reacting simvastatin with mPEG via ROP can lead to a simple one-step synthesis of a 
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polyprodrug with unique characteristics.  The reaction takes advantage of simvastatin 
being a prodrug, changing its closed-ring form into monomeric units of its active 
hydroxyacid, the opened-ring form of simvastatin (Figure 3.1a).  The ester bond initially 
in the lactone ring of simvastatin would be embedded in the backbone of its polymer as a 
result of opening the ring.  Thus, polymer degradation and drug release would occur by 
the hydrolysis of labile ester bonds, allowing the copolymer to degrade into biomolecules 
of simvastatin hydroxyacid and mPEG (Figure 3.1b).  These components are metabolized 
in the liver and excreted by the kidneys, respectively.
132
   
 
3.4.2 Polymerization Mechanism 
Lactone-based molecules, such as glycolide, lactide, ε-caprolactone, and their 
combinations, have been used as monomers for the synthesis of PLGA, PLA, and other 
aliphatic polyesters.
133-135
  Like these molecules, simvastatin possesses a lactone moiety 
capable of chemically opening and developing into a polymer block by the ROP 
mechanism using stannous octoate, a well-known tin metal catalyst.  Aluminum and 
yttrium isopropoxide (metallic), porcine pancreatic and candida antartica lipases 
(enzymatic), and various carboxylic acids and amines in the presence of an alcohol 
(organic) have also been used as catalysts, which in turn dictate the ROP mechanism that 
occurs.
136
  The mechanism of stannous octoate is pseudo-anionic coordination-insertion 
ROP.
136, 137
  The metal catalyst first forms a complex with the hydroxyl group of the 
initiator to form an alkoxide.  The more reactive alkoxide begins chain propagation by 
coordinating with the lactone ring of the monomer, followed by “insertion” of the ring 
into the alkoxide’s metal-oxygen bond.136, 138  Throughout the process, the alkoxide acts 
as a nucleophile by attacking the carbon of the ring’s carbonyl group, leading to cleavage 
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of the acyl bond and extended chain formation with its end bonded to the alkoxide, which 
is otherwise known as a living polymerization.
138
  A 5 kDa mPEG was used in the 
synthesis of the present polymers so only one reactive hydroxyl group would be available 
for propagation of the poly(simvastatin) chain, creating a diblock copolymer.    
 
3.4.3 Kinetic Analysis   
It was necessary for simvastatin to be in a fluid-like state to ensure homogeneous 
mixing of all components.  This state was possible only above 138 °C,  the melting point 
of simvastatin
139
, hence the high temperature range chosen for conducting melt 
condensation reactions.  However, insignificant growth was seen for the lowest 
temperature reaction.  The same results were also seen for preliminary reactions 
attempted using tin (II) trifluoromethyl sulfonate, and lanthanum and aluminum 
isoproproxide at 150 °C and lipase b candida antarctica at 80 °C in toluene (data not 
shown).  Unlike glycolide and lactide, in which the cyclic lactone is their main structure, 
the lactone ring of simvastatin represents only a portion of the molecule.  The other 
aromatic moieties of simvastatin may interfere with opening the six-membered lactone 
ring.  Lactones of this size also have relatively lower ring strain than do smaller lactones, 
but their strain is still favorable for polymerization.
140
  This characteristic contrasts with 
the cyclohexane counterpart of the lactone ring of simvastatin that does not polymerize 
due to the stable chair conformation it assumes without the ester group present.
141
  Thus, 
minimal chain growth between 150 and 200 °C may be due to a combination of ring 
strain and steric hindrance resulting from the bulky side groups attached to the targeted 
lactone ring of simvastatin, contributing to a lower than necessary reactivity.   
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Evidently, the simvastatin to mPEG molar ratios present in the 240 and 250 °C 
reaction products exceeded the initial 1 to 100 molar ratio in the melt.  This finding may 
indicate low mPEG participation in the reaction and increased interactions between 
neighboring simvastatin molecules due to the higher weight percentage of the molecule 
within the bulk reaction mixture.  In addition to mPEG having a hydroxyl group able to 
serve as the active group for initiation, simvastatin also possesses a secondary hydroxyl 
group attached to its lactone ring, which was unprotected during these reactions.  
Secondary hydroxyl groups are less reactive than their primary counterparts.
142
  
Regardless, this available hydroxyl may have allowed chain propagation among the 
monomeric units to create extensively branched chains before interaction with mPEG to 
create the diblock copolymer.  Simvastatin would then be considered a bifunctional latent 
AB2 monomer capable of both initiating ROP, via the hydroxyl group on its lactone ring, 
and chain propagation through the opening of its lactone ring.
143, 144
  Mevalonolactone, a 
molecule structurally similar to simvastatin, has been used as a monomer for synthesizing 
branched copolymers.
144
  Bifunctionality of the monomer can lead to a dendrimeric 
architecture of the copolymer, and in this case, it can lead to the synthesis of linear–
hyperbranched mPEG–block–poly(simvastatin) copolymer chains fully capable of 
exceeding the initial 1 to 100 mPEG to simvastatin molar ratio, as more simvastatin 
monomers are added to the branched segments.  Also, because simvastatin would be able 
to compete with mPEG in initiating ROP and is in much greater abundance, more mPEG 
would likely remain unreacted, which is represented by the low Mn in Table 1.  The 
neighboring monomer interactions and branching may explain why the profiles strayed 
farther away from achieving a steady state as temperature increased within the given time 
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period.  Regardless, the propagation kinetics of the copolymer reaction exhibited first-
order rates, which is generally found to be the rate order of bulk ROP via insertion-
coordination initiators.
145
  By comparing the temperature-dependent rate constants as a 
function of temperature via the Arrhenius equation, 
 𝑘 = 𝑒−𝐸𝑎 𝑅𝑇⁄                                                                                                                                    (2)  
 
where k is the rate constant, R is the universal gas constant, and T is absolute temperature, 
an activation energy (Ea) of 14.5 kcal mole
-1 
was obtained.  The Ea found of the 
copolymer reaction is slightly lower but comparable to the activation energy of L-lactide 
undergoing ROP via insertion-coordination (19.6 kcal mole
-1
).
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The limited polymer growth below 200 °C indicates how propagation of the 
simvastatin chain was a more kinetically-driven reaction.  The occurrence of ring opening 
and subsequent propagation depends on the size of the lactone ring, the bulkiness of side 
groups attached to the ring, and the inclusion or lack of heteroatoms, all of which affect 
ring conformation.
138
  High ring strain increases lactone reactivity and largely contributes 
to the driving force for ROP.  Thus, ROP may result from the loss of enthalpy (H) caused 
by dissipated ring strain.  Even with cyclic monomers of low ring strain, heteroatoms 
present in the ring can increase the degrees of freedom of the resulting polymer, which 
increases the entropy (S) of the reaction and drives the reaction towards completion.
119
  
Also, depending on the reaction conditions used, such as the solvent and states of the 
monomer and its polymer (i.e., liquid, gas, or amorphous or crystalline solid), the 
monomer would be limited to:  a) polymerizing above a floor temperature (+ΔH and ΔS); 
b) polymerizing below a ceiling temperature (-ΔH and ΔS); c) polymerizing at any 
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temperature (-ΔH, +ΔS); or d) not polymerizing at all (+ΔH, -ΔS).147  The Mw growth 
data show an evident floor temperature with polymerization possible above 150 °C under 
the given the melt condensation conditions.  A more obvious indication of the reaction 
having a floor temperature relates to the high melting point of simvastatin and physical 
state necessary for the reaction to proceed.  Without solvent present in the reaction vessel, 
polymerization was limited to temperatures above 138 °C. 
 
3.4.4 Polydispersity   
Linear polymers made via ROP of lactone rings with low ring strain often have 
broader molecular weight distributions than those made from lactone rings with high 
strain, a major factor necessary for opening the ring and progressing the formation of a 
polymer chain.
138
  High PDIs may result from reactions such as transesterification, 
backbiting, or depolymerization.  These occurrences can be represented by PDIs up to a 
value of 2 by the Flory-Shultz distribution function.
147
  Even higher PDI values may 
represent nonlinear forms of polymerization (i.e., branching).  In the present studies, 
reactions above 200 °C produced higher PDIs, possibly from poly(simvastatin) branching 
considering that there was low mPEG participation in the reaction.  An increased 
occurrence of side reactions likely contributed to a portion of the synthesized crude 
copolymer due to substantially increased kinetic rates at high temperatures.  Although 
stannous octoate is an efficient catalyst, it is also known to promote transesterification
148
, 
which would only be exacerbated at higher temperatures.  Uncontrolled side reactions 
would in turn contribute to higher PDI values.   
The PDIs measured represent solely the copolymer peaks.  The baseline did not 
completely return back to its original intensity after the elution of the copolymer peak, 
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indicating that there was still a residual amount of intermediates and unreacted 
simvastatin remaining in the purified product sample.  Further removal would require an 
additional purification step in the procedure.   
 
3.4.5 NMR Analysis   
The chemical shifts labeled ‘g’ and ‘h’ in the copolymer spectrum represent the 
mPEG block,
149
 while the remaining labeled shifts relate to the poly(simvastatin) block.  
The broadened peaks that represent simvastatin up-field between 2.91 and 0.067 ppm 
indicate polymerization that has occurred to form the poly(simvastatin) block.  However, 
the integration ratio of the poly(simvastatin) area upfield (2.91 to .067) to the area 
downfield (7.22 to 6.71, ratio; 17.0) is far from 1, suggesting some sort of degradation or 
other form of conjugation that may have occurred due to the high temperature of the 
reaction.  The residual side products as a result may explain the shifts seen beyond 6.71 
ppm or it may be an artifact of the environment of copolymer’s proposed branched 
structure. 
 
3.4.6 Functional Groups and Bond Formation 
The carbonyl shift shown in the IR spectrum of the copolymer suggested new 
ester bond formation.  The change in height of the –CH-CH– stretch may be a 
representation of monomer addition (with a –C=O group) to the mPEG block (without a 
–C=O group).  Also, the copolymer spectrum showing peaks characteristic of both 
components indicated that a chemical bond between the two blocks occurred compared to 
the mixed control, which showed only peaks characteristic of simvastatin, regardless of 
the presence of mPEG. 
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3.4.7 Degradation  
The samples in PBS showed an increasing trend in percentage wet mass in the last 
3 weeks compared to those in NaOH.  An increase in surface area due to disk breakage, 
despite a minimal loss in dry mass, may have aided in an increased absorbance of 
medium.  The high water absorbance seen in both groups can also be explained by the 
presence of the hydrophilic mPEG block of the copolymer.  The initial burst and 
subsequent zero-order release observed may indicate small molecules of free simvastatin 
and oligosimvastatin close to the sample surface being easily dispersed into the medium 
with the aid of water absorption by mPEG.  The first-order rate seen in the NaOH group 
may be influenced by the existing concentration of simvastatin in medium or by the 
scission process in which poly(simvastatin) breaks down into simvastatin, which is only 
then detectable in solution.  Even though 108 to 266 µg of simvastatin were released 
from the samples during a 6 week period, release of other degradation byproducts, some 
of which do not have maximum absorption at 240 nm, would account for the remaining 
mass loss measured.   
Degradation of the copolymer is expected to occur by the hydrolysis of labile 
ester bonds in the polymer chains.  In alkaline solutions, simvastatin is also known to 
hydrolyze into its active open-ring form, simvastatin α-hydroxyacid.150  The simvastatin 
hydroxyacid may be included in the components resulting from breakdown, along with 
byproducts that may include oligosimvastatin chains, mPEG, and mPEG with minimal 
monomers of simvastatin attached.  The hypothesized byproducts are based on the 
presence of ester bonds that would be present between the monomeric units and between 
the block components.  The degradation process and products of other polyesters, such as 
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PLGA, have been well-documented in identifying soluble oligomers that then degrade 
into the final products of lactic and glycolic acid in abiotic conditions.
151
 
 The mass spectra of the low molecular weight degradation products showed m/z 
values of 441 and 460, indicating the presence of simvastatin in its closed and open ring 
forms, respectively.  The m/z values for simvastatin and simvastatin hydroxyacid have 
most likely been influenced by salt adducts in the analytes (i.e. Na
+
, K
+
, and H
+
) because 
the ions are produced by cationization.
152
  Salt adducts can be produced from any  salts 
present within the sample, such as the PBS to which degradation products and 
simvastatin and mPEG controls were exposed before prepping the samples for MS 
analysis.  Despite desalting the final sample solutions, a small amount of the salts 
remained present for detection but not nearly enough to inhibit the generation of a clear 
and readable spectrum.  However, salt detection can still contribute to decreased 
ionization efficiency, which possibly influenced the increased baseline noise seen in the 
low molecular weight region, along with low concentration.   
A parent ion value of 441 m/z is likely the result of an attachment of Na
+
 (22 m/z) 
to the parent ion (419 m/z).  A simvastatin hydroxyacid ion would gain a molar mass 
value of 18 due to hydrolysis, leading to an m/z value of 460, seen in the spectrum, if the 
salt adduct is the same as the one on the parent ion and the H
+
 ion also attached.  The 
lower value peaks may represent a combination of fragmented ions of simvastatin,
153
 the 
CHCA matrix (189 m/z), and salt adducts present in the sample.  The same indication 
holds true for the peaks ranging from 490 to 693 m/z and the peak at 702 m/z in 
simvastatin’s spectrum, along with the incorporation of ion clusters produced from the 
matrix
154
 (i.e., molecule (M): 2M+Na
+
 and 2M+H
+
; 379 and 401 m/z, respectively) and 
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the parent ion.  The peaks of 920 and 1062 may incorporate dimer ions of simvastatin 
along with the other combinations previously mentioned.   
The pattern of peaks seen in the mPEG mass spectrum represents the repeating –
CH2CH2O– unit of the polymer.  The rightward shift in peak distribution seen in the high 
molecular weight degradation products indicates simvastatin monomers remaining 
attached to the mPEG block.  Salt adducts and the presence of complex ions can lead to 
less defined peaks otherwise seen as a rise in the baseline under the peaks of the high 
molecular weight products.  Thus, the mass spectral data suggests that the supernatants 
collected from the degrading copolymer contained a broad distribution of degradation 
products, including simvastatin, simvastatin hydroxyacid, dimerized simvastatin, mPEG, 
and mPEG with simvastatin monomers attached, some of which are possibly branched.  
Despite the possibility of a branched architecture being known to accelerate 
degradation rates because of an increased number of end-groups present per polymer 
chain
63
 and the large amount of water uptake of the samples within a 6 week period, 
limited degradation and slow simvastatin release rates were still seen within neutral and 
alkaline environments.  This effect was attributed to the slow cleavage rate of bonded 
simvastatin monomers being the limiting factor and/or possible side reactions during 
polymerization leading to less labile bonds.  Thus, investigating methods to improve the 
synthesis procedure to better control the ROP reaction would be beneficial in minimizing 
the side reaction byproducts produced in the crude copolymer. 
3.5 Conclusions 
A degradable poly(ethylene glycol)-block-poly(simvastatin) copolymer can be 
useful as a polymeric drug delivery system.  The poly(simvastatin) block formed at and 
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above 200 °C, showing potential for increasing the weight percentage of the prodrug in 
the biomaterial.  ROP of simvastatin reveals a new approach for polymerizing prodrugs 
in the statin family and possibly in other classes of lactone-containing prodrugs that may 
have less steric hindrance.  Less bulkiness could provide better chain propagation at more 
ambient reaction conditions.  The minimal synthesis steps of ROP needed to polymerize 
prodrugs, such as simvastatin, can be desirable in scaled-up production.  Although Mw 
increased with temperature and initial degradation was observed, the rate of bond 
cleavage between simvastatin monomers and possible byproducts from side reactions 
hindered mass loss and subsequent drug release.  Despite slow degradation, release of 
open and closed-ring simvastatin as well as simvastatin in poly(oligo)meric forms was 
demonstrated.  By minimizing the side reactions, degradability of the mPEG-
poly(simvastatin) diblock copolymer could be improved, potentially providing sufficient 
concentrations of simvastatin for extended treatment periods.  
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Ch. 4 Tuning Properties of Poly(ethylene glycol)-block-
poly(simvastatin) Copolymers Synthesized via 
Triazabicyclodecene 
 
This chapter was reproduced from a manuscript accepted for publication, “Asafo-Adjei 
T.A., T.D. Dziubla, D.A. Puleo, Tuning Properties of Poly(ethylene glycol)-block-
poly(simvastatin) Copolymers Synthesized via Triazabicyclodecene, (2017), Reactive 
and Functional Polymers.” 
 
4.1 Introduction 
 
A wide range of catalysts with different mechanisms of action have been used to 
synthesize degradable polyesters for biomedical applications.  Common catalysts that 
mediate ring-opening polymerization (ROP) of lactone-incorporated monomers include 
tin (II) ethyl-hexanoate (stannous octoate) and other organotin compounds.
29
  Aluminum-
, lanthanum-, and zinc-based alkoxides have also been used in the synthesis of high 
molecular weight (MW) poly(lactic acid) (PLA), poly(lactic-co-glycolic acid), and 
poly(ε-caprolactone). 29, 31, 155  
Stannous octoate and other metal and alkaline earth catalysts are known to be 
efficient 
148
, while enzymatic, acidic, and organic catalysts have reportedly shown lower 
reactivity, producing low MW polymers.
29, 156
  Catalyst reactivity, however, can be 
altered by modifying reaction conditions, the type or size of lactone monomer 
incorporated into the feed, or functional groups of these catalysts.  For example, changing 
the diamine bridge of aluminum salen complexes from ethylene to dimethylpropylene led 
to significantly increased polymerization rates of small L-lactide, ε-caprolactone, ε-
decalactone, and β-butyrolactone monomers, while low reactivities with ω-
pentadecalactone and other macrolactones were not significantly affected.
157
  Also, ROP 
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reactions with diazabicycloundecene and N-methylated triazabicyclodecene (TBD) 
organocatalysts generated polylactide MWs of 18 and 21 kDa, respectively, in the 
presence of pyrenebutanol in chloroform under optimized conditions. 
54
  The type of 
catalyst used under specific reaction conditions can affect the degree of polymerization 
and the resulting quality of the polymer synthesized. 
In our previous studies, stannous octoate-mediated coordination-insertion ROP 
was used to synthesize a newly developed poly(simvastatin)-poly(ethylene glycol) 
diblock copolymer with potential anti-inflammatory, angiogenic, and osteogenic 
properties following degradation.  While the catalyst was successful in mediating 
poly(simvastatin) propagation with a methyl-terminated poly(ethylene glycol) (mPEG) 
initiator, a narrow and high reaction temperature window served as a limitation that also 
promoted undesirable transesterification reactions.  After preliminary attempts with other 
metal and organocatalysts, TBD was ultimately selected because of its efficient 
performance at ambient temperatures,
54
 ability to work without a co-catalyst, metal-free 
process, and accessibility.   TBD was also reported to rapidly catalyze synthesis of 26 
kDa PLA, of which the MW could be modified by changing the molar ratio of initiator to 
monomer  in the feed.
158
 
In the present study, the TBD-mediated poly(simvastatin) reaction was compared 
with the stannous octoate-mediated reaction under similar conditions.  Polymerization via 
TBD was also evaluated with different MW mPEGs, catalyst percentages, and molar 
ratios of simvastatin to mPEG.  Hydrolytic degradation of the resulting poly(ethylene 
glycol)-block-poly(simvastatin) (PSIM-mPEG) copolymers was also analyzed by 
measuring mass loss and drug release.   
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4.2 Experimental 
4.2.1 Materials 
Simvastatin was purchased from Haorui Pharma-Chem (Edison, NJ).  
Triazabicyclodecene, monomethyl ether poly(ethylene glycol) (mPEG), anhydrous 
toluene, anhydrous diethyl ether, dichloromethane (DCM), and deuterated chloroform 
(CDCl3) were obtained from Sigma-Aldrich (St. Louis, MO).  Tetrahydrofuran (THF) 
stabilized with 3,5-di-tert-butyl-4-hydroxytoluene (BHT) was procured from Fisher 
Scientific (Pittsburgh, PA).  
4.2.2 Methods 
4.2.2.1 Synthesis of poly(ethylene glycol)-block-poly(simvastatin). Microscale 
Microscale reactions of PSIM-mPEG using stannous octoate have been previously 
described.
159
  Macroscale reactions (2 g) were conducted using simvastatin as the 
monomer and mPEG (550, 2000, or 5000 Da) as the initiator.  Molar ratios of 100:2 for 
simvastatin to mPEG 550, and 100:1 for simvastatin to mPEG 2000 or 5000 Da were 
used in the feed to synthesize PSIM-mPEG(550), PSIM-mPEG(2k), and PSIM-
mPEG(5k), respectively.   Simvastatin and mPEG were dried in a round bottom flask 
embedded in a silica sand bath at 120 ºC for 1 hr under a continuous flow of nitrogen gas.  
The internal bulk temperature was increased to 150 ºC for an additional hour before 
adding 1 wt% of TBD to the homogeneous melt.  Each reaction ran for 24 hr.   
Microscale reactions (0.4 g) were also conducted for PSIM-mPEG(550) 
copolymers with a TBD catalyst percentage of 0.1 or 1 wt%, a 100:1, 100:2 or 100:10 
simvastatin to mPEG molar ratio, and crude samples taken at 0, 4, 12, 18, or 24 hr 
reaction times.   
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Polymer dissolved in DCM was slowly added to cold diethyl ether at a 1:7 v/v 
ratio of DCM to ether and vacuum filtered to purify the crude PSIM-mPEG(5k) product,.  
The purification process for PSIM copolymers with lower MW mPEG blocks involved 
slowly adding cold diethyl ether to the polymer in DCM solution at a 1:20 v/v ratio, 
followed by centrifugation and decantation of the supernatant. 
4.2.2.2 Gel Permeation Chromatography (GPC).  A Shimadzu Prominence LC-20 AB 
HPLC system connected to a Waters 2410 refractive index detector was used to measure 
the weight-average molecular weights of simvastatin, mPEG (550, 2000, and 5000 Da), 
and the crude PSIM copolymers. Two Resipore columns in series (300 x 7.5 mm, 3 µm 
particle size; Agilent Technologies) were used for separation.  Samples were dissolved in 
THF at 5 to 10 mg/ml.  THF was also used as the mobile phase at a 1.0 ml/min flow rate.  
Polystyrene standards were used to calculate MW ranged from 160 Da to 430 kDa.   
4.2.2.3 Nuclear Magnetic Resonance (NMR) Spectroscopy.  H-NMR spectra were 
obtained to characterize the PSIM-mPEG (5k) copolymer and a melted mixture of 
simvastatin and mPEG at a 100:1 molar ratio using a 400 MHz Varian Gemini NMR 
instrument connected to a VnmrJ software interface.  Samples weighing 5 to 7 mg each 
were dissolved in 1 ml of CDCl3, transferred into NMR tubes, and analyzed for additional 
structural characterization.   The number of simvastatin monomers present in the diblock 
copolymer was calculated by integrating the area under the peaks representing 
simvastatin relative to those associated with 5 kDa mPEG, of which the number of H 
atoms in its structure was known.  With this ratio, the number of protons in the 
poly(simvastatin) block of the copolymer was calculated and divided by the known 
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number of protons in simvastatin to get the number of simvastatin monomers in the 
diblock copolymer. 
4.2.2.4 Matrix-Assisted Laser Desorption/Ionization – Time of Flight Mass 
Spectrometry (MALDI–TOF MS). Degradation products of PSIM-mPEG(5k) were 
analyzed using a positive ion mode Bruker Ultraflextreme MALDI-TOFMS.  The 
procedure used for sample analysis was previously described.
159
  
4.2.2.5 In Vitro Degradation.  Films of each copolymer (10-15 mg) were made by 
adding a small amount of DCM to polymer to create a viscous solution (700% w/v) that 
was pipetted onto a Teflon sheet to dry overnight.  Each film was gently shaken in 1.5 ml 
of phosphate-buffered saline (PBS), pH 7.4, at 37 ºC.  Supernatant was collected and the 
medium completely replaced every 12 hr the first day, every other day the first week, and 
at 2 to 5 d for the remainder of the 44 d degradation period.  The remaining samples were 
dried and weighed after 6 weeks to measure total mass loss.  
4.2.2.6 High Performance Liquid Chromatography (HPLC).  A Shimadzu Prominence 
LC-20 AB HPLC system was used to analyze supernatants collected from the mass loss 
study.  One Luna C18 column (150 x 4.60 mm, 5 µm particle size) was used with an 
isocratic mobile phase of acetonitrile and water with 0.1% trifluoroacetic acid (70:30 
v/v).  Absorbance was measured at 240 nm. 
4.2.2.7 Statistical Analysis.  Two-way ANOVA with a Bonferroni post-test was 
performed on the kinetic data to test effects of reaction time, catalyst percentage, and 
molar ratio on MW, yield, and percent composition of the copolymer.  The same analysis 
was applied to the simvastatin amounts released during copolymer degradation.  Values 
66 
 
of p≤0.05 were deemed statistically significant.  Data are plotted as mean and standard 
deviation. 
4.3 Results and Discussion 
4.3.1 Polymerization Mechanism 
The ROP mechanism governed by TBD is anionic.   From the literature, one 
theorized mechanism suggests that the amidine imine nitrogen of the nucleophilic 
catalyst attacks the carbonyl group on the lactone ring of simvastatin to form a temporary 
intermediate as the acyl bond is broken.  The secondary amine in the guanidine-based 
organocatalyst attracts the alcohols within the reaction mixture (i.e., both on mPEG and 
the propagating poly(simvastatin) block) via hydrogen bonding.  This action propagates 
the PSIM block of the PSIM-mPEG diblock copolymer.
158
  However, computational 
analysis comparing the transitional state energies of proposed TBD-mediated ROP 
reactions with L-lactide and methanol showed that the intermediate steps carried out via 
hydrogen bonding had lower energy transitional states compared to nucleophilic 
attraction throughout the reaction.  The lower energy states due to hydrogen bonding 
indicated a relatively more stable mechanism.
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In the proposed mechanism shown in Figure 4.1, the amidine imine nitrogen of 
TBD attracts the hydrogen on the alcohol, in this case mPEG, to activate it. The activated 
alcohol then attacks the carbon of the carbonyl group of the lactone ring of simvastatin.  
The catalyst then changes orientation, subsequently hydrogen bonding to the oxygen in 
the C–O bond in the lactone ring, while the secondary amine remains hydrogen bonded to 
the oxygen in the carbonyl group.  This transitional state initiates opening of the lactone 
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ring.  TBD is reformed after the hydrogen migrates away from the amidine imine to form 
the hydroxyl end-group of the propagating polymer. 
160
 
 
 
 
Figure 4.1. ROP mechanism using TBD catalyst via hydrogen bonding. 
 
4.4.2 Stannous Octoate vs. TBD Catalyst Mediated Reactions 
The mole percentages of simvastatin, intermediates, and copolymer throughout 
the reaction using stannous octoate or TBD as a catalyst are displayed in Figure 4.2.  
Within 24 hr, a decrease in simvastatin monomer was observed at a conversion rate of 
0.052 hr
-1
 with 27.2% of simvastatin remaining when using TBD as a catalyst at 150 ˚C.  
In contrast, stannous octoate did not lead to monomer conversion at this temperature.  At 
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200 and 230 ˚C, however, stannous octoate catalyzed rapid conversion, at 0.179 and 
0.351 hr
-1
, respectively, 3 and 7 times the rate for TBD.  Total monomer consumption 
was reached at 12 and 8 hr for the stannous octoate mediated reactions at 200 and 230 ˚C, 
respectively. 
 
   
  
 
 
 
 Figure 4.2 GPC measurements of the percentages of copolymer, intermediates, and 
simvastatin monomer throughout the reactions in the crude products of a) PSIM-
mPEG(5k) synthesized via TBD at 150 ºC, b) PSIM-mPEG(5k) synthesized via stannous 
at 150 ºC, c) PSIM-mPEG(5k) synthesized via stannous at 200 ºC, and d) PSIM-
mPEG(5k) synthesized via stannous at 230 ºC. 
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The degree of polymerization achieved by an ROP reaction is greatly influenced 
by the nature of the catalyst, cyclic monomer, or alcohol incorporated in the feed.  
Stannous octoate has the necessary electrophilic qualities possessed by its metal cation 
center, and it gains nucleophilic properties once formed into an alkoxide, becoming a 
stereoselective catalyst in the mediation of ROP.  The newly formed tin alkoxide is 
subsequently attracted to the carbon of the lactone carbonyl group and cleaves the lactone 
ring of the monomer at the acyl bond, propagating the polymer chain via a pseudo-
anionic coordination-insertion ROP mechanism.  However, stannous octoate is a much 
larger molecule than TBD with a MW of 405 Da, three times that of TBD at 139 Da 
(Figure 4.3).  After forming a complex with the alcohol, or 5 kDa mPEG, the resulting 
metal alkoxide complex becomes even larger. 
 
 
 
Figure 4.3 Structures of stannous octoate and TBD catalysts used in the ROP of PSIM. 
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TBD is highly basic (pKa 26) and requires no cocatalyst, such as thiourea, in the 
ring-opening of cyclic esters, compared to some of its monocyclic phosphazene, amidine, 
and guanidine counterparts.  The bicyclic structure of TBD also has two active nitrogen 
centers that allow for electrophilic and nucleophilic bifunctionality, activating 
simvastatin’s lactone ring and the hydroxyl group of the mPEG initiator, respectively, via 
hydrogen bonding.
161, 162
  This bifunctionality removes a possible limiting step otherwise 
necessary for stannous octoate to form an alkoxide in order to initiate polymerization.  
These advantageous characteristics associated with the smaller and less sterically 
hindered structure may give TBD relatively heightened sensitivity, selectivity, and ease 
in mediating ROP with mPEG and simvastatin at a lower temperature.  These 
characteristics may also explain why TBD was able to catalyze a ROP reaction of PSIM 
at 150 ˚C, where stannous octoate was unsuccessful.  TBD-mediated reactions were also 
carried out at internal temperatures lower than 150 ºC (results not shown). Those 
reactions, however, did not produce significant polymerization, showing that the window 
for polymerization is still small, but still with a lower temperature threshold than would 
be necessary for stannous octoate to polymerize simvastatin. 
Monomer conversion increased with reaction temperature when catalyzed by 
stannous octoate. Even after total monomer consumption, however, the polymer 
composition in the crude product continued to increase as the relative percentage of 
intermediates declined, suggesting an addition of intermediate products to the copolymer 
structure after monomer consumption.  This may be due to the secondary hydroxyl group 
on the simvastatin lactone ring acting as another reactive site, potentially forming 
71 
 
intermediates of dimers and small oligomers that are subsequently incorporated into the 
copolymer. 
4.3.3 NMR and mass spectrometry of PSIM-mPEG (5k) via TBD 
H-NMR was performed to further support the MW of PSIM-mPEG(5k) measured 
via GPC.  As seen in the control of Figure 4.4a, the chemical shifts represented by r, s, 
and t (4.21, 3.71, and 3.48 ppm) represent mPEG within the mixture.  Simvastatin was 
identified by the remaining chemical shifts within the spectrum.  Seventeen simvastatin 
monomers were calculated to be incorporated into the PSIM-mPEG(5k) copolymer 
sample tested, leading to a MW of 12 kDa.   
In the NMR control spectrum, the repeating ethylene oxide unit of mPEG is 
represented by the chemical shift at 3.71 ppm, and the hydroxyl and methyl oxide groups 
of the polymer block are represented by the 4.21 and 3.48 ppm chemical shifts, 
respectively.  The disappearance of the 4.21 ppm chemical shift in the copolymer 
spectrum reflects incorporation of the mPEG hydroxyl moiety into the copolymer 
backbone after initiation.  The absence or shift change of e and f, which represent the 
lactone ring (Figure 4.4a) in the copolymer spectrum reflect a change in the lactone 
structure or molecular environment as a result of ROP.  The broadened peaks in Figure 
4.4b indicate synthesis of a polymerized form of simvastatin.  Broadening of the base of 
the peaks was observed between 5.38 to 6.05 ppm, with letters a through d representing 
more aromatic portions of the simvastatin monomers.  
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Figure 4.4 H-NMR spectra of a) a 100:1 mixed control of simvastatin and mPEG and b) 
the PSIM-mPEG(5k) copolymer synthesized via TBD.  Figure 3a was reproduced from 
Ref. 9 with permission from the Royal Society of Chemistry.  
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Figure 4.5 displays the mass-to-charge ratio (m/z) spectra of PSIM-mPEG(5k) 
degradation products.  The inset in Figure 4.5a shows simvastatin represented by the 
parent ion of 441 m/z.  The low MW degradation product spectrum (Figure 4.5a) 
contained multiple peaks close to that of simvastatin at 404, 422, 439, 457, and 480 m/z, 
but the intensities were low relative to the peak of highest abundance at 522 m/z.  To the 
right of the most abundant species, a multitude of smaller peaks was seen, ranging from 
540 to 957 m/z.   
In the mass spectra of low MW degradation products, the 404 m/z peak represents 
fragmented simvastatin.  The 422 to 480 m/z peaks, alongside the peak of highest relative 
abundance at 522 m/z, reflect open or closed-ring simvastatin in the presence of a 
combination of salt adducts remaining from the PBS (i.e., Na
+
, K
+
, and H
+
) used to carry 
out polymer degradation.  The alpha-cyano-4-hydroxycinnamic acid (CHCA) matrix (189 
m/z) used in the analysis may also contribute to the m/z values.  Peaks ranging from 540 
to 957 m/z indicate the presence of simvastatin dimers and combined salt adducts or 
matrix in the degradation products. 
In the spectrum of the higher MW degradation products (Figure 4.5b), a wide 
distribution was observed, with the highest relative abundance at 5561 m/z. The most 
prevalent peak was slightly higher than the theoretical average MW of the 5 kDa mPEG 
polymer used as an initiator in the synthesis of the PSIM-mPEG copolymer.  The base of 
peaks representing the higher MW degradation products was broadened compared to the 
sharp and distinct peaks seen in the mPEG control (Figure 4b inset), indicating the varied 
distribution of complex ions present in this m/z range, possibly representing mPEG and 
mPEG with attached simvastatin monomer degradation products. 
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Figure 4.5 Mass spectra of a) low MW PSIM-mPEG(5k) degradation products compared 
to simvastatin control and b) high MW PSIM-mPEG(5k) degradation products compared 
to mPEG control. Insets of controls in Figure 2a and 2b were reproduced from Ref. 9 
with permission from the Royal Society of Chemistry. 
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4.3.4 Poly(simvastatin) Copolymer Synthesis using Different mPEGs 
Chromatograms of purified PSIM-mPEG copolymers initiated with 5k, 2k, or 550 
Da mPEG and catalyzed via TBD are shown along with their respective reactants in 
Figure 4.6.  The resulting weight-average MW of PSIM-mPEG(5k), PSIM-mPEG(2k), 
and PSIM-mPEG(550) copolymers synthesized were 15, 13, and 20 kDa, respectively, 
with polydispersity indexes (PDIs) of 2.1, 2.2 and 2.5, respectively.   The mPEG 
initiators with theoretical MWs of 5 and 2 kDa were measured to have slightly higher 
MW values of 7.4 and 2.5 kDa via GPC, while the 550 Da mPEG and simvastatin 
registered lower MW values of 0.4 and 0.2 kDa, respectively.  ROP reactions with 5k 
mPEG led to successful simvastatin polymerization when mediated by stannous octoate.  
With 2k and 550 Da mPEG, however, polymerization reactions were not successful when 
mediated by stannous octoate or other selected catalysts, such as lanthanum isopropoxide, 
aluminum isopropoxide, tin triflate, lipase B from Candida antarctica, HCl∙EtO2, 
potassium methoxide (KOMe), 1,3-dimesitylimidazol-2-ylidene (IMes), and 
diazabicycloundecene (DBU) under varied reaction conditions (results not shown).   
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Figure 4.6 GPC chromatograms of poly(simvastatin) synthesized via TBD using a) 
5kDa, b) 2kDa, and c) 550 Da mPEG initiators compared with reactants. 
 
TBD successfully catalyzed the synthesis of PSIM-mPEG copolymers using 5k, 
2k, and 550 Da mPEG as initiators at 150 ˚C in melt conditions, possibly as a result of 
high reactivity combined with less steric hindrance due to its small molecular size.  The 
poor performance of stannous octoate in the same conditions possibly indicated steric 
hindrance between the catalyst and the simvastatin structure and hindered catalyst 
stereoselectivity.   
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4.3.5 Kinetics 
Based on the copolymer and mPEG MWs measured via GPC, the PSIM 
copolymer initiated with the lowest MW mPEG had the highest percentage of simvastatin 
incorporated in the copolymer at 98%.  PSIM-mPEG(2k) and PSIM-mPEG(5k) had 80 
and 51% of drug incorporated, respectively.  Percent yields of the three copolymers 
exhibited an opposite trend, however, with the 550 Da mPEG-initiated copolymer having 
the lowest yield, which increased as the MW of the mPEG block increased (Table 4.1).  
This trend may be due in part to the decreased solubility of mPEG in ether as its MW 
increases. 
Table 4.1. GPC measurement of simvastatin and mPEG composition in copolymers 
 
Copolymer Molar 
ratio 
  Percent of 
sim in 
copolymer 
# of sim 
monomers 
per mPEG 
initiator 
Percent 
yield 
Percent of 
mPEG in 
copolymer 
PSIM-
mPEG 5k 
100:1   51 39 ~17 to 
30% 
 
49 
PSIM-
mPEG 2k 
100:1   80 52  ~13% 20 
PSIM-
mPEG 550 
100:2   98 96 ~2% 2 
 
 
The initial MWs measured for the three PSIM copolymers were significantly 
different (p<0.0001) due to the MW differences of the mPEG initiators used for each 
reaction (Figure 4.7a).  The MW of the PSIM-mPEG(5k) copolymer remained 
significantly greater than for the other two copolymers throughout the reaction 
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(p<0.0001).  PSIM-mPEG(2k) also had a significantly greater MW than PSIM-
mPEG(550) did after 12 and 18 hr (p<0.001) and 24 hr (p<0.0001). 
The difference between the initial and highest weight-average MW reached 
throughout the reaction, which correlates with the number of simvastatin monomers 
attached, was greatest for the 550 Da mPEG initiator. This difference decreased as MW 
of the mPEG initiator increased. The trend was further reflected by the rates of 
polymerization throughout the 24 hr reaction period.  Within the first 4 hr, the PSIM-
mPEG(550) reaction had the greatest change in MW, increasing by 5 kDa and plateauing 
at approximately 6.1 kDa for the remainder of the reaction period.   PSIM-mPEG(5k) had 
the smallest change in MW growth in the first 4 hr, and the slowest first-order 
polymerization rate of 0.021 h
-1
 for 18 hr before undergoing a MW decrease from 13.4 to 
12.6 kDa.  The PSIM-mPEG(2k) reaction showed a smaller 4 hr MW change and had a 
lower polymerization rate than PSIM-mPEG(5k) did, but its rate was higher than for the 
PSIM-mPEG(550) reaction.  The total MW increase achieved was 6 kDa at a rate of 
0.037 h
-1
.  From initial MWs of 0.67, 3, and 9 kDa, copolymer MWs of 5.8, 9, and 13 
kDa were achieved for PSIM–mPEG(550), PSIM-mPEG(2k), and PSIM-mPEG(5k), 
respectively.   
 Although the differences in MW growth within the first 4 hr were not significant 
in Figure 4.7b, there was a noticeably greater change observed for the reaction initiated 
with a 100:10 ratio of simvastatin to 550 Da mPEG.  Unexpectedly, reactions with the 
smaller amounts of 550 Da mPEG (100:1 and 100:2 molar ratios of simvastatin to 
mPEG) achieved lower MWs after 4 hr (p<0.0001 and p<0.001, respectively) compared 
to the feed containing the most mPEG (100:10 sim to mPEG).  The MW obtained from 
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the 100:1 molar ratio feed remained significantly lower than the others after 12 
(p<0.001), 18, and 24 hr (p<0.0001).  The 100:2 molar ratio feed generated a 
significantly lower MW than only the 100:10 feed after 4 hr (p<0.001). 
The 100:1 and 100:10 sim to 550 Da mPEG molar ratios with the smallest amount 
of catalyst resulted in the greatest MW growth (Figure 4.7c) when comparing the effects 
of different molar ratios and weight percentages of TBD.  MW growth was statistically 
insignificant in the 100:10 melt with 0.2 wt% TBD during the first 4 hr.  Despite the 
initial lag, the polymerization rate during the first 12 hr was 0.221 hr
-1
, leading to an 8.3 
kDa crude copolymer.  In the last 12 hr, the rate decreased to 0.008 hr
-1
, resulting in a 9.1 
kDa crude copolymer product formed.  In the 100:1 melt with 0.2 wt% TBD, a 5.1 kDa 
MW was formed during the first 4 hr, followed by a 0.026 h
-1
 rate for the remainder of 
the reaction to yield a 9.9 kDa polymer. MW differences between the two ratios at 0.2 
wt% were insignificant after 4 hr.  Reactions with 1 wt% TBD were completed within 4 
hr.  Upon completion, however, MWs plateaued at lower values than their counterparts 
did with 0.2 wt% TBD, which were 8.4 and 6.1 kDa for the 100:10 and 100:1 molar ratio 
feeds, respectively.  The final MWs were 8.5 and 5.8 kDa for the 100:10 and 100:1 molar 
ratio feeds, respectively.  The 100:2 melt with 1 wt% TBD reached a MW of 6.9 kDa 
within the first 4 hr and had a first-order rate of 0.011 h
-1
 for the rest of the reaction 
period, resulting in an 8.5 kDa crude product. 
Due to the low yield of PSIM-mPEG(550), the amount of catalyst and molar 
ratios of monomer to initiator were modified to improve yield and the degree of 
polymerization.  The kinetics of the PSIM-mPEG(2k) and PSIM-mPEG(5k) copolymers 
were also monitored over a 24 hr period.  The slower rate of polymerization as the MW 
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of the mPEG initiator increased suggests that the larger mPEG molecules provided 
greater steric hindrance.  The computational analysis of Chuma et al. showed that 
alcohols with bulky, more sterically hindering side groups increase the potential for 
destabilizing the transition state needed to initiate and continue polymerization.
160
  
Although mPEG does not have bulky side groups, this reasoning could apply to the 
mPEG size and resulting conformations it assumes in the melt. 
The majority of MW growth of PSIM-mPEG(550) synthesized with 1 wt% TBD 
was complete within 4 hr, which plateaued for the remainder of the 24 hr reaction period.  
This may be explained by the rapidly reactive nature of TBD.  At 0.1 mol%, TBD was 
shown to fully polymerize lactic acid into PLA in 1 min.
54
  Also, a 6 d polymerization 
reaction with cyclic trimethylene carbonate, carried out by MTBD, a guanidine 
equivalent of TBD, was shown to be complete in a significantly shorter time of 15 min 
when mediated by TBD.
162, 163
  TBD is known to be the most basic of its “superbase” 
counterparts, resulting in polymerization rates that almost equal those catalyzed by N-
heterocyclic carbenes, which can take seconds to complete a reaction. Future potential 
avenues could investigate the kinetics of TBD-mediated PSIM copolymer reactions in a 
shorter time period for more precise polymerization rates within the 4 hr period. 
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Figure 4.7 MW growth kinetics for PSIM-mPEG copolymers synthesized with:  a) 
different mPEG MWs with 1 wt% TBD, b) different molar ratios of simvastatin to mPEG 
(550 Da), and c) two different amounts of catalyst at two different molar ratios. 
 
 
Opposing relationships between catalyst concentration and molecular weight of 
various polymers have been presented in literature.
156, 164, 165
  One of these investigations 
includes the analysis of trioxane monomer to p-chlorophenyldiazonium 
hexafluorophosphate catalyst molar ratios ranging from 5,000 to 20,000.  At ratios up to 
8,000, the resulting polymer molecular weight was inversely proportional to catalyst 
concentration, reaching maximum MW values.  As the catalyst concentration continued 
to decrease with monomer to catalyst ratios between 8,000 and 20,000, the relationship to 
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polymer molecular weight became directly proportional.
164
  A range of different initiator 
concentrations tested with trioxane had no effect on the resulting poly(trioxane) MW in 
melt conditions, but the same range explored in solution caused a decrease in MW as the 
initiator concentration increased.
165
  The type of catalyst used can also influence the 
relationship between catalyst concentration and MW.  Increasing concentrations of 
catalysts such as sulfuric acid and titanium (IV) butylate were shown to mediate synthesis 
of lower molecular weight poly(lactic acid) during polycondensation of L-lactide.
156
  A 
similar inverse relationship was seen in the present studies where polymerization rates 
and resulting MWs of PSIM-mPEG(550) reactions increased as the TBD catalyst weight 
percentage decreased.  This relationship may result from the chosen catalyst to reactant 
ratios leading to reactions above or below a specific energy threshold, where the 
relationship between simvastatin monomer and TBD catalyst is inversely proportional. 
Mechanistically, increasing the catalyst content between 0.2 and 1 wt% may contribute to 
an increase of chain transfer reactions mediated by the catalyst, where the hydroxyl 
terminal end group of a propagating chain, activated by the TBD catalyst, may attack the 
ester group within the backbone of another neighboring or growing chain.
166
 This action 
can lead to a decrease in MW of the polymer chain and, ultimately, a reduced weight-
average MW. 
An increased monomer to initiator ratio typically results in greater MW because 
fewer initiation sites are present, which leads to longer polymer chains at high monomer 
conversion. An example of this occurrence is seen with the ROP of ε-caprolactone using 
a calcium methoxide catalyst, which increased the resulting poly(ε-caprolactone) MW 
from 5 to 11.4 kDa at 100% conversion as monomer/initiator ratio increased from 20 to 
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100.
167
   While this trend was maintained in PSIM-mPEG(550) crude products with 0.2 
wt% TBD, the resulting MW decreased as the initial simvastatin to 550 Da mPEG 
initiator ratio increased using 1 wt% TBD.  This unexpected latter observation may be 
influenced by low monomer conversion in the crude product for the most hydrophobic 
copolymer, which partially explains its low yield.  Increasing the initiator present in the 
melt (i.e., lowering the monomer to initiator ratio) provides more initiator sites for 
potential polymer propagation.   Even though this would lead to shorter chains or a lower 
MW polymer at nearly 100% conversion, the crude products show monomer conversion 
is still far from complete.  At this stage, a larger number of chains present compared to 
the remaining monomer in the crude may exert a greater influence on the overall average 
MW increase seen in the crude products as the 550 Da mPEG initiator amount increased 
in the feed. 
Transesterification reactions and depolymerization with extended time may 
explain the slight decreases in MW nearing the end of reaction for PSIM-mPEG(5k) and 
PSIM-mPEG(550) with 1wt% TBD.  TBD and similar organocatalysts show significantly 
greater binding affinity to cyclic lactones than acyclic esters, which contributes to 
transesterification reactions and may contribute to the low PDIs measured in the crude 
products after 24 hr.
162
 
4.3.6 Crude vs Purified Polymers 
Figure 4.8 shows chromatograms of the PSIM-mPEG(550) copolymer before and 
after purification via DCM/cold ether.  The crude copolymer in the kinetic reactions 
reached a maximum of MW of 6-7 kDa in contrast to the purified 19-20 kDa copolymer 
noted earlier.   After precipitation, the purified product showed a peak that noticeably 
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shifted left to an elution time of 15.1 min compared to the crude peak, which remained at 
16.7 min.  The measured weight-average MW of the polymer peak in the crude product 
was 9 kDa, while the purified form was 21 kDa. 
 
 
 
Figure 4.8 Chromatograms of PSIM-mPEG(550) before and after purification. 
 
The significant difference in MW distribution between the crude PSIM-
mPEG(550) (approximately 6 kDa) and the purified copolymer (20 kDa) was due to the 
large amount of low MW products remaining in the crude samples decreasing the weight 
average MW.  Also, the high MW purified product represented only approximately 2% of 
the crude product.  The PSIM copolymer yield increased as the MW of the mPEG 
incorporated into the feed increased. Analysis of purified samples may have resulted in a 
different MW trend between the copolymers, but the small amounts of crude product 
collected from the microscales reactions (5 to 10 mg) made purification impractical. 
For macroscale reactions, investigating new solvent/anti-solvent phase 
precipitation systems may help to improve the yield of the PSIM-mPEG(550) copolymer.   
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The increased hydrophobicity of the copolymer may be influencing its solubility in the 
DCM/diethyl ether combination used for purifying PSIM-mPEG(5k) and PSIM-
mPEG(2k), thereby affecting its yield. 
 
4.3.7 Degradation 
A degradation study was conducted to compare mass loss and cumulative 
amounts of simvastatin released from the PSIM copolymers (Figure 4.9).  After 6 wk, an 
average total mass loss of 28, 29, and 7% was observed, from which cumulative amounts 
of 12, 5.2, and 0 μg of simvastatin were released from PSIM-mPEG(5k), PSIM-
mPEG(2k), and PSIM-mPEG(550), respectively.  While mass loss for the 5 kDa and 2 
kDa mPEG-initiated PSIM copolymers was similar, both exhibited significantly greater 
mass loss compared to PSIM-mPEG(550), the most hydrophobic copolymer (p<0.05).  
PSIM-mPEG(5k) and PSIM-mPEG(2k) each exhibited differing rates of simvastatin 
release in later stages of degradation compared to the rates seen initially.  From 12 hr up 
to 10 days, 0.578 and 0.230 μg/d of simvastatin was released from PSIM-mPEG(5k) and 
PSIM-mPEG(2k), respectively, which changed to slower rates of 0.124 and 0.052 μg/d, 
respectively, for the remainder of the 44 d study.  In the first 12 hr, a burst release of 1.6 
and 1.1 μg was measured from the two copolymers, respectively.  PSIM-mPEG(5k) 
released a significantly greater amount of simvastatin than PSIM-mPEG(550) did during 
the 44 d period (p<0.0001) and PSIM-mPEG(2k) on day 3 (p<0.001) and the remainder 
of the study (p<0.0001).  Simvastatin release from the PSIM-mPEG(550) copolymer was 
negligible over the 44 d period.  From observation, PSIM-mPEG(5k) experienced the 
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most erosion, which began the earliest. PSIM-mPEG(550) remained the most intact with 
breakage observed much later during the degradation period.   
 
      
 
Figure 4.9 Degradation of PSIM-mPEG(5k, 2k, and 550) diblock copolymers showing a) 
final mass remaining and b) resulting simvastatin release.  
 
87 
 
Degradation of poly(simvastatin) is caused by cleavage of hydrolytically labile 
ester bonds throughout the polymer chain, ultimately releasing molecules of  simvastatin.  
The degradation rate of poly(simvastatin) can potentially be tuned by modifying the 
composition of the diblock copolymer.  While simvastatin, and subsequently its 
respective polymerized form, is hydrophobic, mPEG is hydrophilic, giving the resulting 
PSIM-mPEG copolymer an amphiphilic nature.  The higher the MW of mPEG 
incorporated into the diblock copolymer, the more hydrophilic the resulting copolymer 
becomes.  Generally, the more hydrophilic the copolymer, the faster it should degrade in 
a physiological environment.  While PSIM-mPEG(2k) had a slightly higher average mass 
loss than PSIM-mPEG(5k), this difference was insignificant.   
The order of increasing mass loss during degradation of the PSIM copolymers 
correlated with cumulative release of simvastatin.  An increasing degradation rate with 
increasing hydrophilicity was more evident when comparing the amount of simvastatin 
released.  PSIM-mPEG(5k) released 2.3 times more simvastatin than did the less 
hydrophilic PSIM-mPEG(2k) copolymer, with both releasing significantly more than 
PSIM-mPEG(550), which experienced insignificant degradation.  Concentrations of 0.3-
2.4 µg/ml, 0.07-0.8 µg/ml, and 0-0.01 µg/ml were reached for PSIM-mPEG(5k), PSIM-
mPEG(2k), and PSIM-mPEG(550), respectively.  Concentrations from PSIM-mPEG(5k) 
were within and above the range reported for simvastatin to have therapeutic effects in 
vitro, while the range for PSIM-mPEG(2k) was at the bottom and slightly below this 
window 
168
.  Note, however, the small size (10-15 mg) of the samples; the total amount of 
simvastatin release can be adjusted via the mass of copolymer used.  The negligible 
amount of simvastatin released from PSIM-mPEG(550), the most hydrophobic of the 
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PSIM copolymers, during the 8 wk time period may be due to hydrophobic interactions 
between the PSIM block within the copolymer matrix and potentially free simvastatin 
trapped within the matrix.  Both are extremely hydrophobic, which would lead to a 
considerably slow rate of simvastatin release from the matrix into the aqueous medium, 
as seen by similar drugs incorporated in hydrophobic block copolymer delivery systems. 
169
  A loss of other degradation products, such as mPEG, simvastatin oligomers, or mPEG 
with limited simvastatin monomers attached, most likely contributed to the significantly 
greater total mass loss than simvastatin released. Within a 44 d degradation period, the 
PSIM-mPEG(5k) copolymer synthesized via TBD lost twice as much mass than did the 
same copolymer synthesized via stannous octoate in a previous study.
159
  The comparison 
may indicate a greater amount of side reactions leading to less degradable byproducts 
formed in the stannous octoate mediated reaction as a result of being conducted at a 
higher temperature of 230 ˚C.   
4.4 Conclusions  
Triazabicylodecene, a highly reactive organocatalyst, was able to mediate the 
ROP of poly(simvastatin) diblock copolymer using different MW mPEGs at a lower 
reaction temperature than the previously used stannous octoate catalyst.  This provides 
the advantage of modifying hydrophilicity or hydrophobicity of the biomaterial that, in 
turn, alters degradation rate for therapeutic treatments of different timescales.  The 
potential to polymerize simvastatin at a lower temperature also decreases the incidence of 
side reactions that generate undesirable byproducts that interfere with degradation of the 
polymeric biomaterial.  Lower reaction or processing temperatures would also be more 
energy- and cost-efficient at an industrial manufacturing scale. The resulting hydrophilic 
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copolymer synthesized via TBD was capable of losing significantly more mass within the 
same time period than the same copolymer synthesized via stannous octoate.  Simvastatin 
release was modified as a result of using different MW mPEG initiators for synthesis. 
Synthesizing and developing a poly(simvastatin)-mPEG diblock copolymer with tunable 
degradation properties is desirable for tissue therapeutic applications.  
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Ch. 5 Tuning Degradation and Mechanical Properties of 
Poly(ethylene glycol) – Poly(simvastatin)-based Diblock 
copolymer blends 
 
This chapter was reproduced from a manuscript in preparation, “Asafo-Adjei T.A., T.D. 
Dziubla, D.A. Puleo, Tuning Degradation and Mechanical Properties of Poly(ethylene 
glycol) – Poly(simvastatin)-based Diblock copolymer blends, (2017).” 
 
5.1 Introduction 
Polymeric biomaterials are frequently used for drug delivery applications due to 
the ability to tune the time-scale of polymer degradation to that of therapeutic treatment.  
By changing comonomer or monomer to initiator ratios, blending with other polymers, 
conjugating hydrophilic or hydrophobic blocks to the polymer, or by modifying the end-
group, architecture, or molecular weight, one can substantially alter degradation rate.
170-
174
 Poly(lactic-co-glycolic acid) (PLGA), poly(lactic acid) (PLA), and poly(ε-
caprolactone) (PCL) are biocompatible polyesters widely used as drug delivery vehicles 
that benefit from their tunable characteristics.
25, 175, 176
 Examples of FDA-approved 
products include Arestin
®
, Respiredal
®
, Consta
TM
, Trelstar
®
 Depot, and Sandostatin 
LAR
®
 Depot, which release minocycline, resperidone, triptorelin, pamoate, and 
octreotide acetate for periodontal disease, psychosis, prostate cancer, and acromegaly, 
respectively.
177
  These diverse PLGA microparticle system therapeutics aim to 
circumvent the disadvantages of their oral administration, which include frequent dosage 
due to insufficient bioavailability, burst drug release, and toxic effects.
178
  In addition, 
aliphatic polyester carriers in drug delivery serve to protect drugs against premature 
degradation, extending their half-life in the body to increase bioavailability of these drugs 
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as opposed to forms of oral administration.  In addition, specific polyesters, such as PCL, 
degrade extremely slow, providing low dose, yet sustained, drug release.   
While polymers that degrade in weeks to months are desirable for bone healing 
applications, the period of polymer degradation exhibited by polymers such as PCL may 
extend beyond the necessary period of treatment, impeding rather than aiding the healing 
process.
179
 Furthermore, the associated slow rate of drug release may be therapeutically 
ineffective. As a result, copolymerization with poly(ethylene glycol) (PEG), a 
hydrophilic macromolecule, has been investigated to accelerate the degradation rate of 
hydrophobic and crystalline polyesters, such as PCL.
180
 PEG-PCL block copolymers 
have been used as in situ gels, porous scaffolds, and in collagen/hydroxyapatite/hydrogel 
composites for bone tissue regeneration.
179, 181, 182
  Past investigations have also 
controlled degradation of relatively less hydrophobic and more amorphous PLA and 
PLGA polymers by copolymerizing with PEG to use as composite scaffolds, micro- and 
nanoparticle systems for tissue healing, anti-cancer and gene therapy, and other targeted 
drug delivery applications.
65, 183, 184
 Blending polyesters into different polymers 
potentially combines the desirable physical properties of the individual polymers. For 
example, Tsuji et al. reported that blending a minimal amount of PCL with poly(D,L-
lactic acid) (PDLLA) significantly enhanced elongation before failure, as well as the 
Young’s modulus of the blend, with the opposite effect seen when the same amount of 
PDLLA was added to PCL.
185
 
To further combat the disadvantages of high burst release and insufficient drug 
release, advanced drug delivery systems include polymer chains consisting of repeating 
monomeric units of the drug, such as aspirin, poly(morphine), poly(trolox ester), and 
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curcumin polymers, providing sustained and pseudo-zero order release for select 
systems.
42, 186-188
  These polydrugs include the previously reported synthesis of 
polymerized simvastatin.
159
  Most well-known for regulating cholesterol, simvastatin also 
has osteogenic, angiogenic and anti-inflammatory properties desirable for tissue 
regeneration.
120-122, 127
 
While the weight percentage of simvastatin in poly(ethylene glycol)-block-
poly(simvastatin) (PSIM) can be controlled by the drug to initiator ratio, the hydrophobic 
nature of the  poly(simvastatin) block results in slow polymer degradation even following 
copolymerization with mPEG. Tailorable properties of the block would be more 
advantageous for regenerative drug delivery applications.  Thus, the objective of the 
present studies was to investigate the effects of blending poly(ethylene glycol)-block-
poly(lactic acid) (PLA) copolymers on the degradation and structural properties of PSIM. 
5.2 Experimental 
5.2.1 Materials  
Simvastatin and D,L-lactide were purchased from Haorui Pharma-Chem (Edison, 
NJ) and Alfa Aesar, respectively.  Monomethyl ether poly(ethylene glycol) (mPEG), 
triazabicyclodecene (TBD), tin (II) ethyl-hexanoate (stannous octoate), carboxyl esterase 
from porcine liver, anhydrous toluene, anhydrous diethyl ether, dichloromethane (DCM), 
ethanol (EtOH) and an HMG-CoA Reductase kit were purchased from Sigma-Aldrich 
(product CS1090; St. Louis, MO).  Tetrahydrofuran (THF) stabilized with 3,5-di-tert-
butyl-4-hydroxytoluene (BHT) and acetonitrile (ACN) were purchased from Pharmco-
Aaper (Shelbyville, KY).  
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5.2.2 Methods 
5.2.2.1 Poly(ethylene glycol)-block-poly(simvastatin) synthesis via TBD. Macroscale 
reactions (3 g) were conducted to synthesize copolymers using simvastatin as the 
monomer and mPEG (550, 2000, or 5000 Da) as initiator at a molar ratio of 100 to 1.  
Within a round bottom flask immersed in a silicone oil bath, simvastatin and mPEG were 
dried at 130 ºC for 1 hr under a continuous flow of nitrogen gas.  The temperature was 
increased to 150 ºC for an additional hour before adding 1 wt% of TBD to the 
homogeneous melt.  Each reaction ran for 24 hr.  The reaction procedure and mechanism 
of copolymer polymerization via a metal catalyst, stannous octoate, has been previously 
studied.
159
 
5.2.2.2 Poly(ethylene glycol)-block-poly(lactic acid) Synthesis via Stannous Octoate. 
Macroscale reactions were conducted (5g) using D,L-lactide and mPEG (550, 2000, or 
5000 Da) at a molar ratio of 100:1 monomer to initiator.  Components were mixed and 
dried at 140 ºC for 1 hr under a continuous nitrogen gas purge.  The temperature was 
decreased to 120 ºC for an additional hour before 1 wt% of stannous octoate dissolved in 
toluene was added to the melt.  Each reaction ran for 6 h.
189
 
5.2.2.3 Purification.  Crude PSIM copolymers using 5000, 2000, or 550 Da mPEG 
(PSIM-mPEG(5k), (2k), or (550)) and the PLA copolymers were purified by dissolving 
the crude products in DCM and pipetting the polymer solution into excess cold diethyl 
ether as the anti-solvent.  The purified products were isolated via vacuum filtration.   
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5.2.2.4 Gel Permeation Chromatography (GPC).  A Shimadzu Prominence LC-20 AB 
HPLC system with a waters 2410 refractive index detector was used to measure the MW 
of the copolymers synthesized. Two 300 x 7.5 mm, 3 µm particle size ResiPore columns 
(Agilent Technologies) in series were used for sample separation.  Samples were injected 
using THF as the eluent at a 1.0 ml/min flow rate.  Standard curves were prepared using 
polystyrene standards ranging from 162 Da to 483 kDa. 
5.2.2.5 Film Formulation.  Purified PLA-mPEG with block components of 5000, 2000, 
or 550 Da mPEG (PLA-mPEG(5k), (2k) or (550)) and PSIM-mPEG(5k) were dissolved 
in DCM at 700 μg/ml for a viscous solution.  Each PLA-mPEG copolymer was blended 
with PSIM-mPEG(5k) at 20 wt%, and labelled 80:20 PSIM(5k):PLA(5k), 80:20 
PSIM(5k):PLA(2k), and 80:20 PSIM(5k):PLA(2k), respectively.  The PSIM-mPEG(5k) 
and PLA-mPEG(5k) block copolymers were also blended at a 60:40 weight ratio (60:40 
PSIM(5k):PLA(5k)), respectively.  The mixture was also dissolved in DCM at 70 wt% 
and vortexed into a homogeneous mixture before droplets were pipetted onto a Teflon 
sheet.  Discs were dried overnight. 
5.2.2.6 In vitro Degradation.    A destructive mass loss study was conducted with each 
of the purified copolymers and blended copolymers.  After recording initial mass, each 
copolymer disk was gently shaken at 37 ºC in 1.5 ml of phosphate-buffered saline (PBS), 
pH 7.4, for 60 d.  Additionally, disks of the same polymer blends were shaken in 1.5 ml 
of 0.1% porcine liver carboxyesterase
190, 191
 in PBS at 37 ºC for 60 d.  At 0.5, 1, 3, 7, 14, 
42, and 60 d, three film samples from each copolymer group were withdrawn and dried 
overnight to determine mass loss. After the first day, where supernatant was collected 
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every 12 hr, PBS was replaced every 2-3 days the first week, followed by every 3-5 days 
for the remainder of the 60 d period. 
5.2.2.7 High Performance Liquid Chromatography (HPLC).  Simvastatin 
concentrations in release supernatants were measured using a Hitachi Primaide system 
equipped with a Kinetix Luna C18 column (150 x 4.60 mm, 5 µm particle size; 
Phenomenex).  Acetonitrile and water with 0.1 wt% trifluoroacetic acid (70:30 v/v) was 
used as the mobile phase, and UV absorbance was measured at 240 nm.  
5.2.2.8 Mechanical Testing.  A Teflon mold was used to form cylindrical samples with a 
2:1 height to diameter ratio (5 by 2.5 mm).  Samples were made from PSIM-mPEG(5k), 
the PLA-mPEG copolymers, and the copolymer blends.  Using a Bose Electroforce 3300 
mechanical testing instrument, uniaxial compression tests were run at 0.05 mm/s until a 
displacement of 2.5 mm was reached.
192
  Compressive strength and modulus were 
calculated from the load-displacement data and physical dimensions of the samples.  
When measuring compressive strength, more crystalline polymers were measured at 
yield, which was also peak strength.  For the semi-crystalline polymers, strength was 
measured just above yield and before the plastic region of the load vs. deformation curve. 
The modulus was determined from the slope of the initial linear elastic region of each 
curve. 
5.2.2.9 X-Ray Diffraction (XRD).  Powder and film samples, 10 to 20 mg each, were 
analyzed using a Siemens D500 Diffractometer to determine the relative of crystallinity 
of the PSIM and PLA copolymers and their blends.  A 2θ angle range of 10 to 50 ˚ was 
used for measurement at a rate of 1˚/min.  Diffraction was performed at 30 mA and 40 
kV.  A VisxDACO software interface was used to obtain and analyze data.  Relative 
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percentage crystallinity was calculated by measuring the total area of crystalline peaks to 
the total area of both crystalline and amorphous peaks in the diffractogram.   
5.2.2.10 Biochemical Activity of Degradation Products. The activity of PSIM and PLA 
degradation products in supernatants was tested by evaluating inhibitory activity on 3-
hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase.  A commercially 
available assay kit was used to monitor oxidation of NADPH, which is dependent on the 
conversion of HMG CoA to mevalonate.
193-195
  The optical density of each reaction 
sample was immediately read at 340 nm using a PowerWave HT microplate 
spectrophotometer with a Gen5 analysis software interface. 
5.2.2.11 Statistical Analysis.  Two-way analysis of variance with a Tukey-Kramer post-
test was performed to test the effects of the blending ratio on the degradation rate and 
release of simvastatin from PSIM(5k).  One-way analysis of variance was used to 
compare means of the mechanical properties and HMG CoA reductase activity.  A value 
of p ≤ 0.05 was deemed statistically significant. Data are presented as mean and standard 
deviation. 
5.3 Results 
The starting MW of the PSIM-mPEG(5k), PLA-mPEG(5k), PLA-mPEG(2k), and 
PLA-mPEG(550) copolymers and blends degraded in the mass loss study was 13, 20, 16, 
and  19 kDa, respectively.  Figure 5.1 displays the mass loss and subsequent release of 
simvastatin from the copolymer and blended films.  Within the first 24 hr, significant 
mass loss was observed, with 25, 37, 21, 21, and 20% initial loss from PSIM-mPEG(5k), 
60:40 PSIM(5k):PLA(5k), 80:20 PSIM(5k):PLA(5k), 80:20 PSIM(5k):PLA(2k), and 
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80:20 PSIM(5k):PLA(2k), respectively.  The PLA copolymers lost up to 22% within the 
first 24 hr. 
 At 60 d, the PLA copolymer with the smallest mPEG size experienced the least 
mass loss at 26%.  The amount of mass lost increased with increasing MW of the mPEG 
block incorporated into the PLA copolymer, with up to 94% lost from the PLA-
mPEG(5k) copolymer films.  PSIM-mPEG(5k) and its blended films underwent mass 
loss within this range.  After the initial loss, the rate of mass loss for PSIM and its blends 
was similar, with rates of 0.44, 0.54, 0.6, 0.73, and 0.46 μg/d from the first 24 hr to end 
of the 60 d for PSIM-mPEG(5k), 60:40 PSIM(5k):PLA(5k), 80:20 PSIM(5k):PLA(5k), 
80:20 PSIM(5k):PLA(2k), and 80:20 PSIM(5k):PLA(550), respectively. The blend with 
the highest amount of PLA copolymer (60:40) and highest MW mPEG showed the 
greatest mass loss of 75%.  Blends with a smaller PLA copolymer content (80:20) 
retained more mass than did the 60: 40 blend and continued a trend of decreasing mass 
loss as the mPEG MW in the PLA copolymer decreased, from 63 to 45%.  A total mass 
loss of 50% from the PSIM copolymer was comparable to that of its blend with the PLA 
copolymer having the lowest MW mPEG. 
The largest amount of simvastatin, 15 μg after 60 d, was released from the 80:20 
blend with the highest MW mPEG block (5kDa) incorporated into both of the individual 
copolymers.  The two remaining 80:20 blends and PSIM-mPEG(5k) exhibited similar 
release profiles with an insignificant difference in total simvastatin released, ranging from 
7.8 to 8.3 μg.  The 60:40 blend released 6.2 μg, the smallest total amount of simvastatin.  
Increasing zero-order release rates of 0.24, 0.28,  0.3, 0.33, and 0.72 μg/d were observed 
during the first 10 d followed by lower zero-order rates of 0.078, 0.11, 0.093, 0.094, and 
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0.168 a μg/d for 60:40 PSIM(5k):PLA(5k), PSIM-mPEG(5k), 80:20 
PSIM(5k):PLA(550), 80:20 PSIM(5k):PLA(2k), and 80:20 PSIM(5k):PLA(5k), 
respectively.  The 80:20 PSIM(5k):PLA(5k) blend released a greater amount of 
simvastatin than PSIM-mPEG(5k) and 60:40 PSIM(5k):PLA(5k) did from 3 d (p<0.01) 
to 5 d (p<0.0001) and the remaining 60 d period (p<0.0001), along with 80:20 
PSIM(5k):PLA(2k) (p<0.001) and 80:20 PSIM(5k):PLA(550) (p<0.01) from 7 to 60 d 
(p<0.0001).  Simvastatin released from PSIM-mPEG(5k) and 80:20 PSIM(5k):PLA(550) 
was greater than the amount released from 60:40 PSIM(5k):PLA(5k) from 49 to 60 d 
(p<0.05). 
Overall, approximately 62 wt% of simvastatin was polymerized into the diblock 
copolymer.  An 8 to 15 μg amount of the drug (0.06 to 0.2 % of the monomer) was 
released during the 8 week period.  Throughout degradation of PSIM-mPEG(5k) and the 
60:40 blend, concentrations of 0.08 to 0.5 μg/ml were reached, while the 80:20 blend 
releasing the largest drug amounts reached concentrations between 0.2 and 1.2 μg/ml.   
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Figure 5.1 Degradation of PSIM and PLA copolymers and their blends in PBS, pH 7.4, 
showing a) mass loss and b) drug release profiles. 
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To evaluate the sensitivity of the synthesized polymers to enzymatic degradation, another 
mass loss study was conducted using PBS supplemented with 0.1 mg/ml 
carboxylesterase.  Table 5.1 compares cumulative release of simvastatin with and without 
enzyme after 2 months of degradation.  While the average simvastatin amount released 
was lower in esterase solution for 80:20 PSIM(5k):PLA(5k) and 80:20 
PSIM(5k):PLA(550), no significant difference in release was seen comparing PBS and 
esterase solution conditions with each copolymer or copolymer blend. 
 
 
Table 5.1: Comparison of simvastatin released from PSIM and blends in PBS and PBS 
containing 0.1 wt% esterase. 
Cumulative 
Sim 
Released 
(μg) 
PSIM(5k) 
 
60:40 
PSIM(5k): 
PLA(5k)  
80:20 
PSIM(5k): 
PLA(5k)  
80:20 
PSIM(5k): 
PLA(2k)  
80:20 
PSIM(5k): 
PLA(550) 
PBS 8.01 
±1.71 
6.24 
±0.344 
15.2 
±0.733 
7.82 
±0.523 
8.33 
±1.40 
PBS with 
0.1 wt% 
esterase 
13.3 
±1.28 
8.14 
±2.93 
8.50 
±3.49 
8.98 
±5.27 
2.83 
±0.933 
 
Figure 5.2 shows images of samples used for mechanical testing.  Although 
characteristically orange in color, the PSIM copolymer samples appear somewhat 
transparent along with their PLA copolymer counterparts, as opposed to the blends of 
PSIM with each of the PLA copolymers, which appear opaque.  The PLA-mPEG(5k) 
copolymer was the least translucent of the three PLA copolymers, followed by PLA-
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mPEG(550), and lastly PLA-mPEG(2k).  The mPEG block polymers tested also had a 
characteristic opaqueness, white in color at room temperature. 
 
Figure 5.2. Cylindrical mechanical testing samples of PSIM copolymers and blends.  
From left to right: mPEG (5kDa), mPEG (2kDa), PLA(5k), PLA(2k), PLA(550), 
PSIM(5k), 80:20 PSIM(5k):PLA(5k), and 60:40 PSIM:PLA. 
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Figure 5.3 Mechanical properties of PSIM and PLA copolymers and blended samples:  
a) compressive strength and b) modulus. *p<0.05,**p<0.01, ***p<0.001, ****p<0.0001 
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The average compressive modulus and strength of PSIM-mPEG(5k) were 44 and 
4.5 MPa, respectively (Figure 5.3).   Blending PSIM with PLA copolymers noticeably 
decreased the resulting compressive modulus and strength to ranges of 26-36 MPa and 
2.4-5.4 MPa, respectively.  In contrast, no significant difference in modulus and strength 
was seen between PSIM-mPEG(5k) and its blends. Also, there was no significant 
difference in modulus between the blends and the respective PLA copolymers used for 
each type, with the exception of 60:40 PSIM(5K):PLA(5K), which exhibited a 
significantly lower modulus than did PLA-mPEG(5k).   
Significant differences in compressive strength were seen between the blends and 
the respective PLA copolymers incorporated in each blend type.   The compressive 
strength of 2 kDa and 5 kDa mPEG was significantly lower than that of PSIM-
mPEG(5K).  There was a noticable decrease in compressive modulus and large decrease 
in strength (p<0.0001) as the mPEG block length in the PLA copolymer shortened from 5 
to 2 kDa.  However, the PLA copolymer with the shortest mPEG length (550 Da) 
exhibited a higher modulus (although with high variability) and strength (p<0.0001) than 
did PLA-mPEG(2k), which had a similar modulus but significantly lower strength 
(p<0.01) compared to PLA(5k). 
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Figure 5.4 X-ray diffractograms of mPEG block components, simvastatin and D,L-lactide 
monomer components, PLA-mPEG copolymers, the PSIM-mPEG(5k) copolymer, and 
PSIM:PLA blends. 
 
Figure 5.4 displays the comparative crystalline and amorphous peaks between the 
mPEG, PLA and PSIM polymers and blends, and their respective monomers obtained via 
X-ray diffraction.  The 5 kDa mPEG was normalized at 100% as the most crystalline in 
the group when determining the relative crystalline index (CrI) between mPEG block 
components and copolymers.  The 2 kDa mPEG followed with 90%, and then PSIM-
mPEG(5k), PLA-mPEG(5k), 60:40 PSIM(5k):PLA(5k), and 80:20 PSIM(5k):PLA(5k) 
with 16, 14, 12, and 7.8% relative crystallinity, respectively.  Similar amorphous 
properties to the 5 kDa mPEG-containing blends were exhibited by 80:20 
PSIM(5k):PLA(2k), 80:20 PSIM(5k):PLA(550),  PLA(2k) and PLA(550) with 9, 11, 11, 
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and 8.5% relative crystallinity, respectively. Distinctive peaks were observed at 20 and 
24˚ (2θ) in the more crystalline polymers and blends.  
The diffraction patterns of simvastatin and D,L-lactide also showed a semi-
crystalline nature of the monomers used in copolymerization, at 47.5 and 62.5% 
crystallinity, respectively.  Distinctive peaks of crystallinity characteristic to simvastatin 
were seen at 11.1˚ and from 15 to 27 ˚ (2θ).  The diffraction pattern characteristic to D,L-
lactide exhibited multiple crystalline peaks throughout the 2θ angle range of  11 to 43˚. 
 
Figure 5.5.  Inhibition of HMG-CoA reductase activity in the presence of simvastatin, 
lactide, and PSIM and PLA degradation products at different concentrations. (n = 3) 
*p<0.05, **p<0.01 
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HMG CoA reductase activity was analyzed in the presence of PLA-mPEG(5k) 
and PSIM-mPEG(5k) degradation products (Figure 5.5).  Inhibition of enzyme activity 
was seen with simvastatin at 0.01, 0.1, and 1 μg/ml concentrations and with PSIM 
degradation products at the higher concentrations of 0.1 and 1 μg/ml.  Compared to fresh 
enzyme activity, the levels of enzyme inhibition were 39, 86, and 88% for simvastatin at 
0.01, 0.1, and 1 μg/ml, respectively, and 58 and 68% for PSIM degradation products at 
0.1 and 1 μg/ml, respectively,. The presence of lactide and PLA degradation products 
exhibited minimal to no effect of enzyme inhibition at the concentrations analyzed.  
While multiple noticeable differences in inhibition were observed, statistical significance 
was seen for the PSIM degradation products at 0.1 and 1 μg/ml (p<0.05) compared to the 
same products at 0.01 µg/ml, for which there was no noticeable enzyme inhibition. No 
significant difference in inhibition was seen between the different simvastatin 
concentrations, but the products of PSIM at 0.01 μg/ml exhibited significantly different 
activity from simvastatin at 0.1 and 1 μg/ml (p<0.01).  Simvastatin at 1 μg/ml also 
significantly reduced reductase activity compared to D,L-lactide at 1 μg/ml (p<0.05).  D,L-
lactide and PLA degradation products did not show significant activity at any of the 
concentrations tested.  
5.4 Discussion 
5.4.1 Degradation  
The most influential factor affecting mass loss from the PSIM:PLA blends was 
relative hydrophobicity between PSIM and PLA copolymers within the blends.  This 
factor, in turn, determined the rate of ester bond hydrolysis within the polymer backbone 
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and degree of erosion that occurred.  Simvastatin is hydrophobic due to the aromatic 
rings found within its structure, a characteristic that increases in degree as simvastatin is 
polymerized into its respective polymeric block.  Lactide, a lactone molecule that lacks 
aromatic moieties in its structure, is comparatively less hydrophobic, resulting in the 
synthesis of a less hydrophobic polymer.  Differences in mass loss between the blends 
can be explained by relative hydrophobicity when evaluating the differences between the 
PLA-mPEG diblock copolymers incorporated in the blends.  Increasing the mPEG block 
MW from 550 to 5000 Da created copolymers that decreased in hydrophobicity. This 
trend led to an increased degradation rate as the association of water with oxygen-rich 
mPEG, and subsequent access of water into the polymer matrix, increased with block 
length.  
The degree of compatibility between the PSIM-mPEG(5k) and PLA copolymers 
in the blends and loss of residual mPEG and simvastatin reactants were possible 
contributing factors to the significant initial erosion of the blends observed during the 
first 24 hr.  The initial mass loss from blends that had 20 and 40% of PLA-mPEG(5k) 
may indicate phase separation between the two copolymers that was only exacerbated 
upon increasing the weight percentage of PLA and/or leaching of PLA oligomers from 
the bulk samples.  The amount of PLA lost would not account for the total loss during 
this period, however, as a detectable amount of simvastatin and intermediate PSIM-
mPEG(5k) degradation products were also present in the release supernatant.  The 
slightly larger mass loss from PSIM-mPEG(5k) compared 80:20 blends may result from 
leaching of free mPEG and monomer from the polymer matrix. 
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The PLA degradation products, residual mPEG and simvastatin reactants, and 
PSIM-mPEG(5k) intermediary degradation products, such as simvastatin oligomers, 
would account for the three orders of magnitude difference in mass lost and simvastatin 
monomer released from the blends, because only simvastatin monomer is accounted for 
in the release profiles.  The 80:20 blend most likely released the largest amount of 
simvastatin due to a potentially lower internal pH environment in the bulk relative to the 
other blends and PSIM-mPEG(5k) as a result of the higher degradation rate of PLA-
mPEG(5k) within the blended matrix.  This comparatively accelerated process would, in 
turn, enhance degradation of PSIM-mPEG(5k), leading to greater cumulative release of 
simvastatin.  In contrast, the 60:40 blend releasing the lowest amount of drug was 
possibly linked with the blend prematurely breaking up resulting in the early loss of PLA-
mPEG(5k) from the blended matrix.  Without the faster degrading polymer, pH of the 
internal environment within the remaining PSIM-mPEG(5k) matrix may not have been 
low enough to accelerate cleavage of labile ester bonds to ultimately free larger amounts 
of simvastatin.  Blended polyester systems have shown an increase in polymer 
degradation in the presence a secondary acid producing biodegradable polymer (such as 
PLA) within the matrix.
196
  In contrast, effects of neutralization to reduce degradation 
rate have also been seen following incorporation of basic products in the blends.
168
  
Relatively better integrity observed in the remaining blends correlated with higher 
amounts of simvastatin released. 
The simvastatin concentration range generated from the least hydrophobic 80:20 
blend was within the concentration range of 0.5 to 1.5 μM (i.e., 0.21 to 0.42 μg/ml) 
deemed to have a therapeutic effect in vitro.  Similar simvastatin concentrations were 
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reported by Song et al. to induce significant alkaline phosphatase activity in bone marrow 
stromal cells.
197
  Concentrations from PSIM-mPEG(5k) were also within this range.  
Another study found that a slightly higher concentration range of 1 to 10 μM of 
simvastatin also induced VEGF mRNA expression in osteoblastic cells, showing similar 
therapeutic concentration windows for different effects promoted by simvastatin.
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During degradation of the PSIM copolymer and its blends, open and/or closed-
ring simvastatin and mPEG and other intermediate products may be produced as a result 
of the breakdown of hydrolytically unstable ester bonds.  Potential degradation products 
include mPEG with a few monomers of simvastatin attached and oligomers of 
simvastatin in the absence of mPEG, leading to increasingly hydrophobic 
macromolecules as the number of simvastatin monomers on the oligomeric chain 
increases. Some arguments have been made that in vitro degradation studies of polymer 
drug delivery systems do not accurately represent performance in the physiological 
environment due to the lack of enzymatic components and other biological factors that 
may accelerate degradation of biodegradable polymeric systems.  Tracy et al. showed 
that PLGA microspheres injected into Sprague-Dawley rats exhibited degradation rate 
constants 1.7 to 2.6 times faster than their degradation in vitro in a HEPES and KCl 
buffer.  As a result, the microspheres lasted a shorter time in vivo, from 14 to 60 d 
compared to ~35 to over 60 d  in vitro.
199
  In the present studies, there were no significant 
differences seen between the PSIM:PLA blends degraded in PBS with or without 
carboxylesterase. Porcine liver carboxylesterase was chosen because hepatic 
carboxylesterases are known to contribute to metabolizing simvastatin.
200
   Decreased 
affinity of porcine liver carboxylesterase for PSIM macromolecules, despite its ability to 
110 
 
metabolize simvastatin, could possibly explain the insignificant differences between 
groups.  Different types of liver carboxyl esterases exist show similar activity, but they 
differ in conformation,
201
 which may have better affinity for PSIM.  Further analysis of 
PSIM degradation with different liver carboxyl esterases would better determine if their 
structures would in turn influence affinity for PSIM.  The aromatic side groups of 
simvastatin, more prominent in its polymerized form, may further inhibit access of the 
enzyme to ester bonds compared to PLA and PLGA polyesters, which lack large side 
groups. This potential concern of interfering side groups may be further exacerbated by 
the random entanglement of polymer chains. 
5.4.2 Mechanical and crystalline properties 
While internal defects and voids within the samples played a part in their relative 
opaqueness, inherent differences in their appearance may be due to possible differences 
of  indices between the two copolymers blended together. Refractive differences increase 
light scattering between phases.
202
  For copolymers with similar, if not the same, 
refractive index, light would transmit more easily creating the transparent appearance 
seen in the PLA and PSIM copolymer samples.  The opaqueness of the mPEG polymers 
was due to their highly crystalline nature, much like the appearance of PCL, which is also 
mostly crystalline at room temperature.  Thus, PLA copolymers with the highest MW 
mPEG appeared the least translucent of the three.   
Mechanical properties of biodegradable copolymers play an influential role in the 
balance of bone resorption and growth as the surrounding tissue heals.  The average 
compressive modulus and strength of trabecular bone in elderly adult human mandibles 
are 56±29.6 and 4±2.7 MPa, respectively. For the cortical bone of elderly adult human 
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mandibles, the compressive modulus was found to be  higher at 96.2±40.6 MPa.
203
  The 
mechanical properties of developed polymeric biomaterials for tissue regenerative 
therapies are intended to mimic the properties of the surrounding bone to minimize 
under- or over-compensation of loading put on bone, as described by Wolff’s law, which 
would otherwise lead to decreased or increased bone turnover, respectively.
204
  However, 
for the device to combat fatigue from damage and repeated loading, the argument of 
developing implants with mechanical properties stronger than their surroundings has been 
made because of their typically smaller cross-sectional areas than bone and lack of 
reconstructive capability.
205
 In either case, being able to easily modify the mechanical 
properties of biodegradable polymers via blending is advantageous.   
The modulus and strength of PSIM-mPEG(5k) remaining within the same order 
of magnitude of those for mandibular trabecular bone.
203
 Incorporating the same 
percentages of each PLA copolymer in the blends (80:20) and also blending two different 
amounts of PLA-mPEG(5k) (80:20 and 60:40) further decreased the modulus and 
strength of the resulting blends (excluding the strength of 80:20 blend with PLA-
mPEG(2k)) compared to PSIM-mPEG(5k).  The relative crystallinity of PSIM compared 
to its respective blends correlated with the modulus comparisons between PSIM-
mPEG(5k) and the respective blends.  This result may indicate a plasticizing effect of the 
PLA copolymers incorporated,
206
  however the presence of small voids within the 
blended sample matrix cannot be discounted as a contributor to the decreased properties.  
Miscibility of the two polymers can also influence properties.  While PEG is known to be 
miscible with PLA, often referred to as a “compatibilizer” component of block 
copolymers in polymeric blends, hydrophobic PCL has been shown to be immiscible 
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with PLA.
206
  Low miscibility between hydrophobic PSIM and PLA block segments of 
the copolymers could lead to boundaries between poorly or non-mixed regions within the 
matrix, which could act as regions of stress concentration, thereby leading to lower 
modulus and strength as the amount of PLA-mPEG(5k) increased.  This effect could 
explain the lower average strength of the 60:40 blend compared to its 80:20 counterpart.   
The PLA copolymer samples had a modulus ranging from 26 to 97 MPa, resulting in the 
PLA-mPEG(5k) and PLA-mPEG(550) samples measuring 1.7 times higher than the 
values measured for trabecular bone.    
The lower modulus and strength of the individual mPEG polymers compared to 
the copolymers of PLA-mPEG(5k), PLA-mPEG(550), PSIM-mPEG(5k), and the blends 
is due to the lower molecular weights of the mPEGs, despite their higher crystallinity 
compared to the copolymers and blends. The properties of 550 Da mPEG were not 
measured due to the liquid state of the polymer at ambient temperature.  
The trends seen between the PLA copolymers may be due to competing effects of 
plasticization and crystallization as a result of the length of incorporated mPEG blocks 
and their influence on PLA block segments, relative PEG content of the copolymers, and 
overall orientation of these block segments within various domains of the polymer 
matrix.  The weight percentage of PEG in PLA-mPEG(550), PLA-mPEG(2k), and PLA-
mPEG(5k) was 3, 13, and 25%, respectively.  Kulinski et al. reported a plasticizing effect 
of 600 Da PEG within the PLA domains as the PEG content increased from 5% to 12%, 
resulting in decreased yield stress from 30 to 5 MPa.
207
   Plasticization may also explain 
the decrease in modulus and strength of PLA-mPEG(2k) compared to PLA-mPEG(550). 
The increased plasticization effect predominated the more crystalline nature of 2 kDa 
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mPEG in PLA-mPEG(2k), compared to 550 Da mPEG in PLA(550), which would 
otherwise potentially increase modulus and strength.  Wu et al. showed that attachment 
of a 5 kDa mPEG block impeded spherulite growth and thus chain folding ability of PLA 
in the copolymer compared to PLLA homopolymers.
208
  Among the three PLA 
copolymers synthesized, PLA-mPEG(5k) had the highest compressive modulus and 
strength, which can be attributed to the higher crystallinity of the conjugated 5 kDa 
mPEG block, compared to 2 kDa and 550 Da mPEG, combined with its high percentage 
in the PLA(5k) copolymer. This effect may indicate that a critical ratio exists where 
crystallinity of the high MW PEG begins to dominate over an otherwise plasticizing 
effect.   While PEG hindered PLA chain folding, Wu et al. still calculated large 5 kDa 
mPEG crystals even at low PEG ratios because of the ability of mPEG to crystallize.
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While PSIM-mPEG(5k) and PLA-mPEG(5k) exhibited similar crystallinity, the 
higher modulus of PLA-mPEG(5k) may be the result of the higher MW compared to 
PSIM-mPEG(5k). Stress concentrators from small defects within the samples may have 
also played a role in the resulting compressive strength. Compared to the multiple distinct 
peaks representative of the crystal lattice structure unique to simvastatin and the ordered 
arrangement of mPEG crystallites in the 5 kDa mPEG polymer, the PSIM-mPEG(5k) 
diffractogram has peaks similar to mPEG but a much lower relative intensity, in addition 
to a noticeable halo underneath the two peaks.  The observed diffraction maxima 
observed for PSIM-mPEG(5k) support the conjugation between the mPEG and PSIM 
blocks and between the simvastatin monomers. The lower peak intensities may be 
attributed to the PSIM-mPEG(5k) copolymer chains containing a lower mPEG 
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percentage compared to solely mPEG.  The peaks and halo are representative of the 
crystalline and amorphous regions of the PSIM(5k) copolymer, respectively.
209
 
 
5.4.3 Bioactivity 
Simvastatin is a well-known inhibitor of HMG-CoA reductase, a rate-limiting 
enzyme in the cholesterol biosynthesis pathway.  By inhibiting the enzyme, late-stage 
prenylation of GTPase proteins (Rho, Ras, etc.) is affected, leading to the expression of 
multiple properties.  Apart from its role in lowering lipids, simvastatin has osteogenic, 
anti-inflammatory, and angiogenic properties.
120-123
   
A noticeable concentration-dependent inhibition of enzyme activity was observed 
with both simvastatin and degradation products from the PSIM copolymer, reflecting the 
known ability of simvastatin to act as a competitive substrate for HMG-CoA reductase.  
In contrast, D,L-lactide and PLA degradation products did not show inhibitory activity.  
As such, the D,L-lactide monomer and degradation products of PLA may serve as 
controls in other future bioactivity studies.  Lower activity of the PSIM degradation 
products compared to simvastatin at the same concentrations was most likely due to the 
components incorporated that do not have an effect on reductase activity, such as mPEG 
or oligosimvastatin macromolecules that have not fully degraded into individual 
molecules of simvastatin, which contributed to the total concentrations of the PSIM 
degradation products.  
5.5 Conclusions 
Blending poly(simvastatin) with PLA provided an easier alternative to 
copolymerization for enhancing and tuning degradation.   Different mPEG sizes 
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conjugated to PLA and weight ratios chosen to blend PLA with PSIM copolymers led to 
varied hydrophobicity, which consequently altered degradation and physical properties of 
the blends. Incorporating PLA copolymers at different ratios plasticized 
poly(simvastatin), reducing the compressive modulus, within a range comparable to that 
of trabecular bone. The PSIM degradation products were also active in reductase 
inhibition, a key factor for simvastatin exhibiting biological effects.  PSIM and its 
tailorable properties may be useful in tissue regenerative applications.   
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Ch. 6 In vitro and In vivo bioactivity of poly(simvastatin) – 
poly(ethylene glycol) diblock copolymer for bone therapeutic 
applications 
This chapter was reproduced from a manuscript in preparation, “Asafo-Adjei T.A., T.D. 
Dziubla, D.A. Puleo, In vitro and In vivo bioactivity of poly(simvastatin) – poly(ethylene 
glycol) diblock copolymer for bone therapeutic applications, (2017).” 
 
6.1 Introduction 
Statins such as lovastatin (Mevacor) and simvastatin (Zocor) were approved by 
the FDA in 1987 and 1988, respectively, as potent cholesterol-lowering agents.
210, 211
 
However, these statins were later found to possess multiple properties making them 
desirable for a range of therapeutic applications.  Specific statins are preferred over others 
for treatment depending on their relative potency at a given dose, relative lipophilicity, 
bioavailability, and mechanism of metabolism, which may influence interactions with 
other drugs and potential side effects experienced by patients.
96, 210
  However, simvastatin 
was the most prescribed statin in 2010, the third most prescribed drug in the U.S., and it 
continues to be the most investigated statin in the literature.
210, 212, 213
  Its popularity in 
research is most likely due to the medium-potency and overall cost-effectiveness of the 
prodrug compared to other statins.
214
  Structurally, simvastatin is the only statin aside 
from lovastatin that resides in an inactive lactone form before it is introduced into a 
physiological environment where it becomes active.
210 
When simvastatin is active in its open ring, hydroxyacid form, the molecule 
competes with 3-hydroxy-3-methyl-glutaryl (HMG) as a substrate for HMG-CoA 
reductase, inhibiting the rate-limiting and early step of the mevalonate pathway.   
Isoprenoid precursors, such as geranyl-geranyl and farnesyl pyrophosphates (GGPP and 
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FPP, respectively), which are indirectly inhibited further down the biosynthesis pathway, 
inhibit the prenylation of Ras (via GGPP) and Rho (via FPP) proteins.
215, 216
  Rho 
inhibition results in a significant increase in endothelial cell nitric oxide synthase (eNOS) 
and subsequent nitric oxide (NO) production.
216
  NO and eNOS promote anti-oxidant and 
anti-inflammatory activity through limiting platelet adhesion and promote cell survival 
and blood vessel development through the PI3 kinase/Akt pathway and regulation of 
vascular endothelial growth factors (VEGF).
216, 217
  Prenylation of T-cells is also 
inhibited, leading to reduced macrophage activation and inflammation.
218
  Thus, the early 
inhibition of cholesterol biosynthesis by statins affects other signaling pathways leading 
to anti-atherosclerotic, angiogenic, anti-inflammatory, and anti-oxidant properties 
necessary for tissue health and regeneration.
120-123
  
The discovery by Mundy et al. in 1991 of the osteogenic nature of lovastatin and 
simvastatin prompted a whole new avenue for using statins in biomedical applications.
97
  
Simvastatin was observed to upregulate expression of BMP-2, which consequently 
induced significant bone formation on the calvaria of ovariectomized mice.  Upregulation 
of BMP-2 by simvastatin has since been shown to be caused by the Ras/Smad/Erk/BMP-
2 signaling pathway.
219
  Reduction of mevalonate while BMP-2 is upregulated may also 
be mediated by factors outside inhibition of the cholesterol biosynthesis pathway, 
however.
220
 Mevalonate reduction has been shown to correlate with increased alkaline 
phosphatase activity, an indicator of early osteoblast differentiation.
221, 222
  Additionally, 
Rho inhibition suppresses osteoclast activity, allowing simvastatin to exhibit anti-
resorptive effects as well,
223
 although the anti-resorptive effects of statins are not nearly 
as significant as osteogenic effects.
97
  While simvastatin, as with all treatments, proves to 
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be ineffective below a therapeutic window unique to the drug, simvastatin at high doses 
has promoted inflammation, myositis, rhabdomyolysis, and hepatotoxicity.
99
 To better 
control statin loading and rate of release, a polymerized form of simvastatin was 
previously synthesized via ring opening polymerization.
159
   
The objective of the present studies was to compare in vitro bioactivity of PSIM 
and PLA copolymer degradation products with, simvastatin, D,L-lactide, and BMP-2 
control groups.  A pilot study to evaluate polymer degradation and osteogenic activity in 
vivo was also started. 
6.2 Experimental 
 
6.2.1 Materials 
 
Simvastatin and D,L-lactide were purchased from Haorui Pharma-Chem (Edison, NJ) and 
Alfa Aesar, respectively. Monomethyl ether poly(ethylene glycol) (mPEG),  and 
triazabicyclodecene (TBD), β-glycerophosphate, ascorbic acid, thiazolyl blue tetrazolium 
bromide, magnesium choride, 2-amino-2-methyl-1 propanol, sodium dodecyl sulfate, 
dimethylformamide, and ethylenediaminetetraacetic acid (EDTA) were purchased from 
Sigma Aldrich.  BMP-2 was purchased from (Genscript), Dulbecco's Modified Eagle's 
Medium was obtained from Corning, Fetal bovine serum (FBS) was obtained from 
Atlanta Biologicals, and p-nitrophenyl phosphate was purchased from ---.  
6.2.2 Methods 
6.2.2.1 Copolymer synthesis.  A macroscale reaction of PSIM-mPEG(5k) via TBD or 
stannous octoate (3 g) was conducted using the synthesis procedures previously 
described.
159
  Simvastatin was used as the monomer and mPEG with a weight-average 
MW of 5000 Da at a 100 to 1 monomer to initiator molar ratio.  A macroscale reaction of 
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PLA(5k) using a procedure previously described in Section 5.2.2.2 was conducted (5g) 
using D,L-lactide as the monomer and mPEG with a MW of 5000 Da at a 100 to 1 
monomer to initiator molar ratio.  The crude copolymers were purified by dissolving the 
crude products in DCM and pipetting the polymer solution into excess cold diethyl ether, 
as the anti-solvent.  The purified products were isolated via vacuum filtration. 
6.2.2.2 Degradation Products.  PSIM(5k) and PLA(5k) were each degraded in 5 mL of 
0.1 M NaOH (aq) for 30 d.  Afterwards, supernatant with the degraded products from 
each copolymer was collected and neutralized to pH 7.4 using 1 M HCl.  Various 
concentrations were made from the neutralized PSIM(5k) and PLA(5k) supernatants for 
cell studies. 
6.2.2.3 Cell culture.  Murine myoblast C2C12 cells were obtained from American Type 
Culture Collection (CRL-1772; ATCC, Manassas, VA).  Cells were cultured in DMEM 
with 10% fetal bovine serum (FBS), and incubated at 37 ºC in a 5% CO2 environment.  
Culture medium was replaced every 3 days. 
6.2.2.4 Cytotoxicity.  Cytotoxicity upon exposure to its degradation products was 
assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay.
224
  MTT is reduced into formazan by dehydrogenase enzymes present in viable 
cells.  C2C12 cells were seeded at 20,000 cells/well in a 96-well plate and incubated 
overnight.   Afterwards, 0.001, 0.01, 0.1, 1, and 10 μg/ml of PSIM-mPEG(5k) 
degradation products, PLA-mPEG(5k) degradation products, simvastatin, D,L-lactide,  
and BMP-2 were added to the cells. PSIM-mPEG(5k) and PLA-mPEG(5k) were also 
tested at at 100 μg/ml.  After 24 hr, medium was replaced and 5 mg/ml of MTT in PBS 
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was added to each well before incubating at 37 ºC for 2 h.  Lysing buffer containing 20% 
w/v sodium dodecyl sulfate in 50% dimethylformamide, pH 4.7, was added to each well 
to solubilize the formazan produced by viable cells.  The optical density of formazan was 
read at a maximum absorbance wavelength of 570 nm using a PowerWave HT 
microplate spectrophotometer with Gen5 analysis software.   
6.2.2.5 Alkaline Phosphatase (AP) Activity.  C2C12 cells were seeded at 20,000 
cells/well in 48-well plates for 24 hr, after which the culture medium was replaced with 
αMEM containing 10% FBS, 5 mM β-glycerophosphate, and 50 µg/ml of ascorbic acid.  
Cells were cultured for 4 days to reach confluence before treating with simvastatin, D,L-
lactide, PSIM-mPEG(5k) degradation products, PLA-mPEG(5k) degradation products, 
simvastatin, BMP-2, or PBS.  The same treatments with the addition of 20 µg/ml of 
phenamil, active in BMP-2 upregulation, were run in parallel to assess the effects of the 
compound.  Medium with treatments were replaced every 3 days.  After 3, 5, and 7 d, 
buffer containing 50 mM sodium phosphate, 2 M sodium chloride and 2 mM EDTA was 
added and followed by sonication to ensure cell lysis.  Aliquots of lysate were mixed with 
substrate solution containing 10 mM of p-nitrophenyl phosphate and 4 mM of MgCl2 in 
0.6 M of 2-amino-2-methyl-1 propanol buffer, and the absorbance was measured at 400 
nm as a function of time. 
6.2.2.6 Myotube Staining.  C2C12 cells with the same treatment groups were stained 
with 0.01% of crystal violet for 30 min after fixation with methanol for 5 min.  After 
staining, the dye was aspirated and excess amounts were removed with 4 to 5 washes of 
DI water.  Cells were captured (10x) using an Olympus IX51 inverted microscope. 
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6.2.2.7 Copolymer Disk Formulation.  Poly(simvastatin-block-mPEG) disks were 
formulated by compressing the copolymer, in powder form, into a cylindrical dye with a 
stainless steel rod under 8000 pounds of pressure for 5 min using a carver press.  After 
removing the samples from the dye, samples were annealed at 30 ºC for 24 hr and 
subsequently at 60 ºC for 24 hr to form 4 x 6 mm disks (100 mg). 
6.2.2.8 Pilot Animal Study.  While in vivo analysis is ongoing and will not be completed 
until late 2017 (Table 1), a trial study using a male Sprague-Dawley rat model was 
conducted at the University of Kentucky in accordance with the Institutional Animal Care 
and Use Committee protocol generated for biodegradable poly(simvastatin).  A 
transverse incision was made between the ears and the periosteum was elevated before 
placing a poly(simvastatin-block-mPEG) disk (4 x 6 mm, 100 mg) on the calvarium of 
each animal. Poly(simvastatin-block-mPEG)  disks were implanted to observe initial disk 
behavior and the resulting tissue response up to 4 wk post-implantation.  The calvarium 
with samples still intact were fixated in phosphate buffered formalin for microCT 
(Scanco Medical) to observe bone morphology at and surrounding the implantation site.  
 
 
 
 
 
 
122 
 
 
Table 6.1 In vivo experimental design 
 Weeks after implantation 
Treatments  
(50 mg disks) 
1 wk 2 wks 
 
3 wks 4 wks 6 wks 8 wks 
Poly(simvastatin 
-co-glycolide) 
6 6 6 6 6 6 
Poly(simvastatin-
block-mPEG) 
6 6 6 6 6 6 
PLGA 6 6 6 6 6 6 
PLGA with 
encapsulated 
simvastatin 
6 6 6 6 6 6 
 
6.2.2.9 Statistical Analysis. One-way ANOVA with a Tukey post-test was used to 
analyze differences in cytotoxicity, and Two-way ANOVA with a Bonferroni post-test 
was used for AP expression between treatments.  Mean and standard deviation are 
plotted. A value of p ≤0.05 was deemed statistically significant.  
6.3 Results 
An MTT assay was conducted to determine the cytotoxicity for each treatment 
group before selecting the concentrations to be used for AP expression in C2C12 cells.  
In Figure 6.1, concentrations up to 100 µg/ml of PSIM and PLA degradation products, 
and up to 10 µg/ml of simvastatin, D,L-lactide, and BMP-2 were cytocompatible with 
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C2C12 cells after 24 hrs.  The positive control of ethanol was the only group showing 
significant cell cytotoxicity (p<0.001). 
 
 
Figure 6.1 Cytocompatibility of simvastatin and lactide monomers and poly(simvastatin) 
and poly(lactide) degradation products at different concentrations in C2C12 myoblast cell 
cultures. Δp<0.001 
 Based on effective concentrations for the controls described in the literature and 
cytocompatibility results, C2C12 cells were treated with 1 µg/ml of simvastatin, D,L-
lactide, or BMP-2 and 10 or 50 µg/ml of PSIM or PLA degradation products to measure 
AP expression after 7d of confluency.  
 A 24 hr kinetic run of AP activity showed that activity began to plateau for one or 
more groups after 2 hrs, so the 2 hr timepoint was used to compare groups with and 
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without phenamil (Figure 6.2) at 3, 5, and 7 days post- confluency.  In the absence of 
phenamil, only simvastatin led to a difference in AP expression at 3d (p<0.01), followed 
by both simvastatin and BMP-2 at 5 (p<0.01 and p<0.001, respectively) and 7d (p<0.001 
and p<0.001, respectively).  While there was a slight increase in AP activity with 50 
µg/ml of PSIM(5k) degradation products, and 1.5 times higher than the PBS control, the 
difference was not significant. BMP-2 promoted AP activity 1.5, 4, and 13 times higher 
than the PBS control at 3, 5, and 7 d, respectively.  Simvastatin promoted 2.5, 3, and 2.4 
times more AP activity than PBS at 3, 5, and 7 d, respectively.   
 Simvastatin promoted greater AP expression with phenamil than without at 3 d 
(p<0.001), followed by diminished expression at days 5 and 7 (p<0.05).  BMP-2 was the 
only treatment that resulted in increased AP activity at days 5 (p<0.001) and 7 d 
(p<0.001), promoting higher AP expression compared to treatment without phenamil. 
BMP-2 treatments with phenamil increased activity 1.6, 2.2, and 1.2 times more than 
BMP-2 did in the absence of phenamil at 3, 5, and 7 d, respectively.  Simvastatin with 
phenamil increased AP activity 1.5 and 1.1 times more at 3 and 5 d, respectively, 
followed by 0.16 times less activity at 7 d. PSIM(5k) degradation products at 50 µg/ml 
led to only 1.1 times more AP activity at 5 d.  
125 
 
 
Figure 6.2 Alkaline phosphatase expression by C2C12 myoblast cells in the presence of 
poly(simvastatin) and poly(lactide) degradation products, simvastatin, D,L-lactide, BMP-
2, and untreated controls a) without and b) with phenamil.  *p<0.05, #p<0.01, Δp<0.001 
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Relative myotube thickness between the groups after 7 d is shown in Figure 6.3.  
Cells treated with BMP-2 were excluded from the plot because the protein prevents 
myotube formation, which is seen in Figure 6.3b.  In the absence of phenamil, only 
C2C12 myoblasts treated with simvastatin had significantly smaller myotube diameters 
compared to the PBS control and remaining treatments (p<0.001), including D,L-lactide 
(p<0.01).  Between the remaining groups, D,L-lactide treatment led to significantly 
smaller myotubes formed than PLA(5k) did at 10 µg/ml (p<0.001), but it was not 
different from the PBS control.  A difference in myotube diameter was also seen between 
PLA(5k) at 10 µg/ml having the thickest diameters and PSIM(5k) at 50 µg/ml and D,L-
lactide (p<0.01), but it was not significantly different from the PBS control.   
When phenamil was present, the PBS control showed a difference in myotube 
thickness compared to the other treatments (p<0.001).  Simvastatin with phenamil 
resulted in even smaller myotube thickness compared to the remaining treatments 
(p<0.001), including PLA(5k) at 50 µg/ml (p<0.01).  Smaller myotube thickness from 
PLA(5k) at 10 µg/ml compared to 50 µg/ml was seen as well (p<0.05). 
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Figure 6.3 a) Relative myotube thickness normalized to PBS control at 7 d and b) cell 
images comparing myotube formation between groups. BMP-2 was excluded from the 
plot since myotubes did not form with treatment. n=10, *p<0.05, Δp<0.001. 
 
Observations from up to 4 week trial runs of 4 x 6 mm poly(simvastatin) disks 
implanted on the calvarium, beneath the periosteum, of Sprague-Dawley rats revealed 
slightly varied findings in the physical and degradation behavior of the disks in vivo 
(Figure 6.4).  Within one week, observations ranged from an extensively fragmented 
disk, to a relatively intact disk encased in a fibrous capsule at the implantation site, to 
remnants of the disk remaining at the site.  At the third week, similar disk conditions of 
fragmented or intact disks were seen.  The intact disks looked to have retained most if not 
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all of their initial size up to wk 4, despite the disk conditions and the outlier of only 
particles remaining in one of the animals at wk 1. 
 
  
Figure 6.4 Images of fragmented and intact poly(simvastatin) disk samples at wk 1. 
  
Wk 3  4 
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Figure 6.5 a) Photographs of harvested calvaria with disks intact at 3 and 4 wks.  b) 
MicroCT images of calvaria of the same specimens. 
 
The calvarium was harvested with the disk still encased in the fibrous capsule, 
shown in Figure 6.5.  MicroCT shows slight indentation where the implant was or an 
otherwise different surface morphology compared to bone surrounding the implant, 
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which will be investigated later, histologically.  The observations seen in the pilot aided 
in adjusting the disk dimensions for continuing with the main in vivo study giving insight 
as to what to expect. 
6.4 Discussion 
Simvastatin has been shown to inhibit myoblast formation at 1 µM, and BMP-2 at 
significantly lower concentrations,
225
 so the concentration chosen ensured a range where 
AP activity and myoblast inhibition had been previously seen.  C2C12 myoblasts are 
normally known to differentiate into myotubes, which express characteristic biomarkers 
indicative of muscle.  With BMP-2 treatment, however, differentiation can shift to an 
osteoblastic pathway in which cells express alkaline phosphatase, osteocalcin, and other 
known biomarkers of osteoblastic phenotype. This pathway shift diminishes, if not 
completely inhibits, formation of myotubes within the monolayer.
226
   While treating 
C2C12 cells is not as relevant towards bone promoting applications as MC3T3-E1 pre-
osteoblasts, the cell line was used instead to present a clearer distinction between the 
positive control (BMP-2) and negative control (PBS) regarding AP expression.  
Osteogenic biomarkers such as AP will not be expressed in C2C12 cells as they mature, 
unless the treatment given promotes it, unlike MC3T3-E1 subclone 4 cells where AP 
expression and osteoblast differentiation are inevitable and different forms of treatment 
dictate the rate of that process. 
 BMP-2 is a potent stimulator of osteoblastic differentiation which is mediated by 
a collective family of Smad proteins after BMP-2 binds to the type II receptor that 
directly activates the type I receptor. Cyclin-dependent kinase 6 (cdk6) is subsequently 
repressed via the Rho/Smad pathway, a protein that would otherwise play a key role in 
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inhibiting osteoblastic differentiation.
227
  When added to C2C12 cells, the effects of 
phenamil promoting the expression of osteogenic biomarkers are seen within a day ,
228
 
and are more immediate compared to statins such as simvastatin that must first upregulate 
BMP-2 in order to have the same effect.  While myotube inhibition caused by BMP-2 has 
been linked to the same Rho mechanism, simvastatin has been found to mediate myotube 
inhibition via Rac by HMG-CoA reductase inhibition, different from the suppression of 
Rho leading to BMP-2 upregulation which promotes AP expression in C2C12 cells.
225
  
Regardless, the signaling pathways previously described explain how BMP-2 and 
simvastatin are able to promote significant AP expression in both non-osteoblastic and 
osteoblastic cell lines, which is why they worked well as positive controls.  
Phenamil was chosen to supplement treatments due to its ability to augment the 
osteogenic effects of BMP-2.  Its upregulation of BMP-2 is done by stimulating tribbles 
homolog 3 (Trb3), which enhances the BMP-Smad pathway.
229
  A concentration of 20 
µM was used since one study found it as the highest to promote a dose-dependent.
230
  The 
synergistic effect phenamil had with the active treatments of BMP-2 at 3, 5, and 7 d, and 
simvastatin at 3 and 5 d can be attributed to the mediation of the BMP-Smad pathway.  
The expression level is not cumulative as what would be seen with mineralization of an 
osteogenic cell line, so the trend with decreasing AP activity up to 7 d post-confluency 
seen with simvastatin is not unusual.. The expression levels of AP and other biomarkers 
can change dependent on the differentiation stage of the cell line.    The small effect of 
the PSIM(5k) degradation products without phenamil may be an indication of the amount 
of simvastatin present compared to the other possible degradation products, i.e., 
mPEG(5k), dimerized or trimer simvastatin forms, and simvastatin attached to mPEG.  
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Simvastatin is a very small percent of the products, with simvastatin release profiles from 
the PSIM copolymer referenced in Chapter 4 showing amounts of simvastatin released 
being 2 to 3 orders of magnitude lower than the total mass lost.  The simvastatin 
oligomers may not be active and the rate of degradation into monomers if taken up by the 
cells, remains to be determined.  MPEG could also potentially hinder cellular uptake if 
simvastatin is still attached contributing to minimized activity because of the size, 
hydrophilicity, and uncharged nature of mPEG, rendering it difficult to being taken up by 
cells. 
Fragmentation of some disks when implanted over the calvarium may be due to a 
mechanical stresses imposed on the sample. Possible reasons include initial disk 
movement before formation of the fibrous capsule over the disk, the high activity and 
grooming of the animals at or near the implantation site, and the slightly more brittle 
nature of the disk.  The disk fragments may have also induced a large amount of 
inflammation at the site, further exacerbating the condition of the disk.  The outlier of a 
majority of the disk being resorbed may be due to the residuals being found in the tissue 
more above the intended site. The indentation seen in microCT may indicate possible 
wearing of existing lamellar bone under the disk from minor but repeated disk movement 
within the implantation site.  The morphology may otherwise indicate possible formation 
of new woven bone surrounding the disk as opposed to underneath, accentuating the 
indentation observed. This observation was seen and quantified in an in vivo study 
conducted by Jeon et al., where the thickness of bone underneath the intermittent and 
sustained simvastatin releasing devices was significantly lower than the woven bone 
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thickness surrounding it.
231
  The observation will be further investigated in the main 
study with H&E staining. 
6.5 Conclusions 
Poly(simvastatin) degradation products were cytocompatible with myoblast cells 
at concentration levels at and above therapeutic levels of simvastatin.  However, they 
promoted low to minimal osteogenic activity, which may be attributed to a significant 
percentage of the degradation products still in a conjugated and inactive state. 
Poly(simvastatin) disks in vivo were shown to affect the surface morphology of bone 
under and at the periphery of the disks. Whether these changes are an indication of new 
bone growth remains to be determined, but alongside its cytocompatibility, this 
copolymer shows potential for use as a regenerative biomaterial with further 
development. 
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Ch. 7 Summary and Conclusions 
 
Polymerizing a commercialized cholesterol-regulating prodrug known as 
simvastatin via ROP was explored as a proof of concept.  Degradation, simvastatin 
release, physical properties, and bioactivity of the resulting polymer were evaluated for 
potential use in bone regenerative applications. 
By modifying reaction parameters, variation in reaction temperature was 
ultimately found to have the most effect on increasing the degree of simvastatin 
polymerization via stannous octoate.  Further investigation of different catalysts led to 
desirably lower reaction temperature conditions, via TBD.  Chromatography and 
spectroscopy techniques used to corroborate simvastatin conjugation supported the 
feasibility of utilizing the lactone ring of simvastatin to synthesize a diblock copolymer 
backbone comprised of simvastatin monomers in the secondary block.  This observation 
opens a window to the ROP of many other lactone-incorporated drug precursors 
implemented in a variety of therapeutic drug delivery treatments that would benefit from 
an increased drug wt% while providing controlled release.  
Using the TBD catalyst also allowed for the synthesis of PSIM copolymers 
initiated by mPEGs of decreasing sizes, releasing more simvastatin with decreased 
hydrophobicity.  Blending different hydrophobic PLA-mPEG copolymers with 
poly(simvastatin) also resulted in modified rates of mass loss, simvastatin release and 
modified mechanical properties.  These examples of copolymerization and blending 
demonstrate methods to easily tune poly(simvastatin) degradation and mechanical 
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properties, to better match different time periods of treatments.  Lactide, glycolide, ε-
caprolactone, or ricinoleic acid lactones, their respective polymers, or different PEG 
structures could be randomly or block copolymerized with simvastatin to further alter 
degradation or mechanical properties of the resulting copolymers more suitable to 
different delivery applications. Likewise, poly(simvastatin)-incorporated blends with 
these alternative polyesters or composites utilizing hydroxyapatite or calcium-based 
components could be considered  to investigate the osteogenic nature of the resulting 
biomaterial alongside its structural properties and conformity to abnormal shapes of 
wound-sites in  load-bearing bone.  
Degradation products of PSIM inhibited HMG-CoA reductase potential 
enhancement of osteogenic expression and biocompatibility in vitro and in vivo.  These 
observations demonstrate the potential to promote bone growth.  Because HMG-CoA 
inhibition is linked to the expression of simvastatin’s osteogenic properties, in addition to 
angiogenic and anti-atherosclerotic properties, future investigations of degradable 
poly(simvastatin) can potentially be broadened to include localized applications for 
maintaining vascular health. The tailorable qualities provided by copolymerizing 
pleiotropic simvastatin and co-blending its polymerized form can result in biomaterials 
suitable for a broad range of therapeutic drug delivery applications from vascular to bone 
regeneration.   
 
 
Copyright © Theodora Atta Asafo-Adjei 2017 
  
137 
 
REFERENCES 
1. Stebbins ND, Faig JJ, Yu W, Guliyev R and Uhrich KE. Polyactives: controlled and 
sustained bioactive release via hydrolytic degradation. Biomaterials science. 2015; 3: 1171-87. 
2. Global strategies to reduce the health care burden of craniofacial anomalies: report of 
WHO meetings on international collaborative research on craniofacial anomalies. The Cleft 
palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial 
Association. 2004; 41: 238-43. 
3. Dimitriou R, Jones E, McGonagle D and Giannoudis PV. Bone regeneration: current 
concepts and future directions. Bmc Med. 2011; 9. 
4. Scheller EL and Krebsbach PH. Gene Therapy: Design and Prospects for Craniofacial 
Regeneration. J Dent Res. 2009; 88: 585-96. 
5. Bostrom MPG and Seigerman DA. The Clinical Use of Allografts, Demineralized Bone 
Matrices, Synthetic Bone Graft Substitutes and Osteoinductive Growth Factors: A Survey Study. 
HSS Journal. 2005; 1: 9-18. 
6. Giannoudis PV, Dinopoulos H and Tsiridis E. Bone substitutes: An update. Injury. 2005; 
36: 20-7. 
7. Porter JR, Ruckh TT and Popat KC. Bone Tissue Engineering: A Review in Bone 
Biomimetics and Drug Delivery Strategies. Biotechnol Progr. 2009; 25: 1539-60. 
8. Bostrom MP and Seigerman DA. The clinical use of allografts, demineralized bone 
matrices, synthetic bone graft substitutes and osteoinductive growth factors: a survey study. Hss 
Journal. 2005; 1: 9-18. 
9. Giannoudis PV, Dinopoulos H and Tsiridis E. Bone substitutes: an update. Injury. 2005; 
36 Suppl 3: S20-7. 
10. Mourino V and Boccaccini AR. Bone tissue engineering therapeutics: controlled drug 
delivery in three-dimensional scaffolds. J R Soc Interface. 2010; 7: 209-27. 
11. Suchanek W and Yoshimura M. Processing and properties of hydroxyapatite-based 
biomaterials for use as hard tissue replacement implants. J Mater Res. 1998; 13: 94-117. 
12. Rezwan K, Chen QZ, Blaker JJ and Boccaccini AR. Biodegradable and bioactive porous 
polymer/inorganic composite scaffolds for bone tissue engineering. Biomaterials. 2006; 27: 3413-
31. 
13. Low KL, Tan SH, Zein SHS, Roether JA, Mourino V and Boccaccini AR. Calcium 
phosphate-based composites as injectable bone substitute materials. J Biomed Mater Res B. 2010; 
94B: 273-86. 
14. Shindo ML, Costantino PD, Friedman CD and Chow LC. Facial Skeletal Augmentation 
Using Hydroxyapatite Cement. Arch Otolaryngol. 1993; 119: 185-90. 
15. Garlotta D. A literature review of poly(lactic acid). J Polym Environ. 2001; 9: 63-84. 
16. Dhandayuthapani B, Yoshida Y, Maekawa T and Kumar DS. Polymeric Scaffolds in 
Tissue Engineering Application: A Review. Int J Polym Sci. 2011. 
17. Ajioka M, Enomoto K, Suzuki K and Yamaguchi A. The Basic Properties of Poly(Lactic 
Acid) Produced by the Direct Condensation Polymerization of Lactic-Acid. J Environ Polym 
Degr. 1995; 3: 225-34. 
18. Maurus PB and Kaeding CC. Bioabsorbable implant material review. Operative 
Techniques in Sports Medicine. 2004; 12: 158-60. 
19. Kaito T, Myoui A, Takaoka K, et al. Potentiation of the activity of bone morphogenetic 
protein-2 in bone regeneration by a PLA-PEG/hydroxyapatite composite. Biomaterials. 2005; 26: 
73-9. 
20. Kim HW, Lee HH and Knowles JC. Electrospinning biomedical nanocomposite fibers of 
hydroxyapatite/poly(lactic acid) for bone regeneration. Journal of biomedical materials research 
Part A. 2006; 79: 643-9. 
138 
 
21. Jain RA. The manufacturing techniques of various drug loaded biodegradable 
poly(lactide-co-glycolide) (PLGA) devices. Biomaterials. 2000; 21: 2475-90. 
22. Advanced healthcare materials. Weinheim: Wiley-VCH,, 2012. 
23. Middleton JC and Tipton AJ. Synthetic biodegradable polymers as orthopedic devices. 
Biomaterials. 2000; 21: 2335-46. 
24. Bala I, Hariharan S and Kumar MN. PLGA nanoparticles in drug delivery: the state of 
the art. Crit Rev Ther Drug Carrier Syst. 2004; 21: 387-422. 
25. Wu XS and Wang N. Synthesis, characterization, biodegradation, and drug delivery 
application of biodegradable lactic/glycolic acid polymers. Part II: biodegradation. Journal of 
biomaterials science Polymer edition. 2001; 12: 21-34. 
26. Clark A. Treating Proximal Tibial Growth Plate Injuries Using Poly (Lactic-co-Glycolic 
Acid) Scaffolds. 
27. Song CX, Labhasetwar V, Cui XM, Underwood T and Levy RJ. Arterial uptake of 
biodegradable nanoparticles for intravascular local drug delivery: Results with an acute dog 
model. J Control Release. 1998; 54: 201-11. 
28. Hakkarainen M. Aliphatic polyesters: Abiotic and biotic degradation and degradation 
products. Adv Polym Sci. 2002; 157: 113-38. 
29. Labet M and Thielemans W. Synthesis of polycaprolactone: a review. Chem Soc Rev. 
2009; 38: 3484-504. 
30. Lowry KJ, Hamson KR, Bear L, et al. Polycaprolactone/glass bioabsorbable implant in a 
rabbit humerus fracture model. J Biomed Mater Res. 1997; 36: 536-41. 
31. Ikada Y and Tsuji H. Biodegradable polyesters for medical and ecological applications. 
Macromol Rapid Comm. 2000; 21: 117-32. 
32. Storey RF and Sherman JW. Kinetics and mechanism of the stannous octoate-catalyzed 
bulk polymerization of epsilon-caprolactone. Macromolecules. 2002; 35: 1504-12. 
33. Chuenjitkuntaworn B, Inrung W, Damrongsri D, Mekaapiruk K, Supaphol P and 
Pavasant P. Polycaprolactone/hydroxyapatite composite scaffolds: preparation, characterization, 
and in vitro and in vivo biological responses of human primary bone cells. Journal of biomedical 
materials research Part A. 2010; 94: 241-51. 
34. Williams JM, Adewunmi A, Schek RM, et al. Bone tissue engineering using 
polycaprolactone scaffolds fabricated via selective laser sintering. Biomaterials. 2005; 26: 4817-
27. 
35. Hill JW. Studies on polymerization and ring formation XVII Friedel-Crafts syntheses 
with the polyanhydrides of the dibasic acids. J Am Chem Soc. 1932; 54: 4105-6. 
36. Rosen HB, Chang J, Wnek GE, Linhardt RJ and Langer R. Bioerodible Polyanhydrides 
for Controlled Drug Delivery. Biomaterials. 1983; 4: 131-3. 
37. Kumar N, Langer RS and Domb AJ. Polyanhydrides: an overview. Adv Drug Deliver 
Rev. 2002; 54: 889-910. 
38. Jain JP, Modi S, Domb AJ and Kumar N. Role of polyanhydrides as localized drug 
carriers. J Control Release. 2005; 103: 541-63. 
39. Jampel HD, Leong KW, Dunkelburger GR and Quigley HA. Glaucoma Filtration 
Surgery in Monkeys Using 5-Fluorouridine in Polyanhydride Disks. Arch Ophthalmol-Chic. 
1990; 108: 430-5. 
40. Kimura H, Ogura Y, Moritera T, et al. Injectable Microspheres with Controlled Drug 
Release for Glaucoma Filtering Surgery. Invest Ophth Vis Sci. 1992; 33: 3436-41. 
41. Masters DB, Berde CB, Dutta S, Turek T and Langer R. Sustained Local-Anesthetic 
Release from Bioerodible Polymer Matrices - a Potential Method for Prolonged Regional 
Anesthesia. Pharmaceut Res. 1993; 10: 1527-32. 
42. Schmeltzer RC, Anastasiou TJ and Uhrich KE. Optimized synthesis of salicylate-based 
poly(anhydride-esters). Polym Bull. 2003; 49: 441-8. 
139 
 
43. Odian GG. Principles of polymerization. New York,: McGraw-Hill, 1970, p.xviii, 652 p. 
44. Hoffman AS. Hydrogels for biomedical applications. Ann N Y Acad Sci. 2001; 944: 62-
73. 
45. Maffezzoli A, Della Pietra A, Rengo S, Nicolais L and Valletta G. Photopolymerization 
of dental composite matrices. Biomaterials. 1994; 15: 1221-8. 
46. Xing JF, Zheng ML and Duan XM. Two-photon polymerization microfabrication of 
hydrogels: an advanced 3D printing technology for tissue engineering and drug delivery. Chem 
Soc Rev. 2015; 44: 5031-9. 
47. Sawhney AS, Pathak CP and Hubbell JA. Bioerodible Hydrogels Based on 
Photopolymerized Poly(Ethylene Glycol)-Co-Poly(Alpha-Hydroxy Acid) Diacrylate Macromers. 
Macromolecules. 1993; 26: 581-7. 
48. Domb AJ, Ron E and Langer R. Poly(Anhydrides) .2. One-Step Polymerization Using 
Phosgene or Diphosgene as Coupling Agents. Macromolecules. 1988; 21: 1925-9. 
49. Hyon SH, Jamshidi K and Ikada Y. Synthesis of polylactides with different molecular 
weights. Biomaterials. 1997; 18: 1503-8. 
50. Odian G. Step polymerization. Principles of Polymerization. Fourth Edition ed. 2004, p. 
39-198. 
51. Carbone AL, Song M and Uhrich KE. Iodinated salicylate-based poly(anhydride-esters) 
as radiopaque Biomaterials. Biomacromolecules. 2008; 9: 1604-12. 
52. Kim Y and Verkade JG. Living polymerization of lactide using titanium alkoxide 
catalysts. In Macromolecular Symposia. 2005; 224: 105-18. 
53. Kurcok P, Penczek J, Franek J and Jedlinski Z. Anionic-Polymerization of Lactones .14. 
Anionic Block Copolymerization of Delta-Valerolactone and L-Lactide Initiated with Potassium 
Methoxide. Macromolecules. 1992; 25: 2285-9. 
54. Lohmeijer BGG, Pratt RC, Leibfarth F, et al. Guanidine and amidine organocatalysts for 
ring-opening polymerization of cyclic esters. Macromolecules. 2006; 39: 8574-83. 
55. Jensen TR, Breyfogle LE, Hillmyer MA and Tolman WB. Stereoelective polymerization 
of D,L-lactide using N-heterocyclic carbene based compounds. Chemical communications. 2004: 
2504-5. 
56. Shibasaki Y, Sanada H, Yokoi M, Sanda F and Endo T. Activated monomer cationic 
polymerization of lactones and the application to well-defined block copolymer synthesis with 
seven-membered cyclic carbonate. Macromolecules. 2000; 33: 4316-20. 
57. Gopferich A. Mechanisms of polymer degradation and erosion. Biomaterials. 1996; 17: 
103-14. 
58. Mata-Perez F and Perez-Benito JF. The kinetic rate law for autocatalytic reactions. 
Journal of Chemical Education. 1987; 64: 925-7. 
59. Uhrich KE, Cannizzaro SM, Langer RS and Shakesheff KM. Polymeric systems for 
controlled drug release. Chem Rev. 1999; 99: 3181-98. 
60. Breitenbach A, Li YX and Kissel T. Branched biodegradable polyesters for parenteral 
drug delivery systems. J Control Release. 2000; 64: 167-78. 
61. Wang M, Gan D and Wooley KL. Linear and hyperbranched poly (silyl ester)s: Synthesis 
via cross-dehydrocoupling-based polymerization, hydrolytic degradation properties, and 
morphological analysis by atomic force microscopy. Macromolecules. 2001; 34: 3215-23. 
62. Qiu LY and Bae YH. Polymer architecture and drug delivery. Pharmaceut Res. 2006; 23: 
1-30. 
63. McKee MG, Unal S, Wilkes GL and Long TE. Branched polyesters: recent advances in 
synthesis and performance. Prog Polym Sci. 2005; 30: 507-39. 
64. Zhang J, Zhao YJ, Su ZG and Ma GH. Synthesis of monomethoxy poly(ethylene glycol) 
without diol poly(ethylene glycol). J Appl Polym Sci. 2007; 105: 3782-6. 
140 
 
65. Avgoustakis K, Beletsi A, Panagi Z, et al. Effect of copolymer composition on the 
physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG 
nanoparticles. Int J Pharmaceut. 2003; 259: 115-27. 
66. Banerjee SS, Aher N, Patil R and Khandare J. Poly(ethylene glycol)-Prodrug Conjugates: 
Concept, Design, and Applications. Journal of drug delivery. 2012; 2012: 103973. 
67. Knop K, Hoogenboom R, Fischer D and Schubert US. Poly(ethylene glycol) in Drug 
Delivery: Pros and Cons as Well as Potential Alternatives. Angew Chem Int Edit. 2010; 49: 6288-
308. 
68. Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx : the journal of 
the American Society for Experimental NeuroTherapeutics. 2005; 2: 108-19. 
69. Tormala P. Determination of Glass-Transition Temperature of Poly(Ethylene Glycol) by 
Spin Probe Technique. Eur Polym J. 1974; 10: 519-21. 
70. Li FJ, Zhang SD, Liang JZ and Wang JZ. Effect of polyethylene glycol on the 
crystallization and impact properties of polylactide-based blends. Polym Advan Technol. 2015; 
26: 465-75. 
71. Sungsanit K, Kao N and Bhattacharya SN. Properties of linear poly(lactic 
acid)/polyethylene glycol blends. Polym Eng Sci. 2012; 52: 108-16. 
72. Wischke C and Schwendeman SP. Principles of encapsulating hydrophobic drugs in 
PLA/PLGA microparticles. Int J Pharm. 2008; 364: 298-327. 
73. Butler SM, Tracy MA and Tilton RD. Adsorption of serum albumin to thin films of 
poly(lactide-co-glycolide). J Control Release. 1999; 58: 335-47. 
74. Cleek RL, Ting KC, Eskin SG and Mikos AG. Microparticles of poly (DL-lactic-co-
glycolic acid)/poly (ethylene glycol) blends for controlled drug delivery. J Control Release. 1997; 
48: 259-68. 
75. Ringsdorf H. Structure and Properties of Pharmacologically Active Polymers. J Polym 
Sci Pol Sym. 1975: 135-53. 
76. Joshi HN. Recent Advances in Drug Delivery Systems: Polymeric Prodrugs. 
Pharmaceutical Technology. 1988: 118. 
77. Gupta P, Authimoolam SP, Hilt JZ and Dziubla TD. Quercetin conjugated poly(beta-
amino esters) nanogels for the treatment of cellular oxidative stress. Acta Biomater. 2015; 27: 
194-204. 
78. Patil VS, Dziubla TD and Kalika DS. Static and dynamic properties of biodegradable 
poly (antioxidant β-amino ester) networks based on incorporation of curcumin multiacrylate. 
Polym Bull. 2015; 75: 88-96. 
79. Jeon JH, Thomas MV and Puleo DA. Bioerodible devices for intermittent release of 
simvastatin acid. Int J Pharm. 2007; 340: 6-12. 
80. Jeon JH and Puleo DA. Alternating release of different bioactive molecules from a 
complexation polymer system. Biomaterials. 2008; 29: 3591-8. 
81. Sundararaj SC, Thomas MV, Peyyala R, Dziubla TD and Puleo DA. Design of a multiple 
drug delivery system directed at periodontitis. Biomaterials. 2013; 34: 8835-42. 
82. Fisher PD, Palomino P, Milbrandt TA, Hilt JZ and Puleo DA. Improved small molecule 
drug release from in situ forming poly(lactic-co-glycolic acid) scaffolds incorporating poly(beta-
amino ester) and hydroxyapatite microparticles. Journal of biomaterials science Polymer edition. 
2014; 25: 1174-93. 
83. Brown ME, Zou Y, Peyyala R, Dziubla TD and Puleo DA. Temporal separation in the 
release of bioactive molecules from a moldable calcium sulfate bone graft substitute. Curr Drug 
Deliv. 2014; 11: 605-12. 
84. Orellana BR, Hilt JZ and Puleo DA. Drug release from calcium sulfate-based composites. 
J Biomed Mater Res B Appl Biomater. 2015; 103: 135-42. 
85. Wozney JM. Overview of bone morphogenetic proteins. Spine. 2002; 27: S2-S8. 
141 
 
86. Ebara S and Nakayama K. Mechanism for the action of bone morphogenetic proteins and 
regulation of their activity. Spine (Phila Pa 1976). 2002; 27: S10-5. 
87. Rao SM, Ugale GM and Warad SB. Bone morphogenetic proteins: periodontal 
regeneration. North American journal of medical sciences. 2013; 5: 161-8. 
88. Rai B, Teoh SH, Hutmacher DW, Cao T and Ho KH. Novel PCL-based honeycomb 
scaffolds as drug delivery systems for rhBMP-2. Biomaterials. 2005; 26: 3739-48. 
89. Kempen DH, Lu L, Hefferan TE, et al. Retention of in vitro and in vivo BMP-2 
bioactivities in sustained delivery vehicles for bone tissue engineering. Biomaterials. 2008; 29: 
3245-52. 
90. Laurencin CT, Attawia MA, Lu LQ, et al. Poly(lactide-co-glycolide)/hydroxyapatite 
delivery of BMP-2-producing cells: a regional gene therapy approach to bone regeneration. 
Biomaterials. 2001; 22: 1271-7. 
91. Zhou AJ, Clokie CM and Peel SA. A novel peptide to enhance recombinant BMP-2 
production in mammalian cell cultures. BMC Proc. 2011; 5 Suppl 8: P96. 
92. Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: molecular 
clones and activities. Science. 1988; 242: 1528-34. 
93. Chen NF, Smith ZA, Stiner E, Armin S, Sheikh H and Khoo LT. Symptomatic ectopic 
bone formation after off-label use of recombinant human bone morphogenetic protein-2 in 
transforaminal lumbar interbody fusion: Report of 4 cases. Journal of Neurosurgery: Spine. 2010; 
12: 40-6. 
94. Davignon J and Mabile L. Mechanisms of action of statins and their pleiotropic effects. 
Ann Endocrinol-Paris. 2001; 62: 101-12. 
95. Elavarasu S, Suthanthiran TK and Naveen D. Statins: A new era in local drug delivery. 
Journal of pharmacy & bioallied sciences. 2012; 4: S248-51. 
96. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an 
update. Fund Clin Pharmacol. 2005; 19: 117-25. 
97. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents 
by statins. Science. 1999; 286: 1946-9. 
98. Yazawa H, Zimmermann B, Asami Y and Bernimoulin JP. Simvastatin promotes cell 
metabolism, proliferation, and osteoblastic differentiation in human periodontal ligament cells. J 
Periodontol. 2005; 76: 295-302. 
99. Keogh A, Macdonald P, Kaan A, Aboyoun C, Spratt P and Mundy J. Efficacy and safety 
of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transpl. 2000; 19: 529-
37. 
100. Issues in Aesthetic, Craniofacial, Maxillofacial, Oral, and Plastic Surgery. In: Acton QA, 
(ed.). Atlanta, Georgia: ScholarlyEditions, 2013. 
101. Tonetti MS, D'Aiuto F, Nibali L, et al. Treatment of periodontitis and endothelial 
function. N Engl J Med. 2007; 356: 911-20. 
102. Yoshito I and Tsujh H. Biodegradable polyesters for medical and ecological applications. 
Macromol Rapid Commun. 2000; 21: 117-32. 
103. Gunaitllake PA and Adhikari R. Biodegradable Synthetic Polymers for Tissue 
Engineering. Eur Cell Mater. 2003; 5: 1-16. 
104. Dhandayuthapani B, Yoshida Y, Maekawa T and Kumar DS. Polymeric Scaffolds in 
Tissue Engineering Application: A Review. Int J Polym Sci. 2011; 2011. 
105. Langer R. New Methods of Drug Delivery. Science. 1990; 249: 1527-33. 
106. Rohini NA, Agrawal N, Joseph A and Mukerji A. Polymeric Prodrugs: Recent 
Achievements and General Strategies. J Antivir Antiretrovir S. 2013; 2. 
107. Duncan R. Polymer conjugates as anticancer nanomedicines. Nature 2006; 6: 688-701. 
108. Banerjee SS, Aher N, Patil R and Khandare J. Poly(ethylene glycol)-Prodrug Conjugates: 
Concept, Design, and Applications. J Drug Delivery. 2012; 2012. 
142 
 
109. Joshi HN. Recent Advances in Drug Delivery Systems, Polymeric Prodrugs. Pharm 
Technol. 1988; 12: 120-30. 
110. Cleek RL, Ting KC, Eskin SG and Mikos AG. Microparticles of poly(dl-lactic-co-
glycolic acid)/poly(ethylene glycol) blends for controlled drug delivery. J Controlled Release. 
1997; 48: 259–68. 
111. Yeo Y and Park K. Control of Encapsulation Efficiency and Initial Burst in Polymeric 
Microparticle Systems. Arch Pharm Res. 2004; 27: 1-12. 
112. Saltzman WM and Fung LK. Polymeric implants for cancer chemotherapy. Adv Drug 
Delivery Rev. 1997; 26: 209-30. 
113. Alexis F, Venkatraman SS, Rath SK and Boey F. In vitro study of release mechanisms of 
paclitaxel and rapamycin from drug-incorporated biodegradable stent matrices. J Controlled 
Release. 2004; 98: 67-74. 
114. Huang X and Brazel CS. On the importance and mechanisms of burst release in matrix-
controlled drug delivery systems. J Controlled Release. 2001; 73: 121-36. 
115. Carbone AL and Uhrich KE. Design and Synthesis of Fast-Degrading Poly(anhydride-
esters). Macromol Rapid Commun. 2009; 30: 1021-6. 
116. Wattamwar PP, Mo Y, Wan R, Palli R, Zhang Q and Dziubla TD. Antioxidant Activity 
of Degradable Polymer Poly(trolox-ester) to Suppress Oxidative Stress Injury in the Cells. Adv 
Funct Mater. 2010; 20: 147–54. 
117. Slivniak R and Domb AJ. Macrolactones and polyesters from ricinoleic acid. 
Biomacromolecules. 2005; 6: 1679-88. 
118. Kricheldorf HR, Kreiser-Saunders J and Boettcher C. Polylactones:31. Sn(II)octoate-
initiated polymerization of L-lactide: a mechanistic study. Polym. 1995; 36: 1253-9. 
119. Nuyken O and Pask SD. Ring-Opening Polymerization—An Introductory Review. 
Polym. 2013; 5: 361-403. 
120. Sparrow CP, Burton CA, Hernandez M, et al. Simvastatin Has Anti-Inflammatory and 
Anti-atherosclerotic Activity Independent of Plasma Cholesterol Lowering. Arterioscler Thromb 
Vasc Biol. 2001; 21: 115-21. 
121. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin 
activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. 
Nature medicine. 2000; 6: 1004-10. 
122. Chen PY, Sun JS, Tsuang YH, Chen MH, Weng PW and Lin FH. Simvastatin promotes 
osteoblast viability and differentiation via Ras/Smad/Erk/BMP-2 signaling pathway. Nutrition 
research. 2010; 30: 191-9. 
123. Istvan ES and Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA 
reductase. Science. 2001; 292: 1160-4. 
124. Porter JR, Ruckh TT and Popat KC. Bone tissue engineering: a review in bone 
biomimetics and drug delivery strategies. Biotechnol Prog. 2009; 25: 1539-60. 
125. Wong RW and Rabie AB. Statin-induced osteogenesis uses in orthodontics: a scientific 
review. World journal of orthodontics. 2006; 7: 35-40. 
126. Prueksaritanont T, Gorham LM, Ma B, et al. In vitro metabolism of simvastatin in 
humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. 
Drug metabolism and disposition: the biological fate of chemicals. 1997; 25: 1191-9. 
127. Armitage J, Bowman L, Collins R, Parish S, Tobert J and Group MBHPSC. Effects of 
simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-
controlled trial in 20,536 high-risk people. BMC Clin Pharmacol. 2009; 9. 
128. Dziubla TD, Karim A and Muzykantov VR. Polymer nanocarriers protecting active 
enzyme cargo against proteolysis. J Controlled Release. 2005; 102: 427-39. 
129. Jing Zhang J, Zhao Y, Su Z and Ma G. Synthesis of Monomethoxy Poly(ethylene glycol) 
without Diol Poly(ethylene glycol). J Appl Polym Sci. 2007; 105: 3780–6. 
143 
 
130. Ambike AA, Mahadik KR and Paradkar A. Physico-chemical characterization and 
stability study of glassy simvastatin. Drug development and industrial pharmacy. 2005; 31: 895-
9. 
131. Tessmar JK and Gopferich AM. Customized PEG-derived copolymers for tissue-
engineering applications. Macromolecular bioscience. 2007; 7: 23-39. 
132. Knop K, Hoogenboom R, Fischer D and Schubert US. Poly(ethylene glycol) in drug 
delivery: pros and cons as well as potential alternatives. Angewandte Chemie. 2010; 49: 6288-
308. 
133. Save M, Schappacher M and Soum A. Controlled Ring-Opening Polymerization of 
Lactones and Lactides Initiated by Lanthanum Isopropoxide. Macromol Chem Phys. 2002; 203: 
889-99. 
134. Puaux J, Banu I, Nagy I and Bozga G. A Study of L-Lactide Ring-Opening 
Polymerization Kinetics. Macromol Symp. 259: 318-26. 
135. Kaihara S, Matsumura S, Mikos AG and Fisher JP. Synthesis of poly(L-lactide) and 
polyglycolide by ring-opening polymerization. Nature protocols. 2007; 2: 2767-71. 
136. Labet M and Thielemans W. Synthesis of polycaprolactone: a review. Chem Soc Rev. 
2009; 38: 3484-504. 
137. Storey RF. Kinetics and Mechanism of the Stannous Octoate-Catalyzed Bulk 
Polymerization of e-Caprolactone. Macromolecules. 2002; 35: 1504-12. 
138. Odian G. Principles of Polymerization. 4th ed. Hoboken, NJ: John Wiley & Sons, Inc., 
2004. 
139. Górniak A, Karolewicz B, Żurawska-Płaksej E and Pluta J. Thermal, spectroscopic, and 
dissolution studies of the simvastatin-acetylsalicylic acid mixtures. J Therm Anal Calorim. 2013; 
111: 2125-32. 
140. Aleman C, Betran O, Casanovas J, Houk KN and Hall HKJ. Thermodynamic control of 
the polymerizability of five-, six-, and seven-membered lactones. The Journal of organic 
chemistry. 2009; 74: 6237-44. 
141. Ahuja R, Kundu S, Goldman AS, Brookhart M, Vicente BC and Scott SL. Catalytic ring 
expansion, contraction, and metathesis-polymerization of cycloalkanes. Chem Commun (Camb). 
2008: 253-5. 
142. Otera J. Transesterification. Chem Rev. 1993; 93: 1449-70. 
143. Sunder A, Hanselmann R, Frey H and Mu R. Controlled Synthesis of Hyperbranched 
Polyglycerols by Ring-Opening Multibranching Polymerization. Macromolecules. 1999; 32: 
4240-6. 
144. Tasaka F, Ohya Y and Ouchi T. One-Pot Synthesis of Novel Branched Polylactide 
Through the Copolymerization of Lactide with Mevalonolactone. Macromol Rapid Commun. 
2001; 22: 820-4. 
145. Disjkstra PJ, Du H and Feijen J. Single site catalysts for stereoselective ring-opening 
polymerization of lactides. Polym Chem. 2011; 2: 520-7. 
146. Katiyar V and Nanavati H. Ring-opening polymerization of L-lactide using N-
heterocyclic molecules: mechanistic, kinetics and DFT studies. Polym Chem. 2010; 1: 1491-500. 
147. Duda A and Kowalski A. Handbook of Ring-Opening Polymerization. KGaA, Weinheim: 
Wiley-VCH Verlag GmbH & Co., 2009. 
148. Veld PJA, Velner EM, Witte PVD, Hamhuis J, Dijkstra PJ and Feijen J. Melt Block 
Copolymerization of e-Caprolactone and L-Lactide. J Polym Sci A Polym Chem. 1997; 35: 219-
25. 
149. Xie WH, Zhu WP and Shen ZQ. Synthesis, isothermal crystallization and micellization of 
mPEG-PCL diblock copolymers catalyzed by yttrium complex. Polymer. 2007; 48: 6791-8. 
144 
 
150. Kaesemeyer WH, Caldwell RB, Huang J and Caldwell RW. Pravastatin sodium activates 
endothelial nitric oxide synthase independent of its cholesterol-lowering actions. Journal of the 
American College of Cardiology. 1999; 33: 234-41. 
151. Hakkarainen M and Albertsson A-C. Degradation Products of Aliphatic and Aliphatic–
Aromatic Polyesters. In: Hakkarainen M, Burman L, Albertsson A-C, Gröning M and Strandberg 
C, (eds.). Chromatography for Sustainable Polymeric Materials. Verlag Berlin Heidelberg: 
Springer, 2008, p. 85-116. 
152. Lewis JK, Wei J and Siuzdak G. Matrix-assisted Laser Desorption/Ionization Mass 
Spectrometry in Peptide and Protein Analysis. In: Meyers RA, (ed.). Encyclopedia of Analytical 
Chemistry. Chichester: John Wiley & Sons Ltd, 2000, p. 5880-94. 
153. Wang H, Wu Y and Zhao Z. Fragmentation study of simvastatin and lovastatin using 
electrospray ionization tandem mass spectrometry. Journal of mass spectrometry : JMS. 2001; 
36: 58-70. 
154. Keller BO and Li L. Discerning matrix-cluster peaks in matrix-assisted laser 
desorption/ionization time-of-flight mass spectra of dilute peptide mixtures. Journal of the 
American Society for Mass Spectrometry. 2000; 11: 88-93. 
155. Save M, Schappacher M and Soum A. Controlled Ring‐ Opening Polymerization of 
Lactones and Lactides Initiated by Lanthanum Isopropoxide, 1. General Aspects and Kinetics. 
Macromolecular chemistry and physics. 2002; 203: 889-99. 
156. Hiltunen K, Seppälä JV and Härkönen M. Effect of catalyst and polymerization 
conditions on the preparation of low molecular weight lactic acid polymers. Macromolecules. 
1997; 30: 373-9. 
157. Pepels MPF, Bouyahyi M, Heise A and Duchateau R. Kinetic investigation on the 
catalytic ring-opening (co) polymerization of (macro) lactones using aluminum salen catalysts. 
Macromolecules. 2013; 46: 4324-34. 
158. Pratt RC, Lohmeijer BG, Long DA, Waymouth RM and Hedrick JL. 
Triazabicyclodecene: a simple bifunctional organocatalyst for acyl transfer and ring-opening 
polymerization of cyclic esters. J Am Chem Soc. 2006; 128: 4556-7. 
159. Asafo-Adjei TA, Dziubla TD and Puleo DA. Synthesis and characterization of a 
poly(ethylene glycol)-poly(simvastatin) diblock copolymer. Rsc Adv. 2014; 4: 58287-98. 
160. Chuma A, Horn HW, Swope WC, et al. The reaction mechanism for the organocatalytic 
ring-opening polymerization of l-lactide using a guanidine-based catalyst: hydrogen-bonded or 
covalently bound? J Am Chem Soc. 2008; 130: 6749-54. 
161. Kamber NE, Jeong W, Waymouth RM, Pratt RC, Lohmeijer BG and Hedrick JL. 
Organocatalytic ring-opening polymerization. Chem Rev. 2007; 107: 5813-40. 
162. Kiesewetter MK, Shin EJ, Hedrick JL and Waymouth RM. Organocatalysis: 
opportunities and challenges for polymer synthesis. Macromolecules. 2010; 43: 2093-107. 
163. Nederberg F, Lohmeijer BG, Leibfarth F, et al. Organocatalytic ring opening 
polymerization of trimethylene carbonate. Biomacromolecules. 2007; 8: 153-60. 
164. Chen CSH. Polymerization and copolymerization of trioxane: Factors influencing 
molecular weight and end groups. Journal of Polymer Science: Polymer Chemistry Edition. 1975; 
13: 1183-208. 
165. Rakova GV, Shaginyan AA and Yenikolopyan NS. Effect of temperature and catalyst 
concentration on molecular weight during polymerization of trioxane in solution. Polymer 
Science USSR. 1967; 9: 2916-24. 
166. Simon L and Goodman JM. The mechanism of TBD-catalyzed ring-opening 
polymerization of cyclic esters. J Org Chem. 2007; 72: 9656-62. 
167. Zhong Z, Ankoné MJ, Dijkstra PJ, Birg C, Westerhausen M and Feijen J. Calcium 
methoxide initiated ring-opening polymerization of ε-caprolactone and L-lactide. Polym Bull. 
2001; 46: 51-7. 
145 
 
168. Ambrosio AM, Allcock HR, Katti DS and Laurencin CT. Degradable 
polyphosphazene/poly(alpha-hydroxyester) blends: degradation studies. Biomaterials. 2002; 23: 
1667-72. 
169. Allen C, Han J, Yu Y, Maysinger D and Eisenberg A. Polycaprolactone–b-poly (ethylene 
oxide) copolymer micelles as a delivery vehicle for dihydrotestosterone. J Control Release. 2000; 
63: 275-86. 
170. Park TG. Degradation of Poly(Lactic-Co-Glycolic Acid) Microspheres - Effect of 
Copolymer Composition. Biomaterials. 1995; 16: 1123-30. 
171. Park TG. Degradation of Poly(D,L-Lactic Acid) Microspheres - Effect of Molecular-
Weight. J Control Release. 1994; 30: 161-73. 
172. Celikkaya E, Denkbas EB and Piskin E. Poly (DL‐ lactide)/poly (ethylene glycol) 
copolymer particles. I. Preparation and characterization. J Appl Polym Sci. 1996; 61: 1439-46. 
173. Lee SH, Kim SH, Han YK and Kim YH. Synthesis and degradation of end-group-
functionalized polylactide. J Polym Sci Pol Chem. 2001; 39: 973-85. 
174. Cha Y and Pitt CG. The Biodegradability of Polyester Blends. Biomaterials. 1990; 11: 
108-12. 
175. Oh JK. Polylactide (PLA)-based amphiphilic block copolymers: synthesis, self-assembly, 
and biomedical applications. Soft Matter. 2011; 7: 5096-108. 
176. Bae YH, Huh KM, Kim Y and Park K. Biodegradable amphiphilic multiblock 
copolymers and their implications for biomedical applications. J Control Release. 2000; 64: 3-13. 
177. Mundargi RC, Babu VR, Rangaswamy V, Patel P and Aminabhavi TM. Nano/micro 
technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) 
and its derivatives. J Control Release. 2008; 125: 193-209. 
178. Sastry SV, Nyshadham JR and Fix JA. Recent technological advances in oral drug 
delivery - a review. Pharmaceutical science & technology today. 2000; 3: 138-45. 
179. Kim MS, Kim SK, Kim SH, Hyun H, Khang G and Lee HB. In vivo osteogenic 
differentiation of rat bone marrow stromal cells in thermosensitive MPEG-PCL diblock 
copolymer gels. Tissue Eng. 2006; 12: 2863-73. 
180. Wang SG and Bo Q. Polycaprolactone–poly (ethylene glycol) block copolymer, I: 
synthesis and degradability in vitro. Polym Advan Technol. 1993; 4: 363-6. 
181. Fu SZ, Ni PY, Wang BY, et al. Injectable and thermo-sensitive PEG-PCL-PEG 
copolymer/collagen/n-HA hydrogel composite for guided bone regeneration. Biomaterials. 2012; 
33: 4801-9. 
182. Jiang CP, Chen YY, Hsieh MF and Lee HM. Solid freeform fabrication and in-vitro 
response of osteoblast cells of mPEG-PCL-mPEG bone scaffolds. Biomed Microdevices. 2013; 
15: 369-79. 
183. Wen YH, Gallego MR, Nielsen LF, et al. Biodegradable nanocomposite microparticles as 
drug delivering injectable cell scaffolds. J Control Release. 2011; 156: 11-20. 
184. Dong YC and Feng SS. Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) 
nanoparticles for controlled delivery of anticancer drugs. Biomaterials. 2004; 25: 2843-9. 
185. Tsuji H and Ikada Y. Blends of aliphatic polyesters .1. Physical properties and 
morphologies of solution-cast blends from poly(DL-lactide) and poly(epsilon-caprolactone). J 
Appl Polym Sci. 1996; 60: 2367-75. 
186. Rosario-Melendez R, Harris CL, Delgado-Rivera R, Yu L and Uhrich KE. 
PolyMorphine: An innovative biodegradable polymer drug for extended pain relief. J Control 
Release. 2012; 162: 538-44. 
187. Wattamwar PP, Hardas SS, Butterfield DA, Anderson KW and Dziubla TD. Tuning of 
the pro-oxidant and antioxidant activity of trolox through the controlled release from 
biodegradable poly(trolox ester) polymers. Journal of Biomedical Materials Research Part A. 
2011; 99A: 184-91. 
146 
 
188. Tang HD, Murphy CJ, Zhang B, et al. Curcumin polymers as anticancer conjugates. 
Biomaterials. 2010; 31: 7139-49. 
189. Dziubla TD, Karim A and Muzykantov VR. Polymer nanocarriers protecting active 
enzyme cargo against proteolysis. J Control Release. 2005; 102: 427-39. 
190. Ubeaud G, Hagenbach J, Vandenschrieck S, Jung L and Koffel JC. In vitro inhibition of 
simvastatin metabolism in rat and human liver by naringenin. Life Sci. 1999; 65: 1403-12. 
191. Vree TB, Dammers E, Ulc I, Horkovics-Kovats S, Ryska M and Merkx I. Differences 
Between Lovastatin and Simvastatin Hydrlysis in Healthy Male and Female Volunteers. The 
Scientific World Journal. 2003; 3: 1332-43. 
192. Clark A, Milbrandt TA, Hilt JZ and Puleo DA. Tailoring properties of microsphere-based 
poly(lactic-co-glycolic acid) scaffolds. Journal of biomedical materials research Part A. 2014; 
102: 348-57. 
193. Perchellet JPH, Perchellet EM, Crow KR, et al. Novel synthetic inhibitors of 3-hydroxy-
3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation 
and are structurally unrelated to existing statins. Int J Mol Med. 2009; 24: 633-43. 
194. Roberts CK, Liang KH, Barnard RJ, Kim CH and Vaziri ND. HMG-CoA reductase, 
cholesterol 7 alpha-hydroxylase, LDL receptor, SR-B1, and ACAT in diet-induced syndrome X. 
Kidney Int. 2004; 66: 1503-11. 
195. Baskaran G, Salvamani S, Ahmad SA, Shaharuddin NA, Pattiram PD and Shukor MY. 
HMG-CoA reductase inhibitory activity and phytocomponent investigation of Basella alba leaf 
extract as a treatment for hypercholesterolemia. Drug design, development and therapy. 2015; 9: 
509-17. 
196. Tsuji H and Ikada Y. Blends of aliphatic polyesters. II. Hydrolysis of solution‐ cast 
blends from poly (L‐ lactide) and poly (ε‐ caprolactone) in phosphate‐ buffered solution. 
Journal of applied polymer science. 1998; 67: 405-15. 
197. Song C, Guo Z, Ma Q, et al. Simvastatin induces osteoblastic differentiation and inhibits 
adipocytic differentiation in mouse bone marrow stromal cells. Biochemical and biophysical 
research communications. 2003; 308: 458-62. 
198. Maeda T, Kawane T and Horiuchi N. Statins augment vascular endothelial growth factor 
expression in osteoblastic cells vial inhibition of protein prenylation. Endocrinology. 2003; 144: 
681-92. 
199. Tracy MA, Ward KL, Firouzabadian L, et al. Factors affecting the degradation rate of 
poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials. 1999; 20: 1057-62. 
200. Pasanen MK, Neuvonen M, Neuvonen PJ and Niemi M. SLCO1B1 polymorphism 
markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006; 16: 
873-9. 
201. Horgan DJ, Stoops JK, Webb EC and Zerner B. Carboxylesterases (EC 3.1.1). A large-
scale purification of pig liver carboxylesterase. Biochemistry. 1969; 8: 2000-6. 
202. Thomas S, Grohens Y, Jyotishkumar P and eds. Characterization of polymer blends: 
miscibility, morphology and interfaces. John Wiley & Sons, 2014. 
203. Misch CE, Qu Z and Bidez MW. Mechanical properties of trabecular bone in the human 
mandible: implications for dental implant treatment planning and surgical placement. J Oral 
Maxillofac Surg. 1999; 57: 700-6; discussion 6-8. 
204. Cowin SC. Wolff's law of trabecular architecture at remodeling equilibrium. Journal of 
Biomechanical Engineering. 1986; 108: 83-8. 
205. Evans SL and Gregson PJ. Composite technology in load-bearing orthopaedic implants. 
Biomaterials. 1998; 19: 1329-42. 
206. Na YH, He Y, Shuai X, Kikkawa Y, Doi Y and Inoue Y. Compatibilization effect of 
poly(epsilon-caprolactone)-b-poly(ethylene glycol) block copolymers and phase morphology 
147 
 
analysis in immiscible poly(lactide)/poly(epsilon-caprolactone) blends. Biomacromolecules. 
2002; 3: 1179-86. 
207. Kulinski Z, Piorkowska E, Gadzinowska K and Stasiak M. Plasticization of poly(L-
lactide) with poly(propylene glycol). Biomacromolecules. 2006; 7: 2128-35. 
208. Wu T, He Y, Fan Z, Wei J and Li S. Investigations on the morphology and melt 
crystallization of poly (L‐ lactide)‐ poly (ethylene glycol) diblock copolymers. Polymer 
Engineering & Science. 2008; 48: 425-33. 
209. Mohanty AK, Jana U, Manna PK and Mohanta GP. Synthesis and evaluation of MePEG-
PCL diblock copolymers: surface properties and controlled release behavior. Prog Biomater. 
2015; 4: 89-100. 
210. Wilke RA, Ramsey LB, Johnson SG, et al. The clinical pharmacogenomics 
implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. 
Clinical pharmacology and therapeutics. 2012; 92: 112-7. 
211. Cheng HY, Rogers JD, Sweany AE, et al. Influence of Age and Gender on the Plasma 
Profiles of 3-Hydroxy-3-Methylglutaryl-Coenzyme a (Hmg-Coa) Reductase Inhibitory Activity 
Following Multiple Doses of Lovastatin and Simvastatin. Pharmaceut Res. 1992; 9: 1629-33. 
212. Gonyeau MJ. Statins and osteoporosis: A clinical review. Pharmacotherapy. 2005; 25: 
228-43. 
213. Krauth D, Anglemyer A, Philipps R and Bero L. Nonindustry-Sponsored Preclinical 
Studies on Statins Yield Greater Efficacy Estimates Than Industry-Sponsored Studies: A Meta-
Analysis. Plos Biol. 2014; 12. 
214. Aitken M, Berndt ER and Cutler DM. Prescription Drug Spending Trends In The United 
States: Looking Beyond The Turning Point. Health Affair. 2009; 28: W151-W60. 
215. Davignon J and Mabile L. Mechanisms of action of statins and their pleiotropic effects. 
Ann Endocrinol. 2001; 62: 101. 
216. Liao JK and Laufs U. Pleiotropic effects of statins. Annual review of pharmacology and 
toxicology. 2005; 45: 89-118. 
217. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin 
activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. 
Nature medicine. 2000; 6: 1004-10. 
218. Leung BP, Sattar N, Crilly A, et al. A novel anti-inflammatory role for simvastatin in 
inflammatory arthritis. Journal of immunology. 2003; 170: 1524-30. 
219. Chen PY, Sun JS, Tsuang YH, Chen MH, Weng PW and Lin FH. Simvastatin promotes 
osteoblast viability and differentiation via Ras/Smad/Erk/BMP-2 signaling pathway. Nutrition 
research. 2010; 30: 191-9. 
220. Sugiyama M, Kodama T, Konishi K, Abe K, Asami S and Oikawa S. Compactin and 
simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma 
cells. Biochemical and biophysical research communications. 2000; 271: 688-92. 
221. Park JB. Use of simvastatin in bone regeneration. Med Oral Patol Oral Cir Bucal. 2009; 
14: 485-8. 
222. Uzzan B, Cohen R, Nicolas P, Cucherat M and Perret GY. Effects of statins on bone 
mineral density: a meta-analysis of clinical studies. Bone. 2007; 40: 1581-7. 
223. Rogers MJ. Statins: lower lipids and better bones? Nature medicine. 2000; 6: 21-3. 
224. Wattamwar PP, Mo YQ, Wan R, Palli R, Zhang QW and Dziubla TD. Antioxidant 
Activity of Degradable Polymer Poly(trolox ester) to Suppress Oxidative Stress Injury in the 
Cells. Adv Funct Mater. 2010; 20: 147-54. 
225. Baba TT, Nemoto TK, Miyazaki T and Oida S. Simvastatin suppresses the differentiation 
of C2C12 myoblast cells via a Rac pathway. Journal of muscle research and cell motility. 2008; 
29: 127-34. 
148 
 
226. Katagiri T, Yamaguchi A, Komaki M, et al. Bone Morphogenetic Protein-2 Converts the 
Differentiation Pathway of C2C12 Myoblasts into the Osteoblast Lineage. Journal of Cell 
Biology. 1994; 127: 1755-66. 
227. Ogasawara T, Kawaguchi H, Jinno S, et al. Bone Morphogenetic Protein 2-Induced 
Osteoblast Differentiation Requires Smad-Mediated Down-Regulation of Cdk6. Molecular and 
cellular biology. 2004; 24: 6560-8. 
228. Takeda K, Ichijo H, Fujii M, et al. Identification of a novel bone morphogenetic protein-
responsive gene that may function as a noncoding RNA. Journal of Biological Chemistry. 1998; 
273: 17079-85. 
229. Fan J, Guo M, Im CS, et al. Enhanced Mandibular Bone Repair by Combined Treatment 
of Bone Morphogenetic Protein 2 and Small-Molecule Phenamil. Tissue engineering Part A. 
2017; 23: 195-207. 
230. Fan J, Im CS, Cui ZK, et al. Delivery of Phenamil Enhances BMP-2-Induced Osteogenic 
Differentiation of Adipose-Derived Stem Cells and Bone Formation in Calvarial Defects. Tissue 
engineering Part A. 2015; 21: 2053-65. 
231. Jeon JH, Piepgrass WT, Lin YL, Thomas MV and Puleo DA. Localized intermittent 
delivery of simvastatin hydroxyacid stimulates bone formation in rats. J Periodontol. 2008; 79: 
1457-64. 
 
  
149 
 
Vita 
EDUCATION       
 
University of Kentucky, Lexington, KY 
Doctor of Philosophy in Biomedical Engineering, 2017 
Cumulative GPA: 3.51 / 4.00 
 
University of Tennessee, Knoxville, TN 
Bachelor of Science in Biomedical Engineering, 2009 
Cumulative GPA:  3.58 / 4.00 
            
EXPERIENCE     
 
Wright Medical Group N.V., Memphis, TN, 2017 - present 
 Sterility Assurance Engineer 
 
University of Kentucky, Lexington, KY, 2010-2017           
 Graduate Research Assistant 
 Lab: Regenerative Biomaterials 
 Advisor: Dr. David Puleo, Dept. of Biomedical Engineering 
 Co-Advisor: Dr. Thomas Dziubla, Dept. of Chemical and Materials Engineering 
 
University of Tennessee, Knoxville, TN, 2007-2008            
 Undergraduate Research Assistant, Center for Musculoskeletal Research 
 Math Tutorial Center Tutor 
 
PUBLICATIONS 
 
 Asafo-Adjei, T. A., Dziubla, T. D., and Puleo, D. A. (2014). Synthesis and 
characterization of a poly (ethylene glycol)-poly (simvastatin) diblock copolymer. 
RSC Advances, 4(102), 58287-58298. 
 Asafo-Adjei, T. A., Chen, A. J., Najarzadeh, A., and Puleo, D. A. (2016). 
"Advances in Controlled Drug Delivery for Treatment of Osteoporosis." Current 
Osteoporosis Reports (2016):1-13. 
 Asafo-Adjei, T. A., Dziubla, T. D., and Puleo, D. A. (2017). "Tuning Properties 
of Poly(ethylene glycol)-blockpoly(simvastatin) Copolymers Synthesized via 
Triazabicyclodecene." Reactive and Functional Polymers - accepted for 
publication 
 
CONFERENCE PRESENTATIONS  
 
 TA Asafo-Adjei, TD Dziubla and DA Puleo, “Characterization of 
Poly(simvastatin) Copolymers and Blends,” World Biomaterials Congress, 
Montreal, Canada, May 17-22, 2016 - poster presentation 
150 
 
 
 TA Asafo-Adjei, TD Dziubla and DA Puleo, “Characterization of 
Poly(simvastatin) Copolymers and Blends,” Center for Clinical and Translational 
Science (CCTS) Annual Spring Conference, Lexington, KY, April 21st, 2016 - 
poster presentation 
 
 TA Asafo-Adjei, TD Dziubla and DA Puleo, “Characterization of 
Poly(simvastatin) Copolymers and Blends,” Biomaterials Day, University of 
Memphis, Memphis, TN, March 18
th
, 2016 - oral presentation 
 
 TA Asafo-Adjei, TD Dziubla and DA Puleo, “Degradation of Poly(simvastatin) 
Copolymers and Blends,” Biomedical Engineering Society (BMES) Annual 
Meeting, Tampa, FL, Oct. 7-10, 2015 - poster presentation 
 
 TA Asafo-Adjei, TD Dziubla and DA Puleo, “Synthesis and Characterization of a 
Simvastatin Polyprodrug,” Center for Clinical and Translational Science (CCTS) 
Annual Spring Conference, Lexington, KY, March 25
rd
, 2015 - poster 
presentation 
 
 TA Asafo-Adjei, TD Dziubla and DA Puleo, “Synthesis and Characterization of a 
Simvastatin Polyprodrug,” Biomaterials Day, Vanderbilt University, Nashville, 
TN, March 23
rd
,  2015 - poster presentation 
 
 TA Asafo-Adjei, TD Dziubla and DA Puleo, “Synthesis and Characterization of a 
Simvastatin Polyprodrug for Potential Tissue Regeneration Applications,” Tissue 
Engineering and Regenerative Medicine International Society (TERMIS) Annual 
Meeting, Washington, D.C., Dec. 13-16, 2014 - poster presentation 
 
 TA Asafo-Adjei, TD Dziubla and DA Puleo, “Synthesis and Characterization of a 
Simvastatin Polyprodrug,” Biomaterials Day, University of Kentucky, Lexington, 
KY, Sept. 27
th
, 2014 - poster presentation 
 
 S Ramineni, M Brown, B Orellana, N Anderson, P Fisher, T Asafo-Adjei, D 
Puleo, T Brown, “Fundamentals of Controlled Release Systems with Hydrogel as 
an Example,” Education Challenge, Society for Biomaterials (SFB) Annual 
Meeting, Denver, CO, April 16-19, 2014 - group poster presentation 
 
 TA Asafo-Adjei, TD Dziubla and DA Puleo, “Evaluating Two Methods of Ring-
Opening Polymerization for Synthesizing a Degradable, Polymeric Simvastatin 
Prodrug,” Society for Biomaterials (SFB) Annual Meeting, Denver, CO, April 16-
19, 2014 - poster presentation  
 
 TA Asafo-Adjei, TD Dziubla and DA Puleo, “Analysis of Molecular Weight 
Growth and Degradation of a Simvastatin Polymeric Prodrug,” Society for 
151 
 
Biomaterials (SFB) Annual Meeting, Boston, MA, Apri110-13, 2013 - poster 
presentation 
 
 TA Asafo-Adjei, TD Dziubla, and DA Puleo, "A Comparative Analysis of 
Synthesis Techniques for the Formation of an Amphiphilic Polymeric Prodrug for 
Extended Simvastatin Release,” Biomedical Engineering Society (BMES) Annual 
Meeting, Atlanta, GA, Oct. 24-27, 2012 - poster presentation 
 
 TA Asafo-Adjei, TD Dziubla, and DA Puleo, "Synthesis and Characterization of 
a Bioactive Polymeric Prodrug for Bone Regeneration,” Biomaterials Day, 
University of Kentucky, Lexington, KY, Sept. 22
nd
, 2012 - poster presentation 
 
 TA Asafo-Adjei, TD Dziubla, and DA Puleo, "Synthesis and Characterization of 
a Bioactive Polymeric Prodrug for Bone Regeneration", Biomaterials Day, Purdue 
University, West Lafayette, IN, Oct. 29
th
, 2011 - poster presentation 
 
AFFILIATED SOCIETIES  
 
TERMIS, Tissue Engineering and Regenerative Medicine International Society, 
member, 2014- present  
SFB, Society for Biomaterials, member, 2011 - present   
 President, UK-Chapter, Lexington, KY, 2016 
 Secretary, UK-Chapter, Lexington, KY,  2013 - 2014 
BMES, Biomedical Engineering Society, member, 2011 - present 
 Secretary, UK-Chapter, Lexington, KY, 2011 – 2013 
AAAS, American Association for the Advancement of Science, member, 2011 - present 
BGPSA, Black Graduate and Professional Students Association, 2010 - present  
Tau Beta Pi, alpha UTK chapter member, 2007 – 2009 
NSBE, National Society of Black Engineers, member, 2005 - present 
 
HONORS AND AWARDS 
 
University of Kentucky, Lexington, KY, 2010-2016 
 NSF – Integrative Graduate and Educational Research Trainee (IGERT) 
Fellowship 
 Graduate Certificate of Bioactive Interfaces and Devices 
 2nd place poster - Biomaterials Day, Vanderbilt University, March 23rd, 2015 
 1st place (group)- Education Challenge, Society for Biomaterials (SFB) Annual 
Meeting, April 16-19, 2014 
 1st place poster - Biomaterials Day, University of Kentucky, Sept. 27th, 2014 
 2nd place poster - Biomaterials Day, Purdue University, Oct. 29th, 2011 
        
University of Tennessee – Knoxville, TN, 2005-2009          
 University Scholarship 
 TN Lottery HOPE Scholarship 
152 
 
 African American Achievers Scholarship 
 NSBE Board of Corporate Affiliates (BCA) scholarship recipient, 2007 
 
COMMITTEE APPOINTMENTS 
 
College of Engineering, University of Kentucky, Lexington, KY, Spring 2016      
 Graduate Student Representative – Diversity and Inclusion committee 
